Author: "Ardanaz, E." / Topic: medicine.disease - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Ardanaz, E."' showing total 112 results

Start Over Author "Ardanaz, E." Topic medicine.disease

112 results on '"Ardanaz, E."'

1. Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study

Author: Bielska-Lasota, M., Rossi, S., Krzyzak, M., Haelens, A., Domenic, A., De Angelis, R., Maciejczyk, A., Rodriguez-Barranco, M., Zadnik, V., Minicozzi, P., Hackl, M., Ihle, P., Vaneycken, E., Henau, K., Valerianova, Z., Dimitrova, N., Sekerija, M., Cukelj, P., Dusek, L., Zvolsky, M., Magi, M., Aareleid, T., Malila, N., Seppa, K., Velten, M., Guizard, A. V., Faivre, J., Woronoff, A. S., Tretarre, B., Bossard, N., Uhry, Z., Colonna, M., Molinie, F., Cowppli-Bony, A., Bara, S., Lapotre-Ledoux, B., Grosclaude, P., Stabenow, R., Luttmann, S., Eberle, A., Brenner, H., Nennecke, A., Engel, J., Schubert-Fritschle, G., Heidrich, J., Holleczek, B., Katalinic, A., Birgisson, H., Tryggvadottir, L., Clough-Gorr, K., Mazzoleni, G., Bulatko, A., Buzzoni, C., Suterasardo, A., Mancuso, P., Ferretti, S., Barchielli, A., Caldarella, A., Gatta, G., Sant, M., Amati, C., Baili, P., Berrino, F., Bonfarnuzzo, S., Botta, L., Capocaccia, R., Foschi, R., Margutti, C., Meneghini, E., Trama, A., Serraino, D., Dalmaso, L., Deangelis, R., Dibenedetto, C., Caldora, M., Francisci, S., Galati, F., Mallone, S., Pierannunzio, D., Tallon, M., Santaquilani, M., Tavilla, A., Pannozzo, F., Busco, S., Filiberti, R. A., Marani, E., Ricci, P., Spagnoli, G., Cirilli, C., Fusco, M., Vitale, M. F., Usala, M., Vitale, F., Mazzucco, W., Michiara, M., Zanetti, R., Rosso, S., Tumino, R., Mangone, L., Difelice, E., Russo, A. G., Andreano, A., Falcini, F., Caiazzo, A. L., Cesaraccio, R., Piffer, S., Madeddu, A., Tisano, F., Fanetti, A. C., Cometti, I., Candela, P., Scuderi, T., Stracci, F., Bianconi, F., Tagliabue, G., Contiero, P., Rugge, M., Zorzi, M., Pildava, S., Smailyte, G., Azzopardi, M., Calleja, N., Johannesen, T. B., Rachtan, J., Gozdz, S., Macek, P., Blaszczyk, J., Bebenek, M., Forjaz deLacerda, G., Bento, M. J., Antunes, L., Miranda, A., Mayer-da-Silva, A., Safaeidiba, C., Primic-Zakelj, M., Lopez deMunain, A., Gil, L., Diazgarcia, J. M., Marcos-Navarro, A. I., Marcos-Gragera, R., Puigdemont, M., Sanchez, M. J., Chang, D. Y. L., Chirlaque, M. D., Ardanaz, E., Guevara, M., Galceran, J., Carulla, M., Lambe, M., Khan, S., Staehelin, K., Bouchardy, C., Fournier, E., Mousavi, S. M., Ess, S. M., Lorez, M., Mousavi, M., Herrmann, C., Bordoni, A., Spitale, A., Konzelmann, I., Visser, O., Aarts, M., Otter, R., Coleman, M., Allemani, C., Rachet, B., Rashbass, J., Broggio, J., Verne, J., Gavin, A., Donnelly, D., Morrison, D., Black, R., Huws, D. W., Thomas, R., Bielska‑Lasota, M, Rossi, S, Krzyżak, M, Haelens, A, Domenic, A, De Angelis, R, Maciejczyk, A, Rodríguez‑Barranco, M, Zadnik, V, Minicozzi, P, Vitale, F, and Mazzucco, W
Subjects: Morphology, Adult, Male, Stage at diagnosi, Survival, Adolescent, Socio-culturale, Uterine Cervical Neoplasms, Disease, Settore MED/42 - Igiene Generale E Applicata, 03 medical and health sciences, 0302 clinical medicine, Medicine, media_common.cataloged_instance, Humans, European Union, European union, Survival rate, Population-based study, media_common, Aged, Retrospective Studies, Cervical cancer, Aged, 80 and over, Cervical cancer, Europe, Morphology, Population-based study, Stage at diagnosis, Survival, 030219 obstetrics & reproductive medicine, Relative survival, business.industry, Absolute risk reduction, Obstetrics and Gynecology, Retrospective cohort study, Stage at diagnosis, General Medicine, Middle Aged, medicine.disease, Europe, Eastern european, Survival Rate, 030220 oncology & carcinogenesis, Female, business, Demography
Abstract: Purpose: With better access to early diagnosis and appropriate treatment, cervical cancer (CC) burden decreased in several European countries. In Eastern European (EE) countries, which accessed European Union in 2004, CC survival was worse than in the rest of Europe. The present study investigates CC survival differences across five European regions, considering stage at diagnosis (local, regional and metastatic), morphology (mainly squamous versus glandular tumours) and patients’ age. Methods: We analysed 101,714 CC women diagnosed in 2000–2007 and followed-up to December 2008. Age-standardised 5-year relative survival (RS) and the excess risks of cancer death in the 5years after diagnosis were computed. Results: EE women were older and less commonly diagnosed with glandular tumours. Proportions of local stage cancers were similar across Europe, while morphology- and stage-specific RS (especially for non-metastatic disease) were lower in Eastern Europe. Adjusting for age and morphology, excess risk of local stage CC death for EE patients remained higher than that for other European women. Conclusion: Stage, age and morphology alone do not explain worse survival in Eastern Europe: less effective care may play a role, probably partly due to fewer or inadequate resources being allocated to health care in this area, compared to the rest of Europe.
Published: 2019

2. Childhood and adolescent lymphoma in Spain: incidence and survival trends over 20years

Author: Marcos-Gragera R, Solans M, Galceran J, Fernandez-Delgado R, Fernandez-Teijeiro A, Mateos A, Quiros-Garcia J, Fuster-Camarena N, De Castro V, Sanchez M, Franch P, Chirlaque M, Ardanaz E, Martos C, Salmeron D, Peris-Bonet R, and Spanish Childhood Canc
Subjects: 0301 basic medicine, Male, Cancer Research, medicine.medical_specialty, Pediatrics, Childhood and adolescent cancer, Adolescent, Lymphoma, Survival, Population, Kaplan-Meier Estimate, Malignancy, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Epidemiology, medicine, Humans, Registries, education, Child, education.field_of_study, Population based, Observed Survival, business.industry, Incidence (epidemiology), Incidence, Infant, Newborn, Cancer, Infant, General Medicine, Cancer registry, medicine.disease, 030104 developmental biology, Oncology, Spain, 030220 oncology & carcinogenesis, Child, Preschool, Female, business
Abstract: BackgroundLymphoma is the third most common malignancy in children (0-14years) and the first in adolescents (15-19years). This population-based studythe largest ever done in Spainanalyses incidence and survival of lymphomas among Spanish children and adolescents.Patients and methods1664 lymphoma cases (1983-2007) for incidence and 1030 for survival (1991-2005) followed until 31/12/2010, were provided by 11 cancer registries. Age-adjusted incidence rates (ASRw) to the world standard population were obtained; incidence trends were modelled using the Joinpoint programme, observed survival (OS) was estimated with Kaplan-Meier and trends tested with a log-rank test. Results are presented according to the International Classification of Childhood Cancer-3.ResultsIn Spain, the ASRw(0-14) for lymphomas was 17.5 per 1.000.000 child-years and 50.0 the specific rate for adolescents. Overall incidence increased significantly during 1983-1997 with no increases thereafter. Patients over 9years old showed significant rising trends for all subtypes, except for Burkitt lymphoma (BL) in adolescents. During 2001-2005 (age 0-19years), 5-year OS was 94 (90-98), 73 (64-83) and 86 (78-94) for Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and BL, respectively. No improvement in survival was found. The incidence in Spain was higher than overall European rates, but within the range of that in Southern Europe. Comparing OS in Spain 1991-1995 and 2001-2005 with results for Europe of the Automated Childhood Cancer Information System (ACCIS) (1988-1997) and the European cancer registry-based study on survival and care of cancer patients (EUROCARE) (2000-2007), it was similar for HL and lower for NHL and BL.ConclusionsSystematic monitoring and analysis of lymphoma paediatric data would provide clinical and epidemiological information to improve the health care of these patients and the outcomes for these malignancies in Spain.
Published: 2018

3. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)

Author: Matz, M., Coleman, M., Carreira, H., Salmerã³n, D., Chirlaque, M., Allemani, C., Bouzbid, S., Hamdi-chérif, M., Zaidi, Z., Bah, E., Swaminathan, R., Nortje, S., El Mistiri, M., Bayo, S., Malle, B., Manraj, S., Sewpaul-sungkur, R., Fabowale, A., Ogunbiyi, O., Bradshaw, D., Somdyala, N., Stefan, D., Abdel-rahman, M., Jaidane, L., Mokni, M., Kumcher, I., Moreno, F., González, M., Laura, E., Espinola, S., Calabrano, G., Carballo Quintero, B., Fita, R., Garcilazo, D., Giacciani, P., Diumenjo, M., Laspada, W., Green, M., Lanza, M., Ibañez, S., Lima, C., Lobo De Oliveira, E., Daniel, C., Scandiuzzi, C., De Souza, P., Melo, C., Del Pino, K., Laporte, C., Curado, M., De Oliveira, J., Veneziano, C., Veneziano, D., Latorre, M., Tanaka, L., Azevedo E. Silva, G., Galaz, J., Moya, J., Herrmann, D., Vargas, S., Herrera, V., Uribe, C., Bravo, L., Arias-ortiz, N., Jurado, D., Yépez, M., Galán, Y., Torres, P., Martínez-reyes, F., Pérez-meza, M., Jaramillo, L., Quinto, R., Cueva, P., Yépez, J., Torres-cintrón, C., Tortolero-luna, G., Alonso, R., Barrios, E., Nikiforuk, C., Shack, L., Coldman, A., Woods, R., Noonan, G., Turner, D., Kumar, E., Zhang, B., Mccrate, F., Ryan, S., Hannah, H., Dewar, R., Macintyre, M., Lalany, A., Ruta, M., Marrett, L., Nishri, D., Mcclure, C., Vriends, K., Bertrand, C., Louchini, R., Robb, K., Stuart-panko, H., Demers, S., Wright, S., George, J., Shen, X., Brockhouse, J., O'Brien, D., Ward, K., Almon, L., Bates, J., Rycroft, R., Mueller, L., Phillips, C., Brown, H., Cromartie, B., Schwartz, A., Vigneau, F., Mackinnon, J., Wohler, B., Bayakly, A., Clarke, C., Glaser, S., West, D., Hernandez, B., Johnson, C., Jozwik, D., Charlton, M., Lynch, C., Huang, B., Tucker, T., Deapen, D., Liu, L., Hsieh, M., Xc, W., Stern, K., Gershman, S., Knowlton, R., Alverson, J., Copeland, G., Rogers, D., Lemons, D., Williamson, L., Hood, M., Hosain, G., Rees, J., Pawlish, K., Stroup, A., Key, C., Wiggins, C., Kahn, A., Schymura, M., Leung, G., Rao, C., Giljahn, L., Warther, B., Pate, A., Patil, M., Schubert, S., Rubertone, J., Slack, S., Fulton, J., Rousseau, D., Janes, Ta:, S., Bolick, S., Hurley, D., Richards, J., Whiteside, M., Nogueira, L., Herget, K., Sweeney, C., Martin, J., Wang, S., Harrelson, D., Keitheri Cheteri, M., Farley, S., Hudson, A., Borchers, R., Stephenson, L., Espinoza, J., Weir, H., Edwards, B., Wang, N., Yang, L., Chen, J., Song, G., Xp, G., Zhang, P., Hm, G., Zhao, D., Zhang, J., Zhu, F., Tang, J., Shen, Y., Wang, J., Ql, L., Yang, X., Dong, J., Li, W., Cheng, L., Huang, Q., Huang, S., Guo, G., Wei, K., Chen, W., Zeng, H., Demetriou, A., Pavlou, P., Mang, W., Ngan, K., Kataki, A., Krishnatreya, M., Jayalekshmi, P., Sebastian, P., Sapkota, S., Verma, Y., Nandakumar, A., Suzanna, E., Keinan-boker, L., Silverman, B., Ito, H., Nakagawa, H., Hattori, M., Kaizaki, Y., Sugiyama, H., Utada, M., Katayama, K., Narimatsu, H., Kanemura, S., Koike, T., Miyashiro, I., Yoshii, M., Oki, I., Shibata, A., Matsuda, T., Nimri, O., Ab Manan, A., Bhoo-pathy, N., Tuvshingerel, S., Chimedsuren, O., Al Khater, A., Al-eid, H., Jung, K., Won, Y., Chiang, C., Lai, M., Suwanrungruang, K., Wiangnon, S., Daoprasert, K., Pongnikorn, D., Geater, S., Sriplung, H., Eser, S., Yakut, C., Hackl, M., Mühlböck, H., Oberaigner, W., Zborovskaya, A., Aleinikova, O., Henau, K., Van Eycken, L., Dimitrova, N., Valerianova, Z., Šekerija, M., Zvolský, M., Engholm, G., Storm, H., Innos, K., Mägi, M., Malila, N., Seppä, K., Jégu, J., Velten, M., Cornet, E., Troussard, X., Bouvier, A., Faivre, J., Guizard, A., Bouvier, V., Launoy, G., Arveux, P., Maynadié, M., Mounier, M., Fournier, E., Woronoff, A., Daoulas, M., Clavel, J., Le Guyader-peyrou, S., Monnereau, A., Trétarre, B., Colonna, M., Cowppli-bony, A., Molinié, F., Bara, S., Degré, D., Ganry, O., Lapôtre-ledoux, B., Grosclaude, P., Estève, J., Bray, F., Piñeros, M., Sassi, F., Stabenow, R., Eberle, A., Erb, C., Nennecke, A., Kieschke, J., Sirri, E., Kajueter, H., Emrich, K., Zeissig, S., Holleczek, B., Eisemann, N., Katalinic, A., Brenner, H., Asquez, R., Kumar, V., Ólafsdóttir, E., Tryggvadóttir, L., Comber, H., Walsh, P., Sundseth, H., Devigili, E., Mazzoleni, G., Giacomin, A., Bella, F., Castaing, M., Sutera, A., Gola, G., Ferretti, S., Serraino, D., Zucchetto, A., Lillini, R., Vercelli, M., Busco, S., Pannozzo, F., Vitarelli, S., Ricci, P., Pascucci, C., Autelitano, M., Cirilli, C., Federico, M., Fusco, M., Vitale, M., Usala, M., Cusimano, R., Mazzucco, W., Michiara, M., Sgargi, P., Maule, M., Sacerdote, C., Tumino, R., Di Felice, E., Vicentini, M., Falcini, F., Cremone, L., Budroni, M., Cesaraccio, R., Contrino, M., Tisano, F., Fanetti, A., Maspero, S., Candela, G., Scuderi, T., Gentilini, M., Piffer, S., Rosso, S., Sacchetto, L., Caldarella, A., La Rosa, F., Stracci, F., Contiero, P., Tagliabue, G., Dei Tos, A., Zorzi, M., Zanetti, R., Baili, P., Berrino, F., Gatta, G., Sant, M., Capocaccia, R., De Angelis, R., Liepina, E., Maurina, A., Smailyte, G., Agius, D., Calleja, N., Siesling, S., Visser, O., Larønningen, S., Møller, B., Dyzmann-sroka, A., Trojanowski, M., Góźdż, S., Mężyk, R., Grądalska-lampart, M., Radziszewska, A., Didkowska, J., Wojciechowska, U., Błaszczyk, J., Kępska, K., Bielska-lasota, M., Kwiatkowska, K., Forjaz, G., Rego, R., Bastos, J., Silva, M., Antunes, L., Bento, M., Mayer-da-silva, A., Miranda, A., Coza, D., Todescu, A., Valkov, M., Adamcik, J., Safaei Diba, C., Primic-žakelj, M., Žagar, T., Stare, J., Almar, E., Mateos, A., Quirós, J., Bidaurrazaga, J., Larrañaga, N., Díaz García, J., Marcos, A., Marcos-gragera, R., Vilardell Gil, M., Molina, E., Sánchez, M., Franch Sureda, P., Ramos Montserrat, M., Navarro, C., Ardanaz, E., Moreno-iribas, C., Fernández-delgado, R., Peris-bonet, R., Galceran, J., Khan, S., Lambe, M., Camey, B., Bouchardy, C., Usel, M., Ess, S., Herrmann, C., Bulliard, J., Maspoli-conconi, M., Frick, H., Kuehni, C., Schindler, M., Bordoni, A., Spitale, A., Chiolero, A., Konzelmann, I., Dehler, S., Matthes, K., Rashbass, J., Stiller, C., Fitzpatrick, D., Gavin, A., Bannon, F., Black, R., Brewster, D., Huws, D., White, C., Finan, P., Bonaventure, A., Di Carlo, V., Harewood, R., Liu, K., Montel, L., Nikšić, M., Rachet, B., Sanz, N., Spika, D., Stephens, R., Peake, M., Chalker, E., Newman, L., Baker, D., Soeberg, M., Aitken, J., Scott, C., Stokes, B., Venn, A., Farrugia, H., Giles, G., Threlfall, T., Currow, D., You, H., Hendrix, J., Lewis, C., Matz, M, Coleman, M, Carreira, H, Salmeròn, D, Chirlaque, M, Allemani, C, and Mazzucco, W
Subjects: 0301 basic medicine, Oncology, Settore MED/42 - Igiene Generale E Applicata, 0302 clinical medicine, morphology, 80 and over, Stage (cooking), Aged, 80 and over, Ovarian Neoplasms, education.field_of_study, epidemiology, histology, ovarian cancer, stage, survival, Adolescent, Adult, Aged, Female, Humans, Middle Aged, Neoplasm Staging, Obstetrics and Gynecology, Transitional cell carcinoma, 030220 oncology & carcinogenesis, Clear cell carcinoma, Human, medicine.medical_specialty, Population, Socio-culturale, Article, 03 medical and health sciences, Internal medicine, medicine, ovarian cancer, epidemiology, survival, stage, morphology, histology, education, Cancer staging, Gynecology, business.industry, Ovarian Neoplasm, Cancer, medicine.disease, Cancer registry, 030104 developmental biology, Ovarian cancer, business
Abstract: Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15–99years) diagnosed with ovarian cancer during 1995–2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-specific morphology, and estimated age-standardised 5-year net survival for each country by histological group. We also analysed data from 67 cancer registries for 233,659 women diagnosed from 2001 to 2009, for whom information on stage at diagnosis was available. We estimated age-standardised 5-year net survival by stage at diagnosis (localised or advanced). Results Survival from type I epithelial ovarian tumours for women diagnosed during 2005–09 ranged from 40 to 70%. Survival from type II epithelial tumours was much lower (20–45%). Survival from germ cell tumours was higher than that of type II epithelial tumours, but also varied widely between countries. Survival for sex-cord stromal tumours was higher than for the five other groups. Survival from localised tumours was much higher than for advanced disease (80% vs. 30%). Conclusions There is wide variation in survival between histological groups, and stage at diagnosis remains an important factor in ovarian cancer survival. International comparisons of ovarian cancer survival should incorporate histology.
Published: 2017

4. Data quality in rare cancers registraton: The report of the RARECARE data quality study

Author: Trama, A., Marcos-Gragera, R., Perez, M. J. S., van der Zwan, J. M., Ardanaz, E., Bouchardy, C., Melchor, J. M., Martinez, C., Capocaccia, R., Vicentini, M., Siesling, S., Gatta, G., Zielonk, N., Van Eycken, E., Henau, K., Magi, M., Bouvier, A. M., Jooste, V., Faivre, J., Maynadie, M., Manivet, I., Comber, H., Deady, S., Bellu, F., Dal Cappello, T., Ferretti, S., Vercelli, M., Quaglia, A., Federico, M., Cirilli, C., Fusco, M., Michiara, M., Sgargi, P., Giacomin, A., Tumino, R., Cilia, S., Spata, E., Mangone, L., Cinzia, S., Falcini, F., Giorgetti, S., Piffer, S., Franchini, S., Crocetti, E., Caldarella, A., Tagliabue, G., Zambon, P., Fiore, A. R., Dei Tos, A. P., De Angelis, R., England, K., Gozdz, S., Mezyk, R., Zwierko, M., Bielska-Lasota, M., Slowinski, J., Primic-Zakelj, M., Skrlec, F., Mateos, A., Bidaurrazaga, J., Galceran, J., Diaz Garcia, J. M., Martinez-Garcia, C., Sanchez Perez, M. J., Adolfsson, J., Usel, M., Ess, S. M., Spitale, A., Bordoni, A., Konzelmann, I., Visser, O., Otter, R., and Health Technology & Services Research
Subjects: 0301 basic medicine, Male, Cancer Research, medicine.medical_specialty, media_common.quotation_subject, Data quality registraton, Populaton-based cancer registry, Rare cancers, Europe, Female, Humans, Neoplasms, Rare Diseases, Data Accuracy, Registries, 03 medical and health sciences, 0302 clinical medicine, Data accuracy, medicine, Medical physics, Quality (business), media_common, ddc:613, Gynecology, business.industry, Cancer, General Medicine, medicine.disease, 22/4 OA procedure, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Data quality, business
Abstract: Purpose Rare cancers represent 22% of all tumors in Europe; however, the quality of the data of rare cancers may not be as good as the quality of data for common cancer. The project surveillance of rare cancers in Europe (RARECARE) had, among others, the objective of assessing rare cancer data quality in population-based cancer registries (CRs). Eight rare cancers were considered: mesothelioma, liver angiosarcoma, sarcomas, tumors of oral cavity, CNS tumors, germ cell tumors, leukemia, and malignant digestive endocrine tumors. Methods We selected data on 18,000 diagnoses and revised, on the basis of the pathologic and clinical reports (but not on pathologic specimens), unspecified morphology and topography codes originally attributed by CR officers and checked the quality of follow-up of long-term survivors of poor prognosis cancers. Results A total of 38 CRs contributed from 13 European countries. The majority of unspecified morphology and topography cases were confirmed as unspecified. The few unspecified cases that, after the review, changed to a more specific diagnosis increased the incidence of the common cancer histotypes. For example, 11% of the oral cavity epithelial cancers were reclassified from unspecified to more specific diagnoses: 8% were reclassified as squamous cell carcinoma (commoner) and only 1% as adenocarcinoma (rarer). The revision confirmed the majority of long-term survivors revealing a relative high proportion of mesothelioma long-term survivors. The majority of appendix carcinoids changed behavior from malignant to borderline lesions. Conclusions Our study suggests that the problem of poorly specified morphology and topography cases is mainly one of difficulty in reaching a precise diagnosis. The awareness of the importance of data quality for rare cancers should increase among registrars, pathologists, and clinicians.
Published: 2017

5. Adherence to predefined dietary patterns and incident type 2 diabetes in European populations: EPIC-InterAct Study

Author: Kroeger, J, Schulze, MB, Romaguera, D, Guevara, M, Buijsse, B, Boeing, H, Beulens, JWJ, Feskens, EJM, Amiano, P, Ardanaz, E, Agnoli, C, Buckland, G, Clavel-Chapelon, F, Dahm, CC, Fagherazzi, G, Franks, PW, Kaaks, R, Key, TJ, Khaw, KT, Lajous, M, Mattiello, A, Menendez Garcia, V, Navarro, C, Nilsson, PM, Overvad, K, Palli, D, Ricceri, F, Rolandsson, O, Sanchez, M-J, Slimani, N, Spijkerman, AMW, Tjonneland, A, Tumino, R, van der A, DL, Langenberg, C, Sharp, SJ, Forouhi, NG, Riboli, E, Wareham, NJ, and Consortium, I
Subjects: Male, Questionnaires, Health Knowledge, Attitudes, Practice, Nutrition and Disease, Mediterranean diet, Endocrinology, Diabetes and Metabolism, Carbonated Beverages, Type 2 diabetes, Alternative Healthy Eating Index, Risk Factors, Voeding en Ziekte, Surveys and Questionnaires, Vegetables, Medicine, Prospective Studies, Dietary patterns, physical-activity, risk-factors, quality index, Incidence, Reduced rank regression, Middle Aged, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Europe, nutrition, Female, Dietary Proteins, Adult, medicine.medical_specialty, DASH diet, European Continental Ancestry Group, Case-cohort, Diet Surveys, Article, White People, dash diet, insulin-resistance, Beverages, Insulin resistance, Internal medicine, Diabetes mellitus, Dash, Internal Medicine, cancer, Humans, Refined grains, VLAG, Aged, business.industry, mediterranean diet, Feeding Behavior, fatty-acids, medicine.disease, Dietary Fats, Diet, Endocrinology, Diabetes Mellitus, Type 2, Case-Control Studies, Fruit, Sweetening Agents, Dairy Products, Food Habits, Energy Intake, business, chronic disease, Risk Reduction Behavior, Dietary Approaches to Stop Hypertension, Demography
Abstract: Aims/hypothesis Few studies have investigated the relationship between predefined dietary patterns and type 2 diabetes incidence; little is known about the generalisability of these associations. We aimed to assess the association between predefined dietary patterns and type 2 diabetes risk in European populations. Methods From among a case-cohort of 12,403 incident diabetes cases and 16,154 subcohort members nested within the prospective European Prospective Investigation into Cancer and Nutrition study, we used data on 9,682 cases and 12,595 subcohort participants from seven countries. Habitual dietary intake was assessed at baseline with country-specific dietary questionnaires. Two diet-quality scores (alternative Healthy Eating Index [aHEI], Dietary Approaches to Stop Hypertension [DASH] score) and three reduced rank regression (RRR)-derived dietary-pattern scores were constructed. Country-specific HRs were calculated and combined using a random-effects meta-analysis. Results After multivariable adjustment, including body size, the aHEI and DASH scores were not significantly associated with diabetes, although for the aHEI there was a tendency towards an inverse association in countries with higher mean age. We observed inverse associations of the three RRR-derived dietary-pattern scores with diabetes: HRs (95% CIs) for a 1-SD difference were 0.91 (0.86, 0.96), 0.92 (0.84, 1.01) and 0.87 (0.82, 0.92). Random-effects meta-analyses revealed heterogeneity between countries that was explainable by differences in the age of participants or the distribution of dietary intake. Conclusions/interpretation Adherence to specific RRR-derived dietary patterns, commonly characterised by high intake of fruits or vegetables and low intake of processed meat, sugar-sweetened beverages and refined grains, may lower type 2 diabetes risk. Electronic supplementary material The online version of this article (doi:10.1007/s00125-013-3092-9) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
Published: 2013

6. Alcohol drinking and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study

Author: Fedirko, V, Jenab, M, Rinaldi, S, Biessy, C, Allen, NE, Dossus, L, Onland-Moret, NC, Schütze, M, Tjønneland, A, Hansen, L, Overvad, K, Clavel-Chapelon, F, Chabbert-Buffet, N, Kaaks, R, Lukanova, A, Bergmann, MM, Boeing, H, Trichopoulou, A, Oustoglou, E, Barbitsioti, A, Saieva, C, Tagliabue, G, Galasso, R, Tumino, R, Sacerdote, C, Peeters, PH, Bueno-de-Mesquita, HB, Weiderpass, E, Gram, IT, Sanchez, S, Duell, EJ, Molina-Montes, E, Arriola, L, Chirlaque, MD, Ardanaz, E, Manjer, J, Lundin, E, Idahl, A, Khaw, KT, Romaguera-Bosch, D, Wark, PA, Norat, T, and Romieu, I
Subjects: Adult, Oncology, medicine.medical_specialty, Alcohol Drinking, Epidemiology, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Surveys and Questionnaires, Internal medicine, Confidence Intervals, Odds Ratio, Humans, Medicine, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, Life Style, Aged, Proportional Hazards Models, Gynecology, business.industry, Proportional hazards model, Alcoholic Beverages, Incidence, Incidence (epidemiology), Endometrial cancer, Odds ratio, Middle Aged, medicine.disease, Endometrial Neoplasms, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Europe, Socioeconomic Factors, 030220 oncology & carcinogenesis, Female, business, Hormone, Cohort study
Abstract: Purpose: Alcohol intake may adversely affect the concentrations of endogenous sex hormones, and thus increase the risk of endometrial cancer. However, epidemiologic studies have provided conflicting results. Therefore, we investigated the association between alcohol intake and endometrial cancer risk a large, multicenter, prospective study. Methods: From 1992 through 2010, 301,051 women in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort were followed for incident endometrial cancer (n = 1382). Baseline alcohol consumption was assessed by country-specific, validated dietary questionnaires. Information on past alcohol consumption was collected by lifestyle questionnaires. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated from Cox proportional hazard models. Results: The multivariable HRs (and 95% CIs) compared with light drinkers (0.1-6 g/d) were 1.03 (0.88-1.20) for 0 g of alcohol per day at baseline, 1.01 (0.86-1.17) for 6.1-12 g/d, 1.03 (0.87-1.22) for 12.1-24 g/d, 1.07 (0.87-1.38) for 24.1-36 g/d, and 0.85 (0.61-1.18) for more than 36 g/d (ptrend = 0.77). No association was observed among former drinkers (OR, 1.28; 95% CI, 0.98-1.68 compared with light drinkers). Null associations were also found between alcohol consumption at age 20 years, lifetime pattern of alcohol drinking, and baseline alcohol intake from specific alcoholic beverages and endometrial cancer risk. Conclusions: Our findings suggest no association between alcohol intake and endometrial cancer risk. © 2013 Elsevier Inc.
Published: 2016

7. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study

Author: De Angelis R, Sant M, Coleman, Mp, Francisci, S, Baili, P, Pierannunzio, D, Trama, A, Visser, O, Brenner, H, Ardanaz, E, Bielska Lasota, M, Engholm, G, Nennecke, A, Siesling, S, Berrino, F, Capocaccia R. Hackl, M, Zielonke, N, Oberaigner, W, Henau, K, Van Eycken, E, Dimitrova, N, Valerianova, Z, Znaor, A, Dušek, L, Zvolský, M, Storm, H, Mägi, M, Aareleid, T, Malila, N, Seppä, K, Velten, M, Belot, A, Troussard, X, Launoy, G, Guizard, A, Bouvier, A, Faivre, J, Arveux, P, Maynadié, M, Woronoff, A, Robaszkiewicz, M, Baldi, I, Monnereau, A, Tretarre, B, Bossard, N, Estève, J, Colonna, M, Molinié, F, Bara, S, Schvartz, C, Lapôtre Ledoux, B, Grosclaude, P, Meyer, M, Stabenow, R, Eberle, A, Luttmann, S, Engel, J, Schubert Fritschle, G, Kieschke, J, Batzler, W, Holleczek, B, Katalinic, A, Jónasson, J, Tryggvadóttir, L, Comber, H, Bulatko, A, Mazzoleni, G, Buzzoni, C, Giacomin, A, Mancuso, P, Sardo, A, Ferretti, S, Caldarella, A, Crocetti, E, Amati, C, Bonfarnuzzo, S, Botta, L, Foschi, R, Gatta, G, Margutti, C, Minicozzi, P, Sant, M, Tereanu, C, Dal Maso, L, Serraino, D, Caldora, M, Capocaccia, R, Carrani, E, De Angelis, R, Mallone, S, Roazzi, P, Rossi, S, Santaquilani, M, Tavilla, A, Busco, S, Pannozzo, F, Quaglia, A, Vercelli, M, Gennaro, V, Ricci, P, Bisanti, L, Randi, G, PONZ DE LEON, Maurizio, Federico, Massimo, Fusco, M, Vitale, M, Usala, M, Traina, A, Zarcone, M, Cusimano, R, Vitale, F, Michiara, M, Tumino, R, Di Felice, E, Rossi, P, Falcini, F, Iannelli, A, Budroni, M, Sechi, O, Piffer, S, Madeddu, A, Tisano, F, Fanetti, A, Tessandori, R, Rosso, S, Zanetti, R, Candela, P, Scuderi, T, Bianconi, F, La Rosa, F, Contiero, P, Tagliabue, G, Guzzinati, S, Zambon, P, Pildava, S, Smailyte, G, Agius, D, Micallef, R, Johannesen, T, Góźdź, S, Mężyk, R, Rachtan, J, Bębenek, M, Błaszczyk, J, Forjaz de Lacerda, G, Antunes, L, Bento, M, Mayer da Silva, A, Miranda, A, Coza, D, Nicula, F, Diba, C, Primic Zakelj, M, Almar, E, Mateos, A, Bidaurrazaga, J, Larrañaga, N, Torrella Ramos, A, Díaz García, J, Jimenez Chillaron, R, Izquierdo Font, A, Marcos Gragera, R, Martinez, C, Sanchez, M, Chirlaque, M, Navarro, C, Moreno Iribas, C, García, S, Peris Bonet, R, Carulla, M, Galceran, J, Khan, S, Lambe, M, Jundt, G, Bouchardy, C, Usel, M, Frick, H, Lorez, M, Ess, S, Herrmann, C, Bordoni, A, Spitale, A, Konzelmann, I, Lutz, J, Coebergh, J, Lemmens, V, Aben, K, Otter, R, Allemani, C, Coleman, M, Rachet, B, Davies, E, Easey, N, Lawrence, G, Meechan, D, Moran, T, Rashbass, J, Roche, M, Verne, J, Wilkinson, J, Bannon, F, Gavin, A, Brewster, D, Reynolds, S., Faculty of Behavioural, Management and Social Sciences, De Angelis, R, Sant, M, Coleman, M, Francisci, S, Baili, P, Pierannunzio, D, Trama, A, Visser, O, Brenner, H, Ardanaz, E, Bielska Lasota, M, Engholm, G, Nennecke, A, Siesling, S, Berrino, F, Capocaccia, R, Vitale, F., Bouchardy Magnin, Christine, and Usel, Massimo
Subjects: Gerontology, Adult, Male, Time Factors, Adolescent, Colorectal cancer, Population, Settore MED/42 - Igiene Generale E Applicata, IR-88481, NO, Prostate cancer, Breast cancer, METIS-300341, Neoplasms, medicine, Humans, Lung cancer, education, Age Factors, Aged, Europe, Female, Middle Aged, Retrospective Studies, ddc:613, education.field_of_study, Relative survival, business.industry, Oncology, cancer survival, eurocare, Cancer, Retrospective cohort study, cancer survival, age, country, Eurocare 5, medicine.disease, Cancer survival, Oncology, Neoplasms/mortality, business, Demography
Abstract: Background: Cancer survival is a key measure of the effectiveness of health-care systems. EUROCARE-the largest cooperative study of population-based cancer survival in Europe-has shown persistent differences between countries for cancer survival, although in general, cancer survival is improving. Major changes in cancer diagnosis, treatment, and rehabilitation occurred in the early 2000s. EUROCARE-5 assesses their effect on cancer survival in 29 European countries. Methods: In this retrospective observational study, we analysed data from 107 cancer registries for more than 10 million patients with cancer diagnosed up to 2007 and followed up to 2008. Uniform quality control procedures were applied to all datasets. For patients diagnosed 2000-07, we calculated 5-year relative survival for 46 cancers weighted by age and country. We also calculated country-specific and age-specific survival for ten common cancers, together with survival differences between time periods (for 1999-2001, 2002-04, and 2005-07). Findings: 5-year relative survival generally increased steadily over time for all European regions. The largest increases from 1999-2001 to 2005-07 were for prostate cancer (73·4% [95% CI 72·9-73·9] vs 81·7% [81·3-82·1]), non-Hodgkin lymphoma (53·8% [53·3-54·4] vs 60·4% [60·0-60·9]), and rectal cancer (52·1% [51·6-52·6] vs 57·6% [57·1-58·1]). Survival in eastern Europe was generally low and below the European mean, particularly for cancers with good or intermediate prognosis. Survival was highest for northern, central, and southern Europe. Survival in the UK and Ireland was intermediate for rectal cancer, breast cancer, prostate cancer, skin melanoma, and non-Hodgkin lymphoma, but low for kidney, stomach, ovarian, colon, and lung cancers. Survival for lung cancer in the UK and Ireland was much lower than for other regions for all periods, although results for lung cancer in some regions (central and eastern Europe) might be affected by overestimation. Survival usually decreased with age, although to different degrees depending on region and cancer type. Interpretation: The major advances in cancer management that occurred up to 2007 seem to have resulted in improved survival in Europe. Likely explanations of differences in survival between countries include: differences in stage at diagnosis and accessibility to good care, different diagnostic intensity and screening approaches, and differences in cancer biology. Variations in socioeconomic, lifestyle, and general health between populations might also have a role. Further studies are needed to fully interpret these findings and how to remedy disparities. Funding: Italian Ministry of Health, European Commission, Compagnia di San Paolo Foundation, Cariplo Foundation. © 2014 Elsevier Ltd.
Published: 2014

8. Lung cancer susceptibility locus at 5p15.33

Author: McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, Zaridze D, Mukeria A, Szeszenia Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, McLaughlin J, Shepherd F, Montpetit A, Narod S, Krokan HE, Skorpen F, Elvestad MB, Vatten L, Njølstad I, Axelsson T, Chen C, Goodman G, Barnett M, Loomis MM, Lubiñski J, Matyjasik J, Lener M, Oszutowska D, Field J, Liloglou T, Xinarianos G, Cassidy A, EPIC Study, Vineis P, Clavel Chapelon F, Palli D, Tumino R, Krogh V, González CA, Ramón Quirós J, Martínez C, Navarro C, Ardanaz E, Larrañaga N, Kham KT, Key T, Bueno de Mesquita HB, Peeters PH, Trichopoulou A, Linseisen J, Boeing H, Hallmans G, Overvad K, Tjønneland A, Kumle M, Riboli E, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Matsuda F, Blanche H, Gut I, Heath S, Lathrop M, Brennan P., PANICO, SALVATORE, McKay, J.D., Hung, R.J., Gaborieau, V., Boffetta, P., Chabrier, A., Byrnes, G., Zaridze, D., Mukeria, A., Szeszenia-Dabrowska, N., Lissowska, J., Rudnai, P., Fabianova, E., Mates, D., Bencko, V., Foretova, L., Janout, V., McLaughlin, J., Shepherd, F., Montpetit, A., Narod, S., Krokan, H.E., Skorpen, F., Elvestad, M.B., Vatten, L., Njølstad, I., Axelsson, T., Chen, C., Goodman, G., Barnett, M., Loomis, M.M., Lubiski, J., Matyjasik, J., Lener, M., Oszutowska, D., Field, J., Liloglou, T., Xinarianos, G., Cassidy, A., Zelenika, D., Boland, A., Delepine, M., Foglio, M., Lechner, D., Matsuda, F., Blanche, H., Gut, I., Heath, S., Lathrop, M., Brennan, P., Vineis, P., Clavel-Chapelon, F., Palli, D., Tumino, R., Krogh, V., Panico, S., González, C.A., Ramón Quirós, J., Martínez, C., Navarro, C., Ardanaz, E., Larrãaga, N., Kham, K.T., Key, T., Bueno-De-Mesquita, H.B., Peeters, P.H.M., Trichopoulou, A., Linseisen, J., Boeing, H., Hallmans, G., Overvad, K., Tjønneland, A., Kumle, M., Riboli, E., Mckay, Jd, Hung, Rj, Gaborieau, V, Boffetta, P, Chabrier, A, Byrnes, G, Zaridze, D, Mukeria, A, Szeszenia Dabrowska, N, Lissowska, J, Rudnai, P, Fabianova, E, Mates, D, Bencko, V, Foretova, L, Janout, V, Mclaughlin, J, Shepherd, F, Montpetit, A, Narod, S, Krokan, He, Skorpen, F, Elvestad, Mb, Vatten, L, Njølstad, I, Axelsson, T, Chen, C, Goodman, G, Barnett, M, Loomis, Mm, Lubiñski, J, Matyjasik, J, Lener, M, Oszutowska, D, Field, J, Liloglou, T, Xinarianos, G, Cassidy, A, Epic, Study, Vineis, P, Clavel Chapelon, F, Palli, D, Tumino, R, Krogh, V, Panico, Salvatore, González, Ca, Ramón Quirós, J, Martínez, C, Navarro, C, Ardanaz, E, Larrañaga, N, Kham, Kt, Key, T, Bueno de Mesquita, Hb, Peeters, Ph, Trichopoulou, A, Linseisen, J, Boeing, H, Hallmans, G, Overvad, K, Tjønneland, A, Kumle, M, Riboli, E, Zelenika, D, Boland, A, Delepine, M, Foglio, M, Lechner, D, Matsuda, F, Blanche, H, Gut, I, Heath, S, and Lathrop, M
Subjects: Lung Neoplasms, Locus (genetics), Genome-wide association study, Apoptosis, Biology, Article, Genetics, medicine, Humans, Genetic Predisposition to Disease, Lung cancer, Gene, Telomerase, Principal Component Analysis, Respiratory disease, Smoking, Case-control study, Cancer, Membrane Proteins, medicine.disease, Lung cancer susceptibility, Molecular biology, Neoplasm Proteins, Case-Control Studies, Immunology, Chromosomes, Human, Pair 5, Genome-Wide Association Study
Abstract: We carried out a genome-wide association study of lung cancer (3,259 cases and 4,159 controls), followed by replication in 2,899 cases and 5,573 controls. Two uncorrelated disease markers at 5p15.33, rs402710 and rs2736100 were detected by the genome-wide data (P = 2 × 10-7 and P = 4 × 10-6) and replicated by the independent study series (P = 7 × 10-5 and P = 0.016). The susceptibility region contains two genes, TERT and CLPTM1L, suggesting that one or both may have a role in lung cancer etiology. © 2008 Nature Publishing Group.
Published: 2008

9. The advantage of women in cancer survival: An analysis of EUROCARE-4 data

Author: Micheli, A., Ciampichini, R., Oberaigner, W., Ciccolallo, L., de Vries, E., Izarzugaza, I., Zambon, P., Gatta, G., De Angelis, R., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hedelin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadie, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Molinie, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., D. e. Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Patriarca, S., Zanetti, R., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gozdz, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Zakelj, M., Mateos, A., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sanchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talback, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Basque Country Cancer Registry, Vitoria-Gasteiz, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and Public Health
Subjects: Oncology, Male, Pathology, Cancer Research, cancer survival - women, MESH : Age Distribution, MESH : Aged, MESH: Risk Assessment, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Residence Characteristics, Neoplasms, 80 and over, Gender differences, Sex hormones, MESH: Neoplasms, MESH : Female, MESH: Residence Characteristics, Young adult, Age of Onset, MESH : Risk Assessment, MESH : Sex Distribution, MESH: Diagnosis-Related Groups, MESH: Aged, Aged, 80 and over, 0303 health sciences, education.field_of_study, MESH: Middle Aged, Relative survival, Thyroid, MESH: Sex Distribution, Middle Aged, MESH : Adult, 3. Good health, MESH : Age of Onset, Europe, MESH : Diagnosis-Related Groups, medicine.anatomical_structure, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH : Residence Characteristics, Female, EUROCARE, Adult, medicine.medical_specialty, Adolescent, MESH: Age of Onset, MESH : Male, MESH : Sex Factors, Population, MESH : Europe, MESH : Young Adult, Rectum, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, Risk Assessment, 03 medical and health sciences, Young Adult, Age Distribution, Sex Factors, MESH: Sex Factors, SDG 3 - Good Health and Well-being, Internal medicine, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, Sex Distribution, education, MESH : Aged, 80 and over, MESH: Age Distribution, Survival analysis, Diagnosis-Related Groups, 030304 developmental biology, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, Cancer survival, Survival Analysis, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, MESH: Europe, Age of onset, MESH : Survival Analysis, business, MESH: Female
Abstract: We analysed 1.6 million population-based EUROCARE-4 cancer cases (26 cancer sites, excluding sex-specific sites, and breast) from 23 countries to investigate the role of sex in cancer survival according to age at diagnosis, site, and European region. For 15 sites (salivary glands, head and neck, oesophagus, stomach, colon and rectum, pancreas, lung, pleura, bone, melanoma of skin, kidney, brain, thyroid, Hodgkin disease and non-Hodgkin's lymphoma) age- and region-adjusted relative survival was significantly higher in women than men. By multivariable analysis, women had significantly lower relative excess risk (RER) of death for the sites listed above plus multiple myeloma. Women significantly had higher RER of death for biliary tract, bladder and leukaemia. For all cancers combined women had a significant 5% lower RER of death. Age at diagnosis was the main determinant of the women's advantage, which, however, decreased with increasing age, becoming negligible in the elderly, suggesting that sex hormone patterns may have a role in women's superior ability to cope with cancer. (C) 2008 Elsevier Ltd. All rights reserved.
Published: 2009

10. Dietary glycemic index, glycemic load, and digestible carbohydrate intake are not associated with risk op type 2 diabetes in eight European countries

Author: Sluijs I, Beulens JW, van der Schouw YT, van der A. DL, Buckland G, Kuijsten A, Schulze MB, Amiano P, Ardanaz E, Balkau B, Boeing H, Gavrila D, Grote VA, Key TJ, Li K, Nilsson P, Overvad K, Palli D, Quir?s JR, Rolandsson O, Roswall N, Sacerdote C, S?nchez MJ, Sieri S, Slimani N, Spijkerman AM, Tj?nneland A, Tumino R, Sharp SJ, Langenberg C, Feskens EJ, Forouhi NG, Riboli E, Wareham NJ, InterAct consortium, PANICO, SALVATORE, Epidemiology and Data Science, ACS - Diabetes & metabolism, ACS - Heart failure & arrhythmias, APH - Health Behaviors & Chronic Diseases, Sluijs, I, Beulens, Jw, van der Schouw, Yt, van der A., Dl, Buckland, G, Kuijsten, A, Schulze, Mb, Amiano, P, Ardanaz, E, Balkau, B, Boeing, H, Gavrila, D, Grote, Va, Key, Tj, Li, K, Nilsson, P, Overvad, K, Palli, D, Panico, Salvatore, Quir?s, Jr, Rolandsson, O, Roswall, N, Sacerdote, C, S?nchez, Mj, Sieri, S, Slimani, N, Spijkerman, Am, Tj?nneland, A, Tumino, R, Sharp, Sj, Langenberg, C, Feskens, Ej, Forouhi, Ng, Riboli, E, Wareham, Nj, and Interact, Consortium
Subjects: Male, Nutrition and Disease, Medicine (miscellaneous), Type 2 diabetes, Gastroenterology, Cohort Studies, prevention, Risk Factors, Surveys and Questionnaires, Voeding en Ziekte, Medicine, Prospective Studies, Nutrition and Dietetics, cohort, Middle Aged, European Prospective Investigation into Cancer and Nutrition, Europe, Glycemic index, nutrition, Population study, Digestion, Female, women, Adult, medicine.medical_specialty, Diabetes risk, life-style, Diabetes mellitus, Internal medicine, Glycemic load, Dietary Carbohydrates, Humans, cancer, Aged, VLAG, Global Nutrition, Wereldvoeding, disease, business.industry, Case-control study, Reproducibility of Results, fiber intake, medicine.disease, Diet, Endocrinology, Diabetes Mellitus, Type 2, Food, Glycemic Index, Case-Control Studies, business, energy-intake, human activities, Follow-Up Studies, mellitus
Abstract: The association of glycemic index (GI) and glycemic load (GL) with the risk of type 2 diabetes remains unclear. We investigated associations of dietary GI, GL, and digestible carbohydrate with incident type 2 diabetes. We performed a case-cohort study nested within the European Prospective Investigation into Cancer and Nutrition Study, including a random subcohort (n = 16,835) and incident type 2 diabetes cases (n = 12,403). The median follow-up time was 12 y. Baseline dietary intakes were assessed using country-specific dietary questionnaires. Country-specific HR were calculated and pooled using random effects meta-analysis. Dietary GI, GL, and digestible carbohydrate in the subcohort were (mean +/- SD) 56 +/- 4, 127 +/- 23, and 226 +/- 36 g/d, respectively. After adjustment for confounders, GI and GL were not associated with incident diabetes [HR highest vs. lowest quartile (HRQ4) for GI: 1.05 (95% CI = 0.96, 1.16); HRQ4 for GL: 1.07 (95% CI = 0.95, 1.20)]. Digestible carbohydrate intake was not associated with incident diabetes [HRQ4: 0.98(95% CI = 0.86, 1.10)]. In additional analyses, we found that discrepancies in the GI value assignment to foods possibly explain differences in GI associations with diabetes within the same study population. In conclusion, an expansion of the GI tables and systematic GI value assignment to foods may be needed to improve the validity of GI values derived in such studies, after which GI associations may need reevaluation. Our study shows that digestible carbohydrate intake is not associated with diabetes risk and suggests that diabetes risk with high-GI and -GL diets may be more modest than initial studies suggested. J. Nutr. 143: 93-99, 2013.
Published: 2013

11. The prospective association between total and type of fish intake and type 2 diabetes in 8 European countries: EPIC-InterAct Study

Author: Patel PS, Forouhi NG, Kuijsten A, Schulze MB, van Woudenbergh GJ, Ardanaz E, Amiano P, Arriola L, Balkau B, Barricarte A, Beulens JW, Boeing H, Buijsse B, Crowe FL, de Lauzon Guillan B, Fagherazzi G, Franks PW, Gonzalez C, Grioni S, Halkjaer J, Huerta JM, Key TJ, K?hn T, Masala G, Nilsson P, Overvad K, Quir?s JR, Rolandsson O, Sacerdote C, S?nchez MJ, Schmidt EB, Slimani N, Spijkerman AM, Teucher B, Tjonneland A, Tormo MJ, Tumino R, van der A. DL, van der Schouw YT, Sharp SJ, Langenberg C, Feskens EJ, Riboli E, Wareham NJ, InterAct Consortium, PANICO, SALVATORE, Patel, P, Forouhi, Ng, Kuijsten, A, Schulze, Mb, van Woudenbergh, Gj, Ardanaz, E, Amiano, P, Arriola, L, Balkau, B, Barricarte, A, Beulens, Jw, Boeing, H, Buijsse, B, Crowe, Fl, de Lauzon Guillan, B, Fagherazzi, G, Franks, Pw, Gonzalez, C, Grioni, S, Halkjaer, J, Huerta, Jm, Key, Tj, K?hn, T, Masala, G, Nilsson, P, Overvad, K, Panico, Salvatore, Quir?s, Jr, Rolandsson, O, Sacerdote, C, S?nchez, Mj, Schmidt, Eb, Slimani, N, Spijkerman, Am, Teucher, B, Tjonneland, A, Tormo, Mj, Tumino, R, van der A., Dl, van der Schouw, Yt, Sharp, Sj, Langenberg, C, Feskens, Ej, Riboli, E, Wareham, Nj, Interact, Consortium, Epidemiology and Data Science, ACS - Diabetes & metabolism, ACS - Heart failure & arrhythmias, and APH - Health Behaviors & Chronic Diseases
Subjects: Adult, Male, validity, Nutrition and Disease, design, Medicine (miscellaneous), Type 2 diabetes, project, Diabetes mellitus, Environmental health, Voeding en Ziekte, Fatty Acids, Omega-3, Animals, Humans, Medicine, cancer, Prospective Studies, Food science, consumption, Prospective cohort study, omega-3-fatty-acids, Shellfish, Proportional Hazards Models, VLAG, risk, Nutrition and Dietetics, Proportional hazards model, business.industry, Incidence, Incidence (epidemiology), Fishes, Middle Aged, medicine.disease, calibration, Dietary Fats, Diet, European Prospective Investigation into Cancer and Nutrition, Europe, nutrition, Diabetes Mellitus, Type 2, Seafood, Quartile, Female, Energy Intake, business, Follow-Up Studies, mellitus
Abstract: Background: Epidemiologic evidence of an association between fish intake and type 2 diabetes (T2D) is inconsistent and unresolved. Objective: The objective was to examine the association between total and type of fish intake and T2D in 8 European countries. Design: This was a case-cohort study, nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) study, with 3.99 million person-years of follow-up, 12,403 incident diabetes cases, and a random subcohort of 16,835 individuals from 8 European countries. Habitual fish intake (lean fish, fatty fish, total fish, shellfish, and combined fish and shellfish) was assessed by country-specific dietary questionnaires. HRs were estimated in each country by using Prentice-weighted Cox regression models and pooled by using a random-effects meta-analysis. Results: No overall association was found between combined fish and shellfish intake and incident T2D per quartile (adjusted HR: 1.00; 95% Cl: 0.94, 1.06; P-trend = 0.99). Total fish, lean fish, and shellfish intakes separately were also not associated with T2D, but fatty fish intake was weakly inversely associated with T2D: adjusted HR per quartile 0.97 (0.94, 1.00), with an HR of 0.84 (0.70, 1.01), 0.85 (0.76, 0.95), and 0.87 (0.78, 0.97) for a comparison of the second, third, and fourth quartiles with the lowest quartile of intake, respectively (P-trend = 0.06). Conclusions: These findings suggest that lean fish, total fish, and shellfish intakes are not associated with incident diabetes but that fatty fish intake may be weakly inversely associated. Replication of these findings in other populations and investigation of the mechanisms underlying these associations are warranted. Meanwhile, current public health recommendations on fish intake should remain unchanged. Am J Clin Nutr 2012;95:1445-53
Published: 2012

12. Childhood cancer survival in Europe

Author: Gatta, G., Corazziari, I., Magnani, C., Peris Bonet, R., Roazzi, P., Stiller, C., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Aareleid, T., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesech, I., Faivre, I., Chaplain, G., Carli, P. M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estève, I., Kaatsch, P., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Micheli, A., Sant, M., Taussig, E., Capocaccia, R., Carrani, E., De Angelis, R., Hartley, S., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Ferretti, S., Crosignani, P., Tagliabue, G., Conti, E., Vercelli, M., Pannelli, F., Mosciatti, P., Federico, Massimo, Artioli, M. E., De Lisi, V., Serventi, L., Pastore, G., Gafà, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Dalmas, M., Langmark, F., Andersen, A, Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pleško, I., Obsitníková, A., Pompe Kirn, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Barlow, L., Möller, T., Lutz, J. M., Usel, M., Coebergh, J. W. W., Van Der Does Van Den Berg, A., Visser, O., Coleman, M. P., Black, R., and Brewster, D.
Subjects: Male, Pediatrics, medicine.medical_specialty, Adolescent, Population, Disease, Malignancy, Childhood Cancer Survival Trends, Neoplasms, medicine, Humans, Child, education, education.field_of_study, business.industry, Incidence (epidemiology), Gold standard, Age Factors, Cancer, Hematology, medicine.disease, Survival Analysis, Childhood tumours, Europe, Population-based study, Survival variation, Lymphoma, Europe, Survival Rate, Oncology, Child, Preschool, Female, Major Diagnostic Category, business
Abstract: BACKGROUND: EUROCARE-3 collected data from 45 population-based cancer registries in 20 countries on 24 620 European children aged from 0 to 14 years diagnosed with malignancy in the period 1990-1994. METHODS: Five-year survival between countries was compared for all malignancies and for the major diagnostic categories, adjusting for age, and estimated average European survival weighting for differences in childhood populations. RESULTS: For all cancers combined, survival variation was large (45% in Estonia to 90% in Iceland), and was generally low (60-70%) in eastern Europe and high (> or =75%) in Switzerland, Germany and the Nordic countries (except Denmark). The Nordic countries had the highest survival for four of the seven major tumour types: nephroblastoma (92%), acute lymphoid leukaemia (85%), CNS tumours (73%) and acute non-lymphocytic leukaemia (62%). The eastern countries had lowest survival: 89% for Hodgkin's disease, 71% for nephroblastoma, 68% for acute lymphoid leukaemia, 61% for non-Hodgkin's lymphoma, 57% for central nervous system (CNS) tumours and 29% for acute non-lymphocytic leukaemia. CONCLUSIONS: The Nordic countries represent a survival gold standard to which other countries can aspire. Since most childhood cancers respond well to treatment, survival differences are attributable to differences in access (including referral and timely diagnosis) and use of modern treatments; however, the obstacles to access and application of standard treatments probably vary markedly with country.
Published: 2003

13. EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary

Author: Sant, M., Aareleid, T., Berrino, F., Bielska Lasota, M., Carli, P. M., Faivre, J., Grosclaude, P., Hédelin, G., Matsuda, T., Møller, H., Möller, T., Verdecchia, A., Capocaccia, R., Gatta, G., Micheli, A., Santaquilani, M., Roazzi, P., Lisi, D., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Hakulinen, T., Tron, I., Le Gall, E., Launoy, G., Macé Lesech, J., Chaplain, G., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Estève, J., Kaatsch, P., Ziegler, H., Hölzel, D., Schubert Fritschle, G., Tryggvadottir, L., Allemani, C., Baili, P., Ciccolallo, L., Taussig, E., Carrani, E., De Angelis, R., Hartley, S., Tavilla, A., Valente, F., Ferretti, S., Crosignani, P., Contiero, P., Conti, E., Vercelli, M., Pannelli, F., Vitarelli, S., Mosciatti, P., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Serventi, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafà, Aw, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Dalmas, M., Langmak, F., Andersen, A., Rachtan, J., Wronkowski, Z., Zwierko, M., Pinheiro, P. S., Pleško, I., Obsitníková, A., Pompe Kirn, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris Bonet, R., Barlow, L., Jundt, G., Lutz, J. M., Usel, M., Coebergr, J. W. W., Van Der Does Van Den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Bell, J., Botha, J. L., Lawrence, G., Black, R., Brewster, D., and Steward, J. A.
Subjects: Male, Urologic Neoplasms, medicine.medical_specialty, Lung Neoplasms, Skin Neoplasms, Genital Neoplasms, Female, Breast Neoplasms, Digestive System Neoplasms, Sex Factors, Case mix index, Testicular Neoplasms, Neoplasms, Internal medicine, Epidemiology, medicine, Humans, Registries, Thyroid Neoplasms, cancer survival, Survival rate, Testicular cancer, Survival analysis, Brain Neoplasms, business.industry, Prostatic Neoplasms, Cancer, Hematology, medicine.disease, Survival Analysis, Age-standardised relative survival, Cancer survival, Europe, International comparison, Population-based cancer registries, Lymphoma, Surgery, Europe, Survival Rate, Oncology, Head and Neck Neoplasms, Hematologic Neoplasms, Female, business
Abstract: EUROCARE-3 analysed the survival of 1815584 adult cancer patients diagnosed from 1990 to 1994 in 22 European countries. The results are reported in tables, one per cancer site, coded according to the International Classification of Diseases (ICD)-9 classification. The main findings of the tables are summarised and commented on in this article. For most solid cancers, wide differences in survival between different European populations were found, as also reported by EUROCARE-1 and EUROCARE-2, despite a remarkable (10%) overall increase in cancer survival from 1985 to 1994. Survival was highest in northern Europe (Sweden, Norway, Finland and Iceland), and fairly good in central-southern Europe (France, Switzerland, Austria and Spain). Survival was particularly low in eastern Europe, low in Denmark and the UK, and fairly low in Portugal and Malta. The mix of tumour stage at diagnosis explains much of the survival differences for cancers of the digestive tract, female reproductive system, breast, thyroid, and also skin melanoma. For tumours of the urinary tract and prostate, the differences were explained mainly by differences in diagnostic criteria and procedures. The case mix by anatomic subsite largely explains differences in survival for head and neck cancers. For oesophagus, pancreas, liver and brain cancer, with poor prognoses, survival differences were limited. Tumours, for which highly effective treatments are available, such as testicular cancer, Hodgkin's lymphoma and some haematological malignancies, had fairly uniform survival across Europe. Survival for all tumours combined (an indicator of the overall cancer care performance of a nation's health system) was better in young than old patients, and better in women than men. The affluence of countries influenced overall cancer survival through the availability of adequate diagnostic and treatment procedures, and screening programmes.
Published: 2003

14. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century

Author: Coleman, M. P., Gatta, G., Verdecchia, A., Estève, J., Sant, M., Storm, H., Allemani, C., Ciccolallo, L., Santaquilani, M., Berrino, F., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Aareleid, T., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesec'h, J., Faivre, J., Chaplain, G., Carl, P. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estèv, Z, Kaatsch, P., Ziegler, H., Hölzel, D., Schubert Fritschle, G., Tryggvadottir, L., Baili, P., Micheli, A., Taussig, E., Capocaccia, R., Carrani, E., De Angelis, R., Hartley, S., Roazzi, P., Tavilla, A., Valente, F., Ferretti, S., Crosignani, P., Contiero, P., Conti, E., Vercelli, M., Pannelli, F., Vitarelli, S., Mosciatti, P., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Serventi, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafà, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P. Guzzinati S., Dalmas, M., Langmark, F., Andersen, A., Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pinheiro, P. S., Pleško, I., Obsitníková, A., Pompe Kirn, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris Bonet, R., Barlow, L., Möller, T., Jundt, G. Lutz J. M., Usel, M., Coebergh, J. W. W., Van Der Does Van Den Berg, A., Visser, O., Godward, S., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Møller, H., Bell, J., Botha, J. L., Lawrence, G., Black, R., Brewster, D., Steward, J. A., Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, [SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT], Pathology, medicine.medical_specialty, population-based cancer registries, Lung Neoplasms, Skin Neoplasms, Population, Uterine Cervical Neoplasms, Breast Neoplasms, Disease, Sex Factors, Testicular Neoplasms, Stomach Neoplasms, Neoplasms, Epidemiology, Health care, Humans, Medicine, Registries, cancer survival, Child, education, Survival rate, Survival analysis, education.field_of_study, business.industry, Age Factors, international comparison, Prostatic Neoplasms, Cancer, Hematology, medicine.disease, Survival Analysis, Cancer survival, Europe, Survival Rate, Oncology, Colonic Neoplasms, Female, Observational study, business, Demography
Abstract: Summary International differences and trends in cancer survival withinEurope are larger than can reasonably be accounted for by arte-fact, bias or chance. The geographical patterns and trends in sur-vival are often broadly consistent with geographical differences ortrends in the type of cancer, diagnostic investigations or overallinvestment in health care, and for several major cancers, support-ing evidence is available from population-based studies of clinicalinformation. Incomplete ascertainment of cancer cases, particu-larly of long-term survivors, may contribute to some regional andinternational differences in survival, however, and more system-atic information on completeness is required. We may concludethat large international differences in survival do exist for manycancers, but we should be cautious in drawing quantitative orcausal conclusions from observational survival data.We do not yet have a fully satisfactory interpretation of thesedifferences, but we have few alternatives to this type of study if weare to understand the determinants of improved outcome for allcancer patients, and to enable better planning of their health care.The EUROCARE Working Group has developed several strategiesto disentangle the various possible explanations [73]. These includefurther development of high-resolution studies to examine theimpact on survival differences of disease stage, staging techniquesand treatment; and further development of mathematical modelsof cure. Extension of systematic international survival compari-sons to other regions of the world, such as Australia, Canada, Japanand the USA, is also in progress (the CONCORD study) [22].Oncologists and epidemiologists may provide insight into thegeographic differences and trends in survival reported by thisstudy, and may suggest further lines of enquiry. Do we need morerefined studies of survival to monitor progress against cancer andto plan future cancer care? Will such analyses help us quantify theeffect of new treatments arising from recent progress in the basicsciences and genomics on population cancer survival rates? Sub-stantial human and financial resources are required to improve theoutcome of cancer treatment. Will future investments in cancerservices include matching investment to monitor their impact onsurvival and mortality?Earlier diagnosis and prompt, universal access to optimal treat-ment would be expected to reduce international differences incancer survival in Europe. To achieve this, oncologists and healthcare planners will need better information on the comparativeperformance of their health systems. Population-based cancer reg-istries provide some of the information for such comparisons, buttheir traditional output may no longer be sufficient to evaluate theeffectiveness of health systems, and especially to explain geo-graphical differences in survival. In some countries, their role isalso under threat. Confidentiality constraints recently inhibitedthe collection of cancer registration data in the UK [90], and thelinkage of cancer registrations and deaths is currently illegal inEstonia [91]. Both activities are essential for internationally com-parable survival rates. Legal protection for cancer registrationacross Europe will be required.The mission of cancer registries should be reconsidered, and thepriority shifted from classical descriptive epidemiology and geo-graphical pathology toward more analytical monitoring ofprogress against cancer, including the probability of survival andcure, the burden of cancer prevalence, and the late effects oftherapy. Several European studies of this type have been reportedrecently [3, 36, 9294] and others are in progress. Many cancer–registries are developing closer relationships with cancer clini-cians and general practitioners, and some now systematicallycollect detailed clinical information that was collected eitherirregularly or not at all in the past. These developments willimprove the power of population-based cancer data to explain dif-ferences in cancer survival, and should enhance their relevance toclinical practice.European average survival rates are useful for comparativepurposes, but they should not become the goal for cancer controlprogrammes: the benchmark should always be the highest achiev-able survival rates.The aim of exploring geographic differences in cancer survivalis not to establish international league tables or to excite nationalrivalries, but to estimate the range of survival rates, and to identifyregions or countries in which survival could be improved.
Published: 2003

15. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

Author: Allemani, Claudia, Weir, Hannah K., Carreira, Helena, Harewood, Rhea, Spika, Devon, Wang, Xiao-Si, Bannon, Finian, Ahn, Jane V, Johnson, Christopher J., Bonaventure, Audrey, Marcos-Gragera, Rafael, Stiller, Charles, Azevedo E Silva, Gulnar, Chen, Wan-Qing, Ogunbiyi, Olufemi J., Rachet, Bernard, Soeberg, Matthew J, You, Hui, Matsuda, Tomohiro, Bielska-Lasota, Magdalena, Storm, Hans, Tucker, Thomas C., Coleman, Michel, P, CONCORD Working Group (Bouzbid, S, Hamdi-Chérif, M, Zaidi, Z, Bah, E, Swaminathan, R, Nortje, Sh, Stefan, Cd, El Mistiri MM, Bayo, S, Malle, B, Manraj, Ss, Sewpaul-Sungkur, R, Fabowale, A, Ogunbiyi, Oj, Bradshaw, D, Somdyala, Ni, Abdel-Rahman, M, Jaidane, L, Mokni, M, Kumcher, I, Moreno, F, González, Ms, Laura, E, Pugh, Fv, Torrent, Me, Carballo Quintero, B, Fita, R, Garcilazo, D, Giacciani, Pl, Diumenjo, Mc, Laspada, Wd, Green, Ma, Lanza, Mf, Ibañez, Sg, Lima, Ca, Lobo, E, Daniel, C, Scandiuzzi, C, De Souza PC, Del Pino, K, Laporte, C, Curado, Mp, de Oliveira JC, Veneziano, Cl, Veneziano, Db, Alexandre, Ts, Verdugo, As, Koifman, S, e Silva G, Azevedo, Galaz, Jc, Moya, Ja, Herrmann, Da, Jofre, Am, Uribe, Cj, Bravo, Le, Lopez Guarnizo, G, Jurado, Dm, Yepes, Mc, Galán, Yh, Torres, P, Martínez-Reyes, F, Jaramillo, L, Quinto, R, Cueva, P, Yépez, J, Torres-Cintrón, Cr, Tortolero-Luna, G, Alonso, R, Barrios, E, Russell, C, Shack, L, Coldman, Aj, Woods, Rr, Noonan, G, Turner, D, Kumar, E, Zhang, B, Mccrate, Fr, Ryan, S, Hannah, H, Dewar, Ra, Macintyre, M, Lalany, A, Ruta, M, Marrett, L, Nishri, De, Vriends, Ka, Bertrand, C, Louchini, R, Robb, Ki, Stuart-Panko, H, Demers, S, Wright, S, George, J, Shen, X, Brockhouse, Jt, O'Brien, Dk, Almon, L, Young, Jl, Bates, J, Rycroft, R, Mueller, L, Phillips, C, Ryan, H, Walrath, J, Schwartz, A, Vigneau, F, Mackinnon, Ja, Wohler, B, Bayakly, R, Ward, Kc, Davidson-Allen, K, Glaser, S, West, D, Green, Md, Hernandez, By, Johnson, Cj, Lynch, Cf, Mckeen, Km, Huang, B, Tucker, Tc, Deapen, D, Liu, L, Hsieh, Mc, Wu, Xc, Stern, K, Gershman, St, Knowlton, Rc, Copeland, G, Spivak, G, Rogers, Db, Lemons, D, Williamson, Ll, Hood, M, Jerry, H, Hosain, Gm, Rees, Jr, Pawlish, Ks, Stroup, A, Key, C, Wiggins, C, Kahn, Ar, Schymura, Mj, Leung, G, Rao, C, Giljahn, L, Warther, B, Pate, A, Patil, M, Shipley, Dk, Esterly, M, Otto, Rd, Fulton, Jp, Rousseau, Dl, Janes, Ta, Schwartz, Sm, Bolick, Sw, Hurley, Dm, Tenney, Ra, Whiteside, Ma, Hakenewerth, A, Williams, Ma, Herget, K, Sweeney, C, Martin, J, Wang, S, Harrelson, Mg, Keitheri Cheteri MB, Hudson, Ag, Borchers, R, Stephenson, L, Espinoza, Jr, Weir, Hk, Edwards, Bk, Wang, N, Yang, L, Chen, Js, Song, Gh, Gu, Xp, Zhang, P, Ge, Hm, Zhao, Dl, Zhang, Jh, Zhu, Fd, Tang, Jg, Shen, Y, Wang, J, Li, Ql, Yang, Sp, Dong, Jm, Li, Ww, Cheng, Lp, Chen, Jg, Huang, Qh, Huang, Sq, Guo, Gp, Wei, K, Chen, Wq, Zeng, H, Demetriou, Aw, Pavlou, P, Mang, Wk, Ngan, Kc, Kataki, Ac, Krishnatreya, M, Jayalekshmi, Pa, Sebastian, P, Sapkota, Sd, Verma, Y, Nandakumar, A, Suzanna, E, Keinan-Boker, L, Silverman, Bg, Ito, H, Hattori, M, Sugiyama, H, Utada, M, Katayama, K, Natsui, S, Matsuda, T, Nishino, Y, Koike, T, Ioka, A, Nakata, K, Kosa, K, Oki, I, Shibata, A, Nimri, O, Ab Manan, A, Bhoo Pathy, N, Ochir, C, Tuvshingerel, S, Al Khater AM, Al-Eid, H, Jung, Kw, Won, Yj, Park, S, Chiang, Cj, Lai, Ms, Suwanrungruang, K, Wiangnon, S, Daoprasert, K, Pongnikorn, D, Geater, Sl, Sriplung, H, Eser, S, Yakut, Ci, Hackl, M, Zielonke, N, Mühlböck, H, Oberaigner, W, Piñeros, M, Zborovskaya, Aa, Henau, K, Van Eycken, L, Dimitrova, N, Valerianova, Z, Šekerija, M, Znaor, A, Zvolský, M, Engholm, G, Storm, H, Aareleid, T, Mägi, M, Malila, N, Seppä, K, Velten, M, Cornet, E, Troussard, X, Bouvier, Am, Faivre, J, Guizard, Av, Bouvier, V, Launoy, G, Arveux, P, Maynadié, M, Mounier, M, Woronoff, As, Daoulas, M, Clavel, J, Le Guyader-Peyrou, S, Monnereau, A, Trétarre, B, Colonna, M, Delacour-Billon, S, Molinié, F, Bara, S, Degré, D, Ganry, O, Lapôtre-Ledoux, B, Grosclaude, P, Lutz, Jm, Belot, A, Estève, J, Forman, D, Sassi, F, Stabenow, R, Eberle, A, Nennecke, A, Kieschke, J, Sirri, E, Kajueter, H, Emrich, K, Zeissig, Sr, Holleczek, B, Eisemann, N, Katalinic, A, Brenner, H, Asquez, Ra, Kumar, V, Ólafsdóttir, Ej, Tryggvadóttir, L, Comber, H, Walsh, Pm, Sundseth, H, Dal Cappello, T, Mazzoleni, G, Giacomin, A, Castaing, M, Sciacca, S, Sutera, A, Corti, M, Gola, G, Ferretti, S, Serraino, D, Zucchetto, A, Lillini, R, Vercelli, M, Busco, S, Pannozzo, F, Vitarelli, S, Ricci, P, Pascucci, V, Autelitano, M, Cirilli, C, Federico, M, Fusco, M, Vitale, Mf, Usala, M, Cusimano, R, Vitale, F, Michiara, M, Sgargi, P, Sacerdote, C, Tumino, R, Mangone, L, Falcini, F, Cremone, L, Budroni, M, Cesaraccio, R, Madeddu, A, Tisano, F, Maspero, S, Tessandori, R, Candela, G, Scuderi, T, Piffer, S, Rosso, S, Zanetti, R, Caldarella, A, Crocetti, E, La Rosa, F, Stracci, F, Contiero, P, Tagliabue, G, Zambon, P, Baili, P, Berrino, F, Gatta, G, Sant, M, Capocaccia, R, De Angelis, R, Verdecchia, A, Liepina, E, Maurina, A, Smailyte, G, Agius, D, Calleja, N, Siesling, S, Laronningen, S, Møller, B, Dyzmann-Sroka, A, Trojanowski, M, Góźdż, S, Mężyk, R, Gądalska-Lampart, M, Radziszewska, Au, Didkowska, J, Wojciechowska, U, Błaszczyk, J, Kępska, K, Bielska-Lasota, M, Forjaz, G, Rego, Ra, Bastos, J, Antunes, L, Bento, Mj, da Costa Miranda AM, Mayer-da-Silva, A, Coza, D, Todescu, Ai, Krasilnikov, A, Valkov, M, Adamcik, J, Safaei Diba, C, Primic Žakelj, M, Žagar, T, Stare, J, Almar, E, Mateos, A, Argüelles, Mv, Quirós, Jr, Bidaurrazaga, J, Larrañaga, N, Díaz García JM, Marcos, Ai, Marcos-Gragera, R, Vilardell Gil ML, Molina, E, Sánchez, Mj, Ramos Montserrat, M, Chirlaque, Md, Navarro, C, Ardanaz, E, Felipe Garcia, S, Peris-Bonet, R, Galceran, J, Khan, S, Lambe, M, Camey, B, Bouchardy, C, Usel, M, Ess, Sm, Hermann, C, Levi, Fg, Maspoli-Conconi, M, Kuehni, Ce, Mitter, Vr, Bordoni, A, Spitale, A, Chiolero, A, Konzelmann, I, Dehler, Si, Laue, Ri, Meechan, D, Poole, J, Greenberg, D, Rashbass, J, Davies, E, Linklater, K, Morris, E, Moran, T, Bannon, F, Gavin, A, Black, Rj, Brewster, Dh, Roche, M, Mcphail, S, Verne, J, Murphy, M, Stiller, C, Huws, Dw, White, C, Lawrence, G, Brook, C, Wilkinson, J, Finan, P, Ahn, Jv, Allemani, C, Bonaventure, A, Carreira, H, Coleman, Mp, Harewood, R, Rachet, B, Sanz, N, Spika, D, Wang, Xs, Stephens, R, Butler, J, Peake, M, Chalker, E, Newman, L, Baker, D, Soeberg, Mj, Scott, C, Stokes, Bc, Venn, A, Farrugia, H, Giles, Gg, Threlfall, T, Currow, D, You, H, Lewis, C, Miles, SA), Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, I-20133 Milano, Italy, Bouchardy Magnin, Christine, Usel, Massimo, Allemani, C, Weir, H, Carreira, H, Harewood, R, Spika, D, Wang, X, Bannon, F, Ahn, J, Johnson, C, Bonaventure, A, Marcos Gragera, R, Stiller, C, Silva, G, Chen, W, Ogunbiyi, O, Rachet, B, Soeberg, M, You, H, Matsuda, T, Bielska Lasota, M, Storm, H, Tucker, T, Coleman, M, Vitale, F, University of Zurich, and Coleman, Michel P
Subjects: Male, europe 1999-2007, Pathology, Càncer -- Estadístiques, Survival, [SDV]Life Sciences [q-bio], 2700 General Medicine, Global Health, Settore MED/42 - Igiene Generale E Applicata, Neoplasms, 80 and over, Global health, Registries, Stomach cancer, Child, cancer survival, Breast-cancer, ComputingMilieux_MISCELLANEOUS, cancer registry, worldwide, Cervical cancer, Aged, 80 and over, education.field_of_study, childhood-cancer, Medicine (all), 1. No poverty, General Medicine, population-based registries, surveillance, Middle Aged, 3. Good health, ovarian-cancer, Child, Preschool, population-based registrie, Female, net survival, Neoplasms/mortality, rectal-cancer, nordic countries, data quality, care, stage, Adult, medicine.medical_specialty, Adolescent, Population, Socio-culturale, 610 Medicine & health, Age Distribution, Aged, Humans, Infant, Infant, Newborn, Sex Distribution, Survival Analysis, Young Adult, Article, Breast cancer, SDG 3 - Good Health and Well-being, cancer registries, medicine, Preschool, education, Supervivència, Survival analysis, ddc:613, Cancer -- Statistics, business.industry, Cancer, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), Newborn, medicine.disease, Cancer registry, business, Demography
Abstract: Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the eff ectiveness of health systems, and to inform global policy on cancer control. Methods Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15–99 years) and 75 000 children (age 0–14 years) diagnosed with cancer during 1995–2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. Findings 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005–09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15–19% in North America, and as low as 7–9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10–20% between 1995–99 and 2005–09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995–99 and 2005–09 have generally been slight. For women diagnosed with ovarian cancer in 2005–09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005–09 was high (54–58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18–23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major defi ciencies in the management of a largely curable disease. Interpretation International comparison of survival trends reveals very wide diff erences that are likely to be attributable to diff erences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer survival should become an indispensable source of information for cancer patients and researchers and a stimulus for politicians to improve health policy and health-care systems This work was funded by the Canadian Partnership Against Cancer, Cancer Focus Northern Ireland, Cancer Institute New South Wales, Cancer Research UK (C1336/A16148), US Centers for Disease Control and Prevention (CDC; 12FED03123, ACO12036), Swiss Re, Swiss Cancer Research foundation, Swiss Cancer League, and the University of Kentucky (3049024672-12-568)
Published: 2014

16. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project

Author: Stiller, C. A, Trama, A., Brewster, D. H., Verne, J., Bouchardy, C., Navarro, C., Chirlaque, M. D., Marcos Gragera, R., Visser, O., Serraino, D., Weiderpass, E., Dei Tos, A. P., Ascoli, V., Zielonk, N., Van Eycken, E., Sundseth, H., Hedelin, G., Bouvier, A. M., Woronoff, A. S., Buemi, A., Tretarre, B., Colonna, M., Bara, S., Ganry, O., Grosclaude, P., Baconnier, S., Holleczek, B., Geissler, J., Wartenberg, M., Tryggvadottir, L., Deady, S., Bellu, F., Ferretti, Stefano, Vercelli, M., Vitarelli, S., Federico, M., Fusco, M., Michiara, M., Giacomin, A., Tumino, R., Mangone, L., Falcini, F., Senatore, G., Budroni, M., Piffer, S., Crocetti, E., La Rosa, F., Tagliabue, G., Zambon, P., Gatta, G., Gronchi, A., Licitra, L., Ruzza, M., Sowe, S., Capocaccia, R., De Angelis, R., Mallone, S., Tavilla, A., England, K., Ursin, G., Rachtan, J., Gozdz, S., Zwierko, M., Bielska Lasota, M., Slowinski, J., Miranda, A., Safaei Diba, C., Primic Zakelj, M., Mateos, A., Bidaurrazaga, J., Torrella Ramos, A., Ardanaz, E., Galceran, J., Martinez Garcia, C., Sanchez Perez, M. J., Melchor, J. M., Adolfsson, J., Lambe, M., Möller, T. R., Ringborg, U., Jundt, G., Usel, M., Ess, S. M., Spitale, A., Konzelmann, I., Lutz, J. M., Coebergh, J. W. W., Otter, R., Siesling, S., van der Zwan, J. M., Schouten, H., Greenberg, D. C., Wilkinson, J., Roche, M., Meechan, D., Lawrence, G., Mackay, J., Gavin, A., Kunkler, I., and White, C.
Subjects: Adult, Male, Pediatrics, medicine.medical_specialty, Cancer Research, Survival, Epidemiology, Population, Socio-culturale, Kaposi, Bone Sarcoma, Acquired immunodeficiency syndrome (AIDS), medicine, Prevalence, Humans, Rare cancers, education, Sarcoma, Kaposi, ddc:613, Aged, Population-based study, education.field_of_study, Europe, Incidence, Kaposi sarcoma, Female, Middle Aged, Survival Analysis, Oncology, Medicine (all), Classic Kaposi Sarcoma, Relative survival, business.industry, Incidence (epidemiology), Cancer, Sarcoma, medicine.disease, Surgery, business
Abstract: Kaposi sarcoma (KS) is a virus-related malignancy which most frequently arises in skin, though visceral sites can also be involved. Infection with Kaposi sarcoma herpes virus (KSHV or HHV-8) is required for development of KS. Nowadays, most cases worldwide occur in persons who are immunosuppressed, usually because of HIV infection or as a result of therapy to combat rejection of a transplanted organ, but classic Kaposi sarcoma is predominantly a disease of the elderly without apparent immunosuppression. We analyzed 2667 KS incident cases diagnosed during 1995-2002 and registered by 75 population-based European cancer registries contributing to the RARECARE project. Total crude and age-standardized incidence rate was 0.3 per 100,000 per year with an estimated 1642 new cases per year in the EU27 countries. Age-standardized incidence rate was 0.8 per 100,000 in Southern Europe but below 0.3 per 100,000 in all other regions. The elevated rate in southern Europe was attributable to a combination of classic Kaposi sarcoma in some Mediterranean countries and the relatively high incidence of AIDS in several countries. Five-year relative survival for 2000-2002 by the period method was 75%. More than 10,000 persons were estimated to be alive in Europe at the beginning of 2008 with a past diagnosis of KS. The aetiological link with suppressed immunity means that many people alive following diagnosis of KS suffer comorbidity from a pre-existing condition. While KS is a rare cancer, it has a relatively good prognosis and so the number of people affected by it is quite large. Thus it provides a notable example of the importance of networking in diagnosis, therapy and research for rare cancers.
Published: 2014

17. Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: a cohort study

Author: Ritte, R, Lukanova, A, Tjønneland, A, Olsen, A, Overvad, K, Mesrine, S, Fagherazzi, G, Dossus, L, Teucher, B, Steindorf, K, Boeing, H, Aleksandrova, K, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Palli, D, Grioni, S, Mattiello, A, Tumino, R, Sacerdote, C, Quirõs, JR, Buckland, G, Molina-Montes, E, Chirlaque, MD, Ardanaz, E, Amiano, P, Bueno-De-Mesquita, B, Van Duijnhoven, F, Van Gils, CH, Peeters, PH, Wareham, N, Khaw, KT, Key, TJ, Travis, RC, Krum-Hansen, S, Gram, IT, Lund, E, Sund, M, Andersson, A, Romieu, I, Rinaldi, S, McCormack, V, Riboli, E, and Kaaks, R
Subjects: Cancer Research, Nutrition and Disease, population, Physiology, exposures, Risk Factors, Voeding en Ziekte, Prospective Studies, Prospective cohort study, estrogen-receptor, education.field_of_study, Age Factors, Middle Aged, Prognosis, European Prospective Investigation into Cancer and Nutrition, Europe, Receptors, Estrogen, Oncology, Cohort, Menarche, Female, Receptors, Progesterone, associations, Adult, medicine.medical_specialty, body-size, growth, Population, Breast Neoplasms, Breast cancer, Biomarkers, Tumor, medicine, Humans, Risk factor, education, VLAG, childhood, Gynecology, Leg, leg length, business.industry, Proportional hazards model, Estrogens, medicine.disease, Body Height, adolescence, participants, business, Follow-Up Studies
Abstract: Associations of breast cancer overall with indicators of exposures during puberty are reasonably well characterized; however, uncertainty remains regarding the associations of height, leg length, sitting height and menarcheal age with hormone receptor-defined malignancies. Within the European Prospective Investigation into Cancer and Nutrition cohort, Cox proportional hazards models were used to describe the relationships of adult height, leg length and sitting height and age at menarche with risk of estrogen and progesterone receptor negative (ER-PR-) (n = 990) and ER+PR+ (n = 3,524) breast tumors. Height as a single risk factor was compared to a model combining leg length and sitting height. The possible interactions of height, leg length and sitting height with menarche were also analyzed. Risk of both ER-PR- and ER+PR+ malignancies was positively associated with standing height, leg length and sitting height and inversely associated with increasing age at menarche. For ER+PR+ disease, sitting height (hazard ratios: 1.14[95% confidence interval: 1.08-1.20]) had a stronger risk association than leg length (1.05[1.00-1.11]). In comparison, for ER-PR- disease, no distinct differences were observed between leg length and sitting height. Women who were tall and had an early menarche (≤13 years) showed an almost twofold increase in risk of ER+PR+ tumors but no such increase in risk was observed for ER-PR- disease. Indicators of exposures during rapid growth periods were associated with risks of both HR-defined breast cancers. Exposures during childhood promoting faster development may establish risk associations for both HR-positive and -negative malignancies. The stronger associations of the components of height with ER+PR+ tumors among older women suggest possible hormonal links that could be specific for postmenopausal women. What's new? Adult height and early age at menarche are established risk factors for breast cancer. In this study, the authors examined these factors in relation to the hormone-receptor status of breast tumors, with height divided into leg length vs. sitting height. They found that women who were tall and had an early menarche (≤13 years) had almost double the risk of developing estrogen/progesterone-positive (ER+PR+) tumors. Leg length and early menarche were also associated with increased risk for receptor-negative (ER-PR-) tumors. In addition, the data suggest possible hormonal links that could be specific for postmenopausal women. Copyright © 2012 UICC.
Published: 2013

18. Physical activity reduces the risk of incident type 2 diabetes in general and in abdominally lean and obese men and women: the EPIC-InterAct Study

Author: Ekelund, U, Palla, L, Brage, S, Franks, PW, Peters, T, Balkau, B, Diaz, MJT, Huerta, JM, Agnoli, C, Arriola, L, Ardanaz, E, Boeing, H, Clavel-Chapelon, F, Crowe, F, Fagherazzi, G, Groop, L, Hainaut, P, Johnsen, NF, Kaaks, R, Khaw, KT, Key, TJ, de Lauzon-Guillain, B, May, A, Monninkhof, E, Navarro, C, Nilsson, P, Ostergaard, JN, Norat, T, Overvad, K, Palli, D, Panico, S, Redondo, ML, Ricceri, F, Rolandsson, O, Romaguera, D, Romieu, I, Sanchez Perez, MJ, Slimani, N, Spijkerman, A, Teucher, B, Tjonneland, A, Travier, N, Tumino, R, Vos, W, Vigl, M, Sharp, S, Langenberg, C, Forouhi, N, Riboli, E, Feskens, E, Wareham, NJ, and Consortium, I
Subjects: Male, Nutrition and Disease, Endocrinology, Diabetes and Metabolism, body-mass index, Type 2 diabetes, Body Mass Index, Cohort Studies, Risk Factors, Surveys and Questionnaires, Voeding en Ziekte, Abdominal obesity, adiposity, Incidence, improves, Middle Aged, 10 european countries, Europe, fat distribution, Cohort, Female, Waist Circumference, medicine.symptom, medicine.medical_specialty, Waist, life-style, Motor Activity, Article, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, accelerometry, Humans, insulin sensitivity, Case–cohort study, Genetic Predisposition to Disease, Obesity, heart-rate, Life Style, VLAG, Physical activity, business.industry, medicine.disease, Physical activity level, Diabetes Mellitus, Type 2, Incident diabetes, Physical therapy, business, Body mass index, Follow-Up Studies, mellitus
Abstract: Aims/hypothesis We examined the independent and combined associations of physical activity and obesity with incident type 2 diabetes in men and women. Methods The InterAct case–cohort study consists of 12,403 incident type 2 diabetes cases and a randomly selected subcohort of 16,154 individuals, drawn from a total cohort of 340,234 participants with 3.99 million person-years of follow-up. Physical activity was assessed by a four-category index. Obesity was measured by BMI and waist circumference (WC). Associations between physical activity, obesity and case-ascertained incident type 2 diabetes were analysed by Cox regression after adjusting for educational level, smoking status, alcohol consumption and energy intake. In combined analyses, individuals were stratified according to physical activity level, BMI and WC. Results A one-category difference in physical activity (equivalent to approximately 460 and 365 kJ/day in men and women, respectively) was independently associated with a 13% (HR 0.87, 95% CI 0.80, 0.94) and 7% (HR 0.93, 95% CI 0.89, 0.98) relative reduction in the risk of type 2 diabetes in men and women, respectively. Lower levels of physical activity were associated with an increased risk of diabetes across all strata of BMI. Comparing inactive with active individuals, the HRs were 1.44 (95% CI 1.11, 1.87) and 1.38 (95% CI 1.17, 1.62) in abdominally lean and obese inactive men, respectively, and 1.57 (95% CI 1.19, 2.07) and 1.19 (95% CI 1.01, 1.39) in abdominally lean and obese inactive women, respectively. Conclusions/interpretation Physical activity is associated with a reduction in the risk of developing type 2 diabetes across BMI categories in men and women, as well as in abdominally lean and obese men and women. Electronic supplementary material The online version of this article (doi:10.1007/s00125-012-2532-2) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
Published: 2012

19. Oesophageal cancer survival in Europe: A EUROCARE-4 study

Author: Gavin, A. T., Francisci, S., Foschi, R., Donnelly, D. W., Lemmens, V., Brenner, H., Anderson, L. A., Oberaigner, W., Hackl, M., Van Eycken, E., Henau, K., Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Casella, I., Margutti, C., Ciccolallo, L., Gatta, G., Micheli, A., Minicozzi, P., Sant, M., Sowe, S., Tereanu, C., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Vitarelli, S., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., England, K., Micallef, R., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., GoÂ´ zÂ´dzÂ´, S., Siudowska, U., Me?z? yk, R., Bielska-Lasota, M., Sklodowska, M., Zwierko, M., Miranda, A., Diba, C. S., Plesko, I., Primic-Z?akelj, M., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, O., Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Saâ´nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talbaâck, M., Khan, S., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Konzelmann, I., Dehler, S., Lutz, J. M., Pury, P., Siesling, S., Visser, O., Otter, R., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, L., Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Black, R. J., Brewster, D. H., Steward, J. A., Bouchardy Magnin, Christine, and Usel, Massimo
Subjects: Stage, Adult, Male, Cancer Research, Survival, Adolescent, Esophageal Neoplasms, Epidemiology, Socio-culturale, Subtype, Disease, Europe/epidemiology, Young Adult, Cancer, Europe, Oesophagus, Trends, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Registries, Survival Rate, Oncology, medicine, 80 and over, Young adult, Stage (cooking), cancer survival, Survival rate, ddc:613, Relative survival, business.industry, Oesophageal cancer, Cancer survival, medicine.disease, Esophageal Neoplasms/mortality/pathology, business, Demography, Cohort study
Abstract: Oesophageal cancer survival is poor with variation across Europe. No pan-European studies of survival differences by oesophageal cancer subtype exist. This study investigates rates and trends in oesophageal cancer survival across Europe. Data for primary malignant oesophageal cancer diagnosed in 1995-1999 and followed up to the end of 2003 was obtained from 66 cancer registries in 24 European countries. Relative survival was calculated using the Hakulinen approach. Staging data were available from 19 registries. Survival by region, gender, age, morphology and stage was investigated. Cohort analysis and the period approach were applied to investigate survival trends from 1988 to 2002 for 31 registries in 17 countries. In total 51,499 cases of oesophageal cancer diagnosed 1995-1999 were analysed. Overall, European 1- and 5-year survival rates were 33.4% (95% CI 32.9-33.9%) and 9.8% (95% CI 9.4-10.1%), respectively. Males, older patients and patients with late stage disease had poorer 1- and 5-year relative survival. Patients with squamous cell carcinoma had poorer 1-year relative survival. Regional variation in survival was observed with Central Europe above and Eastern Europe below the European pool. Survival for distant stage disease was similar across Europe while survival rates for localised disease were below the European pool in Eastern and Southern Europe. Improvement in European 1-year relative survival was reported (p=0.016). Oesophageal cancer survival was poor across Europe. Persistent regional variations in 1-year survival point to a need for a high resolution study of diagnostic and treatment practices of oesophageal cancer.
Published: 2012

20. Survival of European patients with central nervous system tumors

Author: Sant, Milena, Minicozzi, Pamela, Lagorio, Susanna, BÃ¸rge Johannesen, Tom, Marcos-Gragera, Rafael, Francisci, Silvia, Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Guizard, A. V., Danzon, A., Buemi, A., Tretarre, B., Colonna, M., Bara, S., Ganry, O., Grosclaude, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Margutti, C., Micheli, A., Minicozzi, P., Sant, M., Sowe, S., Tereanu, C., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., De Lisi, V., Bozzani, F., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Miranda, A., Safaei Diba, Chakameh, Primic-Å¹akelj, M., Izarzugaza, I., Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Lutz, J. M., Pury, P., Visser, O., Otter, R., Siesling, S., van der Zwan, J. M., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., van der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., and Usel, Massimo
Subjects: Oncology, Ependymoma, Adult, Male, medicine.medical_specialty, Pathology, Cancer Research, Adolescent, Central Nervous System Neoplasms/mortality, Population, survival, NO, Benign tumor, Central Nervous System Neoplasms, Young Adult, Sex Factors, Internal medicine, morphology, medicine, 80 and over, Humans, Registries, Young adult, central nervous system tumors, Europe, Age Factors, Aged, Aged, 80 and over, Female, Middle Aged, Survival Rate, education, Survival rate, ddc:613, Medulloblastoma, education.field_of_study, Relative survival, business.industry, Cancer survival, Cancer, central nervous system tumors, survival, morphology, Europe, medicine.disease, business
Abstract: We present estimates of population-based 5-year relative survival for adult Europeans diagnosed with central nervous system tumors, by morphology (14 categories based on cell lineage and malignancy grade), sex, age at diagnosis and region (UK and Ireland, Northern, Central, Eastern and Southern Europe) for the most recent period with available data (2000-2002). Sources were 39 EUROCARE cancer registries with continuous data from 1996 to 2002. Survival time trends (1988 to 2002) were estimated from 24 cancer registries with continuous data from 1988. Overall 5-year relative survival was 85.0% for benign, 19.9% for malignant tumors. Benign tumor survival ranged from 90.6% (Northern Europe) to 77.4% (UK and Ireland); for malignant tumors the range was 25.1% (Northern Europe) to 15.6% (UK and Ireland). Survival decreased with age at diagnosis and was slightly better for women (malignant tumors only). For glial tumors, survival varied from 83.5% (ependymoma and choroid plexus) to 2.7% (glioblastoma); and for non-glioma tumors from 96.5% (neurinoma) to 44.9% (primitive neuroectoderm tumor/medulloblastoma). Survival differences between regions narrowed after adjustment for morphology and age, and were mainly attributable to differences in morphology mix; however UK and Ireland and Eastern Europe patients still had 40% and 30% higher excess risk of death, respectively, than Northern Europe patients (reference). Survival for benign tumors increased from 69.3% (1988-1990) to 77.1% (2000-2002); but survival for malignant tumors did not improve indicating no useful advances in treatment over the 14-year study period, notwithstanding major improvement in the diagnosis and treatment of other solid cancers.
Published: 2011

21. Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study

Author: Langenberg, C., Sharp, S., Forouhi, N. G., Franks, P. W., Schulze, M. B., Kerrison, N., Ekelund, U., Barroso, I., Panico, S., Tormo, M. J., Spranger, J., Griffin, S., van der Schouw, Y. T., Amiano, P., Ardanaz, E., Arriola, L., Balkau, B., Barricarte, A., Beulens, J. W.J., Boeing, H., Bueno-de-Mesquita, H. B., Buijsse, B., Lopez, Chirlaque, Clavel-Chapelon, F., Crowe, F. L., de Lauzon-Guillan, B., Deloukas, P., Dorronsoro, M., Drogan, D., Froguel, P., Gonzalez, C., Grioni, S., Groop, L., Groves, C., Hainaut, P., Halkjaer, J., Hallmans, G., Hansen, T., Huerta Castaño, J. M., Kaaks, R., Key, T. J., Khaw, K. T., Koulman, A., Mattiello, A., Navarro, C., Nilsson, P., Norat, T., Overvad, K., Palla, L., Palli, D., Pedersen, O., Peeters, P. H., Quirós, J. R., Ramachandran, A., Rodriguez-Suarez, L., Rolandsson, O., Romaguera, D., Romieu, I., Sacerdote, C., Sánchez, M. J., Sandbaek, A., Slimani, N., Sluijs, I., Spijkerman, A. M.W., Teucher, B., Tjonneland, A., Tumino, R., van der A, D. L., Verschuren, W. M.M., Tuomilehto, J., Feskens, E., McCarthy, M., Riboli, E., Wareham, N. J., Epidemiology and Data Science, ACS - Diabetes & metabolism, ACS - Heart failure & arrhythmias, and APH - Health Behaviors & Chronic Diseases
Subjects: Nutrition and Disease, Endocrinology, Diabetes and Metabolism, prevalence, 030209 endocrinology & metabolism, Type 2 diabetes, 03 medical and health sciences, 0302 clinical medicine, Voeding en Ziekte, Internal Medicine, spain, Medicine, cancer, 030212 general & internal medicine, Prospective cohort study, physical-activity, risk-factors, VLAG, business.industry, Incidence (epidemiology), Retrospective cohort study, medicine.disease, 3. Good health, European Prospective Investigation into Cancer and Nutrition, nutrition, Genetic epidemiology, population-based incidence, Cohort, loci, genome-wide association, business, coronary-heart-disease, Cohort study, Demography
Abstract: Aims/hypothesis Studying gene-lifestyle interaction may help to identify lifestyle factors that modify genetic susceptibility and uncover genetic loci exerting important subgroup effects. Adequately powered studies with prospective, unbiased, standardised assessment of key behavioural factors for gene-lifestyle studies are lacking. This case-cohort study aims to investigate how genetic and potentially modifiable lifestyle and behavioural factors, particularly diet and physical activity, interact in their influence on the risk of developing type 2 diabetes. Methods Incident cases of type 2 diabetes occurring in European Prospective Investigation into Cancer and Nutrition (EPIC) cohorts between 1991 and 2007 from eight of the ten EPIC countries were ascertained and verified. Prentice-weighted Cox regression and random-effects meta-analyses were used to investigate differences in diabetes incidence by age and sex. Results A total of 12,403 verified incident cases of type 2 diabetes occurred during 3.99 million person-years of follow-up of 340,234 EPIC participants eligible for Inter-Act. We defined a centre-stratified subcohort of 16,154 individuals for comparative analyses. Individuals with incident diabetes who were randomly selected into the subcohort (n=778) were included as cases in the analyses. All prevalent diabetes cases were excluded from the study. InterAct cases were followed-up for an average of 6.9 years; 49.7% were men. Mean baseline age and age at diagnosis were 55.6 and 62.5 years, mean BMI and waist circumference values were 29.4 kg/m2 and 102.7 cm in men, and 30.1 kg/m2 and 92.8 cm in women, respectively. Risk of type 2 diabetes increased linearly with age, with an overall HR of 1.56 (95% CI 1.48-1.64) for a 10 year age difference, adjusted for sex. A male excess in the risk of incident diabetes was consistently observed across all countries, with a pooled HR of 1.51 (95% CI 1.39-1.64), adjusted for age. Conclusions/ interpretation InterAct is a large, well-powered, prospective study that will inform our understanding of the interplay between genes and lifestyle factors on the risk of type 2 diabetes development.
Published: 2011

22. Survival trends in European cancer patients diagnosed from 1988 to 1999

Author: Verdecchia, Arduino, Guzzinati, Stefano, Francisci, Silvia, De Angelis, Roberta, Bray, Freddie, Allemani, Claudia, Tavilla, Andrea, Santaquilani, Mariano, Sant, Milena, Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Å½akelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )
Subjects: Male, Cancer Research, Survival, MESH : Mortality, MESH : Age Distribution, MESH : Aged, Colonoscopy, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Prostate, Residence Characteristics, Neoplasms, 80 and over, MESH : Female, MESH: Neoplasms, 030212 general & internal medicine, MESH: Residence Characteristics, Young adult, cancer survival, MESH : Sex Distribution, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, medicine.diagnostic_test, Relative survival, Europe, Population registries, Time trends, Adolescent, Adult, Age Distribution, Aged, Female, Humans, Middle Aged, Mortality, Sex Distribution, Survival Analysis, Young Adult, Oncology, MESH: Sex Distribution, MESH : Adult, 3. Good health, medicine.anatomical_structure, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH : Residence Characteristics, medicine.medical_specialty, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, Rectum, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Internal medicine, MESH : Adolescent, medicine, MESH : Middle Aged, MESH : Aged, 80 and over, Cervix, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, MESH: Mortality, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, Surgery, MESH: Europe, MESH : Survival Analysis, business, MESH: Female
Abstract: International audience; We analysed data from 49 cancer registries in 18 European countries over the period 1988-1999 to delineate time trends in cancer survival. Survival increased in Europe over the study period for all cancer sites that were considered. There were major survival increases in 5 year age-adjusted relative survival for prostate (from 58% to 79%), colon and rectum (from 48% to 54% men and women), and breast (from 74% to 83%). Improvements were also significant for stomach (from 22% to 24%), male larynx (from 62% to 64%), skin melanoma (from 78% to 83%), Hodgkin disease (from 77% to 83%), non-Hodgkin lymphoma (from 49% to 56%), leukaemias (from 37% to 42%), and for all cancers combined (from 34% to 39% in men, and from 52% to 59% in women). Survival did not change significantly for female larynx, lung, cervix or ovary. The largest increases in survival typically occurred in countries with the lowest survival, and contributed to the overall reduction of survival disparities across Europe over the study period. Differences in the extent of PSA testing and mammographic screening, and increasing use of colonoscopy and faecal blood testing together with improving cancer care are probably the major underlying reasons for the improvements in survival for cancers of prostate, breast, colon and rectum. The marked survival improvements in countries with poor survival may indicate that these countries have made efforts to adopt the new diagnostic procedures and the standardised therapeutic protocols in use in more affluent countries.
Published: 2009

23. The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis

Author: De Angelis, Roberta, Francisci, Silvia, Baili, Paolo, Marchesi, Francesca, Roazzi, Paolo, Belot, Aurã©lien, Crocetti, Emanuele, Pury, Pierre, Knijn, Arnold, Coleman, Michel, Capocaccia, Riccardo, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Å½akelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Service de Biostatistique, Hospices Civils de Lyon ( HCL ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Hospices Civils de Lyon (HCL), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Subjects: Cancer Research, MESH: Quality Control, computer.software_genre, MESH: Epidemiologic Methods, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Neoplasms, Medicine, MESH: Neoplasms, 030212 general & internal medicine, cancer survival, education.field_of_study, Database, Relative survival, Incidence (epidemiology), Europe, Population registries, Survival analysis, Vital statistics, Databases as Topic, Epidemiologic Methods, Humans, Quality Control, Oncology, MESH : Quality Control, 3. Good health, 030220 oncology & carcinogenesis, Population, MESH : Europe, MEDLINE, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Epidemiologic Methods, 03 medical and health sciences, education, MESH: Humans, business.industry, MESH : Humans, Cancer, medicine.disease, MESH : Neoplasms, Data quality, MESH: Europe, MESH : Databases as Topic, business, computer, MESH: Databases as Topic, International Classification of Diseases for Oncology
Abstract: International audience; This paper describes the collection, standardisation and checking of cancer survival data included in the EUROCARE-4 database. Methods for estimating relative survival are also described. Incidence and vital status data on newly diagnosed European cancer cases were received from 93 cancer registries in 23 countries, covering 151,400,000 people (35% of the participating country population). The third revision of the International Classification of Diseases for Oncology was used to specify tumour topography and morphology. Records were extensively checked for consistency and compatibility using multiple routines; flagged records were sent back for correction. An algorithm assigned standardised sequence numbers to multiple cancers. Only first malignant cancers were used to estimate relative survival from registry, year, sex and age-specific life tables. Age-adjusted and Europe-wide survival were also estimated. The database contains 13,814,573 cases diagnosed in 1978-2002; 92% malignant. A negligible proportion of records was excluded for major errors. Of 5,753,934 malignant adult cases diagnosed in 1995-2002, 5.3% were second or later cancers, 2.7% were known from death certificates only and 0.4% were discovered at autopsy. The remaining 5,278,670 cases entered the survival analyses, 90% of these had microscopic confirmation and 1.3% were censored alive after less than five years' follow-up. These indicators suggest satisfactory data quality that has improved since EUROCARE-3.
Published: 2009

24. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary

Author: Sant, Milena, Allemani, Claudia, Santaquilani, Mariano, Knijn, Arnold, Marchesi, Francesca, Capocaccia, Riccardo, Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Å½akelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )
Subjects: Male, Cancer Research, MESH : Age Distribution, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Neoplasms, Epidemiology, Medicine, MESH : Female, MESH: Neoplasms, 030212 general & internal medicine, MESH : Sex Distribution, MESH: Aged, MESH: Middle Aged, Relative survival, MESH: Sex Distribution, Population-based cancer registries, Middle Aged, MESH : Adult, Cancer survival, EUROCARE, Adolescent, Adult, Age Distribution, Aged, Europe, Female, Humans, Sex Distribution, Survival Analysis, Oncology, 3. Good health, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Skin melanoma, Stage at diagnosis, medicine.medical_specialty, MESH : Male, MESH : Europe, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, Age and sex, 03 medical and health sciences, MESH : Adolescent, MESH : Middle Aged, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, business.industry, Advanced stage, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, MESH: Europe, MESH : Survival Analysis, business, MESH: Female, Demography
Abstract: International audience; EUROCARE-4 analysed about three million adult cancer cases from 82 cancer registries in 23 European countries, diagnosed in 1995-1999 and followed to December 2003. For each cancer site, the mean European area-weighted observed and relative survival at 1-, 3-, and 5-years by age and sex are presented. Country-specific 1- and 5-year relative survival is also shown, together with 5-year relative survival conditional to surviving 1-year. Within-country variation in survival is analysed for selected cancers. Survival for most solid cancers, whose prognosis depends largely on stage at diagnosis (breast, colorectum, stomach, skin melanoma), was highest in Finland, Sweden, Norway and Iceland, lower in the UK and Denmark, and lowest in the Czech Republic, Poland and Slovenia. France, Switzerland and Italy generally had high survival, slightly below that in the northern countries. There were between-region differences in the survival for haematologic malignancies, possibly due to differences in the availability of effective treatments. Survival of elderly patients was low probably due to advanced stage at diagnosis, comorbidities, difficult access or lack of availability of appropriate care. For all cancers, 5-year survival conditional to surviving 1-year was higher and varied less with region, than the overall relative survival.
Published: 2009

25. The cure of cancer: a european perspective

Author: Francisci, Silvia, Capocaccia, Riccardo, Grande, Enrico, Santaquilani, Mariano, Simonetti, Arianna, Allemani, Claudia, Gatta, Gemma, Sant, Milena, Zigon, Giulia, Bray, Freddie, Janssen-Heijnen, Maryska, Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Å½akelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Eindhoven Cancer Registry, Comprehensive Cancer Centre South, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )
Subjects: Male, Cancer Research, Colorectal cancer, MESH : Age Distribution, MESH : Aged, Gastroenterology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Prostate cancer, 0302 clinical medicine, Breast cancer, MESH: Aged, 80 and over, Colon and rectum cancer, Cure, Lung cancer, Relative survival, Statistical models, Stomach cancer, Oncology, Neoplasms, MESH : Female, MESH: Neoplasms, 030212 general & internal medicine, cancer survival, Aged, 80 and over, MESH: Aged, MESH : Prognosis, MESH: Middle Aged, Middle Aged, MESH : Adult, Prognosis, 3. Good health, Europe, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Female, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, 03 medical and health sciences, Young Adult, Age Distribution, Internal medicine, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, MESH: Age Distribution, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, Survival Analysis, MESH : Neoplasms, MESH: Male, Cancer registry, MESH: Europe, MESH : Survival Analysis, business, MESH: Female
Abstract: International audience; Cancer survival analyses based on cancer registry data do not provide direct information on the main aim of cancer treatment, the cure of the patient. In fact, classic survival indicators do not distinguish between patients who are cured, and patients who will die of their disease and in whom prolongation of survival is the main objective of treatment. In this study, we applied parametric cure models to the cancer incidence and follow-up data provided by 49 EUROCARE-4 (European Cancer Registry-based study, fourth edition) cancer registries, with the aims of providing additional insights into the survival of European cancer patients diagnosed from 1988 to 1999, and of investigating between-population differences. Between-country estimates the proportion of cured patients varied from about 4-13% for lung cancer, from 9% to 30% for stomach cancer, from 25% to 49% for colon and rectum cancer, and from 55% to 73% for breast cancer. For all cancers combined, estimates varied between 21% and 47% in men, and 38% and 59% in women and were influenced by the distribution of cases by cancer site. Countries with high proportions of cured and long fatal case survival times for all cancers combined were characterised by generally favourable case mix. For the European pool of cases both the proportion of cured and the survival time of fatal cases were associated with age, and increased from the early to the latest diagnosis period. The increases over time in the proportions of Europeans estimated cured of lung, stomach and colon and rectum cancers are noteworthy and suggest genuine progress in cancer control. The proportion of cured of all cancers combined is a useful general indicator of cancer control as it reflects progress in diagnosis and treatment, as well as success in the prevention of rapidly fatal cancers.
Published: 2009

26. Long-term survival expectations of cancer patients in Europe in 2000-2002

Author: Brenner, Hermann, Francisci, Silvia, De Angelis, Roberta, Marcos-Gragera, Rafael, Verdecchia, Arduino, Gatta, Gemma, Allemani, Claudia, Ciccolallo, Laura, Coleman, Michel, Sant, Milena, Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Å½akelj, M., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Subjects: Gerontology, Male, Cancer Research, MESH: Registries, Survival, MESH : Life Expectancy, MESH : Age Distribution, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Neoplasms, 80 and over, Medicine, Cancer registries, MESH: Neoplasms, MESH : Female, 030212 general & internal medicine, Registries, Young adult, MESH: Aged, Aged, 80 and over, MESH: Middle Aged, Relative survival, MESH : Adult, Middle Aged, MESH : Survival Rate, Prognosis, 3. Good health, Europe, Survival Rate, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Cohort, Period Analysis, Female, cancer survival - long term, MESH: Life Expectancy, Adult, MESH: Survival Rate, Period analysis, Adolescent, Age Distribution, Aged, Humans, Life Expectancy, Survival Analysis, Young Adult, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, MESH : Adolescent, MESH : Middle Aged, MESH : Aged, 80 and over, Survival rate, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, Life expectancy, MESH: Europe, MESH : Survival Analysis, business, MESH: Female, MESH : Registries, Demography
Abstract: International audience; Period analysis has been shown to provide more up-to-date estimates of long-term cancer survival rates than traditional cohort-based analysis. Here, we provide detailed period estimates of 5- and 10-year relative survival by cancer site, country, sex and age for calendar years 2000-2002. In addition, pan-European estimates of 1-, 5- and 10-year relative survival are provided. Overall, survival estimates were mostly higher than previously available cohort estimates. For most cancer sites, survival in countries from Northern Europe, Central Europe and Southern Europe was substantially higher than in the United Kingdom and Ireland and in countries from Eastern Europe. Furthermore, relative survival was also better in female than in male patients and decreased with age for most cancer sites.
Published: 2009

27. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States

Author: Sant, Milena, Allemani, Claudia, De Angelis, Roberta, Carbone, Antonino, De SanJose, Silvia, Gianni, Alessandro M., Giraldo, Pilar, Marchesi, Francesca, Marcos-Gragera, Rafael, Martos-Jimenez, Carmen, Maynadie, Marc, Raphael, Martine, Berrino, Franco, Oberaigner, W., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hedelin, G., Tron, I., Le Gall, E., Launoy, G., MacE-Lesec'h, J., Faivre, J., Chaplain, G., Carli, P. -. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estãve, J., Kaatsch, P., Ziegler, H., Holzel, D., Schubert Fritschle, G., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Crosignani, P., Gatta, G., Micheli, A., Sant, M., Ferretti, S., Contil, E., Ramazzotti, V., Vercelli, M., Quaglia, A., Pannelli, F., Federico, M., Artioli, M. E., Ponz De Leon, M., Benatti, P., De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Capocaccia, R., Carrani, E., De Angelis, R., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Rachtan, J., Bielska-Lasota, M., Wronkowski, Z., Plesko, I., Obsitnikova, A., Pompe-Kirn, V., Izarzugaza, I., Martinez-Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris-Bonet, R., Barlow, L., Moller, T., Jundt, G., Lutz, J. M., Usel, M., Coebergh, J. W. W., Van Der Does-Van Den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Mã¸ller, H., Bell, J., Botha, J. L., Lawrence, G., Black, R., Steward, J. A., Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Hospital Miguel Servet, Registre des hémopathies malignes de Côte d'Or, Laboratoire d'Hématologie, Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre, Department of Preventive & Predictive Medicine, Fondazione IRCCS-Istituto Nazionale dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Hospital Universitario Miguel Servet, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Subjects: Oncology, Cancer Research, Survival, Lymphoma, MESH: Registries, MESH : Age Distribution, MESH : Aged, MESH : Child, Preschool, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, MESH: Lymphoma, Non-Hodgkin, MESH : Child, MESH: Child, hemic and lymphatic diseases, 80 and over, Medicine, Registries, Child, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH : Prognosis, Relative survival, Lymphoma, Non-Hodgkin, EUROCARE, Non-Hodgkin's lymphoma, Population cancer registries, US SEER, Adolescent, Adult, Age Distribution, Aged, Child, Preschool, Europe, Feasibility Studies, Humans, Infant, Middle Aged, Prognosis, United States, Absolute risk reduction, MESH : Infant, MESH : Adult, MESH: Infant, 3. Good health, 030220 oncology & carcinogenesis, morphology - survival - non Hodgkin lymphoma - Europe - US, epidemiology, medicine.medical_specialty, MESH : United States, MESH : Feasibility Studies, MESH : Europe, Socio-culturale, Non-Hodgkin, [SDV.CAN]Life Sciences [q-bio]/Cancer, survival, MESH: Prognosis, cancer, 03 medical and health sciences, Internal medicine, MESH : Adolescent, MESH: United States, MESH : Lymphoma, Non-Hodgkin, MESH : Middle Aged, Preschool, MESH : Aged, 80 and over, MESH: Age Distribution, MESH: Adolescent, MESH: Humans, business.industry, MESH: Child, Preschool, MESH : Humans, Cancer, MESH: Adult, medicine.disease, Confidence interval, Cancer registry, Hodgkin lymphoma, MESH: Europe, business, MESH: Feasibility Studies, MESH : Registries, 030215 immunology
Abstract: International audience; We explored the influence of morphology on geographic differences in 5-year survival for non-Hodgkin lymphoma (NHL) diagnosed in 1990-1994 and followed for 5years: 16,955 cases from 27 EUROCARE-3 cancer registries, and 22,713 cases from 9 US SEER registries. Overall 5-year relative survival was 56.1% in EUROCARE west, 47.1% in EUROCARE east and 56.3% in SEER. Relative excess risk (RER) of death was 1.05 (95% confidence interval (CI) 1.01-1.10) in EUROCARE west, 1.52 (95% CI 1.44-1.60) in EUROCARE east (SEER reference). Excess risk of death was significantly above reference (diffuse B lymphoma) for Burkitt's and NOS lymphoma; not different for lymphoblastic and other T-cell; significantly below reference (in the order of decreasing relative excess risk) for NHL NOS, mantle cell/centrocytic, lymphoplasmacytic, follicular, small lymphocytic/chronic lymphocytic leukaemia, other specified NHL and cutaneous morphologies. Interpretation of marked variation in survival with morphology is complicated by classification inconsistencies. The completeness and standardisation of cancer registry morphology data needs to be improved.
Published: 2008

28. Trends in cervical cancer survival in Europe, 1983-1994: a population-based study

Author: Bielska-Lasota, M., Inghelmann, R., van de Poll-Franse, L., Capocaccia, R., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hedelin, G., Tron, I., Le Gall, E., Launoy, G., Mace-Lesec'h, J., Faivre, J., Chaplain, G., Carli, P. -M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, B., Grosclaude, P., Esteve, J., Kaatsch, P., Ziegler, H., Holzel, D., Schubert Fritschle, G., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Crosignani, P., Gatta, G., Micheli, A., Sant, M., Taussig, E., Sowe, S., Ferretti, S., Conti, E., Vercelli, M., Quaglia, A., Pannelli, F., Federico, M., Artioli, M. E., Ponz De Leon, M., Benatti, P., De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Carrani, E., De Angelis, R., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Pinheiro, P., Rachtan, J., Wronkowski, Z., Zwierko, M., Plesko, I., Obsitnikova, A., Pompe-Kirn, V., Primic-Zakelj, M., Izarzugaza, I., Martinez-Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris-Bonet, R., Barlow, L., Moller, T., Jundt, G., Lutz, J. M., Bouchardy, C., Coebergh, J. W. W., van der Does-van den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Moller, H., Bell, J., Botha, H., Lawrence, G., Black, R., Steward, J. A., Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Subjects: MESH: Registries, MESH : Mortality, MESH : Aged, Uterine Cervical Neoplasms, Disease, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Aged, 80 and over, 0302 clinical medicine, MESH : Female, Registries, MESH: Aged, Cervical cancer, Aged, 80 and over, 0303 health sciences, education.field_of_study, MESH: Middle Aged, MESH : Prognosis, Relative survival, Absolute risk reduction, Obstetrics and Gynecology, Middle Aged, MESH : Adult, Prognosis, MESH : Survival Rate, 3. Good health, MESH: Uterine Cervical Neoplasms, Europe, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Adenocarcinoma, Female, Adult, medicine.medical_specialty, MESH: Survival Rate, Adolescent, Population, MESH : Uterine Cervical Neoplasms, MESH : Europe, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, Trends - cervical cancer - survival, 03 medical and health sciences, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, Mortality, education, MESH : Aged, 80 and over, Survival rate, 030304 developmental biology, Aged, MESH: Adolescent, Gynecology, MESH: Humans, MESH: Mortality, business.industry, MESH : Humans, Cancer, MESH: Adult, Population-based study, Survival, Trends, medicine.disease, MESH: Europe, business, MESH: Female, MESH : Registries, Demography
Abstract: International audience; OBJECTIVE: To evaluate trends in survival from cervical cancer in Europe and in European countries participating in the EUROCARE study as a function of age, morphology and stage at diagnosis. METHODS: Relative survival and relative excess risk of death within 5 years of diagnosis, as a function of age, morphology and stage, among 73,022 women aged 15-99 years diagnosed during 1983-1994 and followed up to 1999 in each of 18 European countries participating in the EUROCARE study, using data from 34 population-based cancer registries. RESULTS: Overall five-year relative survival was 62%, rising by 2% during the period 1983-1994. The highest survival occurred in Northern and Western Europe and the lowest in Central Europe. Survival falls with age at diagnosis, but mainly for localised disease. Survival is higher for adenocarcinoma in younger women, but higher for squamous cell carcinoma in older women. The proportions of younger women, localised cancer and adenocarcinoma all increased. The main improvements in survival were for women under 65, and for metastatic disease. CONCLUSIONS: Survival in Europe has improved slowly but steadily, but the trend is not geographically uniform. Central European countries and the UK saw little or no improvement, and survival in those countries remains the lowest among participating countries in Europe. Further reduction of cervical cancer mortality in Europe may be expected from expansion of screening, and improvement in the treatment of older women, and of metastatic disease.
Published: 2007

29. Survival from rare cancer in adults: a population-based study

Author: Gatta, G., Ciccolallo, L., Kunkler, I., Capocaccia, R., Berrino, F., Coleman, M. P., De Angelis, R., Faivre, J., Lutz, J. M., Martinez, C., Möller, T., Sankila, R., Oberaigner, W., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesec'h, J., Chaplain, G., Carli, P. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, B., Grosclaude, P., Estève, J., Kaatsch, P., Ziegler, H., Hölzel, D., Schubert Fritschle, G., Tryggvadottir, L., Allemani, C., Baili, P., Crosignani, P., Micheli, A., Sant, M., Taussig, E., Sowe, S., Ferretti, S., Conti, E., Vercelli, M., Quaglia, A., Pannelli, F., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Carrani, E., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Pinheiro, P., Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pleško, I., Obsitníkováa, A., Pompe Kirn, V., Primic Zakelj, M., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris Bonet, R., Barlow, L., Jundt, G., Bouchardy, C., Coebergh, J. W. W., van der Does van den Berg, A., Visser, O., Godward, S., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Møller, H., Bell, J., Botha, H., Lawrence, G., Black, R., Steward, J. A., Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive & Predictive Medicine, Fondazione IRCCS-Istituto Nazionale dei Tumori, Registre Bourguignon des Cancers Digestifs, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Registre Genevois des Tumeurs, CHU Genève, Service of Preventive Medicine, Hospital Clínico San Carlos, Madrid, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Subjects: Male, Oncology, MESH : Risk, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Neoplasms, Angiosarcoma, MESH: Neoplasms, MESH : Female, MESH: Quality of Health Care, MESH: Aged, 0303 health sciences, MESH: Risk, MESH: Middle Aged, Relative survival, MESH : Quality of Health Care, Rare cancer survival, population-based cancer study, international comparison, Middle Aged, MESH : Adult, 3. Good health, Europe, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH : Rare Diseases, Female, Sarcoma, Adult, Risk, MESH: Rare Diseases, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Europe, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Rare Diseases, Internal medicine, MESH : Adolescent, medicine, Carcinoma, Humans, MESH : Middle Aged, Testicular cancer, Survival analysis, Aged, Quality of Health Care, 030304 developmental biology, MESH: Adolescent, MESH: Humans, Uterine sarcoma, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, Survival Analysis, MESH : Neoplasms, MESH: Male, MESH: Europe, MESH : Survival Analysis, business, MESH: Female
Abstract: International audience; BACKGROUND: Rare cancers are a challenge to clinical practice, and treatment experience, even in major cancer centres to which rare cancers are usually referred, is often limited. We aimed to study the epidemiology of rare cancers in a large population of several countries. METHODS: We analysed survival by age, sex, subsite, and morphology in 57,144 adults with 14 selected rare cancers diagnosed 1983-94. Variations in survival over time and between European regions were also assessed for variations in quality of care. We also estimated the adjusted relative excess risk of death for every rare cancer. FINDINGS: Overall 5-year relative survival was good (ie, >65%) for placental choriocarcinoma (85.4% [95% CI 81.4-89.5]), thyroid medullary carcinoma (72.4% [69.2-75.5]), ovarian germ-cell cancer (73.0% [70.0-76.0]), lung carcinoid (70.1% [67.3-72.9]), and cervical adenocarcinoma (65.5% [64.3-66.6]); intermediate (ie, 35-65%) for testicular cancer at age 65 years or older (64.0% [59.3-68.7]), sarcoma of extremities (60.0% [58.9-61.2]), digestive-system endocrine cancers (55.6% [54.9-56.3]), anal squamous-cell carcinoma (53.1% [51.5-54.8]), and uterine sarcoma (43.5% [42.0-44.9]); low for carcinoma of adrenal-gland cortex (32.7% [28.3-37.2]) and bladder squamous-cell carcinoma (20.4% [18.8-22.0]); and poor for angiosarcoma of liver (6.4% [1.8-11.0]) and mesothelioma (4.7% [4.3-5.2]). Survival was usually better for women than men and poor in those aged 75 years or older. Survival significantly improved over time for ovarian germ-cell cancer, sarcomas of extremities, digestive-system endocrine tumours, anal squamous-cell carcinoma, and angiosarcoma of liver. Survival in northern Europe was higher than in the other geographic groupings for most cancers. INTERPRETATION: Because effective treatments are available for several of the rare cancers we assessed, further research is needed to ascertain why survival is lower in some European countries than in others, particularly in older patients. Audit of best practice for rare cancers with treatment protocols would be useful.
Published: 2006

30. The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis

Author: Capocaccia, R., Gatta, G., Roazzi, P., Carrani, E., Santaquilani, M., De Angelis, R., Tavilla, A., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Aareleid, T., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesech, J., Faivre, J. n. Chaplain G., Carli, P. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estève, J., Kaatch, P., Ziegler, H., Hölzel, D., Fritschle, G. S., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Micheli, A., Sant, M., Taussig, E., Hartley, S., Valente, F., Verdecchia, A., Ferretti, S., Crosignani, P., Tagliabue, G., Conti, E., Vercelli, M., Pannelli, F., Vitarelli, S., Mosciatti, P., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Serventi, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafà, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Dalmas, M., Langmark, F., Andersen, A., Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pinheiro, P. S., Pleško, I., Obsitníková, A., Pompe Kim, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Perisbonet, R., Barlow, L., Möller, T., Jundt, G., Lutz, J. M., Usel, M., Coebergh, J. W. W., Van Der Does Van Den, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Møller, H., Bell, J., Botha, J. L., Lawrence, G., Black, R., Brewster, D., and Steward, J. A.
Subjects: Adult, Male, Quality Control, computer.software_genre, Stomach Neoplasms, Neoplasms, Autopsy Only, Cancer survival, Data quality, Population-based cancer registries, standardisation - quality control - statistical analysis, medicine, Humans, Statistical analysis, Registries, Medical diagnosis, Stage (cooking), Child, cancer survival, methodology - data collection, Data collection, Database, Relative survival, business.industry, Data Collection, Age Factors, Cancer, Hematology, medicine.disease, Survival Analysis, Europe, Survival Rate, Databases as Topic, Oncology, Data quality, Female, Colorectal Neoplasms, business, computer
Abstract: The EUROCARE database contains data on 6.5 million cancer patients diagnosed from 1978 to 1994 in populations covered by 67 cancer registries in 22 European countries. The quality-checked entries specify age, sex, diagnosis date, cancer site, morphology, microscopic confirmation and vital status, as well as containing broad indicators of stage. For EUROCARE-3, which refers to diagnoses from 1990 to 1994, 3389 cases with major data problems and 142,525 second or subsequent cancers were removed, leaving more than 2 million cases for analysis. From these data, observed and relative survival for each cancer site and country were calculated at 1, 3 and 5 years from diagnosis. Overall European survival for each cancer site and for all cancers combined were calculated combining country-specific survival figures. Overall, 1.1% of cases were lost to follow-up, 4.2% were known from death certificates only and 1.2% were known at autopsy only. The percentage of microscopically confirmed cases varied with cancer site and country, and was always higher in northern European countries. Comparison of quality indicators for the EUROCARE-3 database with earlier EUROCARE databases indicates that data quality and standardisation have improved.
Published: 2003

31. Level of education and the risk of lymphoma in the European prospective investigation into cancer and nutrition

Author: Hermann, S., Rohrmann, S., Linseisen, J., Nieters, A., Khan, A., Gallo, V., Overvad, K., Tjonneland, A., Raaschou-Nielsen, O., Bergmann, M.M., Boeing, H., Becker, N., Kaaks, R., Bueno-de-Mesquita, H.B., May, A.M., Vermeulen, R.C.H., Bingham, S, Khaw, K.T., Key, T.J., Travis, R.C., Trichopoulou, A., Georgila, C., Triantafylou, D., Celentano, E., Krogh, V., Masala, G., Tumino, R., Agudo, A., Altzibar, J.M., Ardanaz, E., Martinez-Garcia, C., Arguelles, M.V., Tormo, M.J., Braaten, T., Lund, E., Manjer, J., Zackrisson, S., Hallmans, G., Malmer, B., Boffetta, P., Brennan, P., Slimani, N., Vineis, P., Riboli, E., Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, Hermann, S., Rohrmann, S., Linseisen, J., Nieters, A., Khan, A., Gallo, V., Overvad, K., Tjønneland, A., Raaschou-Nielsen, O., Bergmann, M.M., Boeing, H., Becker, N., Kaaks, R., Bas Bueno-De-Mesquita, H., May, A.M., Vermeulen, R.C.H., Bingham, S., Khaw, K.-T., Key, T.J., Travis, R.C., Trichopoulou, A., Georgila, C., Triantafylou, D., Celentano, E., Krogh, V., Masala, G., Tumino, R., Agudo, A., Altzibar, J.M., Ardanaz, E., Martínez-García, C., Suárez, M.V.A., Tormo, M.J., Braaten, T., Lund, E., Manjer, J., Zackrisson, S., Hallmans, G., Malmer, B., Boffetta, P., Brennan, P., Slimani, N., Vineis, P., and Riboli, E.
Subjects: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, lymphoma, European, Risk Assessment, Sex Factors, Risk Factors, immune system diseases, Surveys and Questionnaires, Internal medicine, hemic and lymphatic diseases, Prevalence, medicine, Humans, cancer, Prospective Studies, ddc:610, Risk factor, Prospective cohort study, Proportional Hazards Models, education, business.industry, Incidence, Lymphoma, Non-Hodgkin, Incidence (epidemiology), General Medicine, Middle Aged, medicine.disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Diet, Non-Hodgkin's lymphoma, European Prospective Investigation into Cancer and Nutrition, Lymphoma, Europe, nutrition, Immunology, Educational Status, Female, Lymphoma, Large B-Cell, Diffuse, business, Diffuse large B-cell lymphoma, Cohort study
Abstract: Introduction: Lymphomas belong to the few cancer sites with increasing incidence over past decades, and only a few risk factors have been established. We explored the association between education and the incidence of lymphoma in the prospective EPIC study. Materials and methods: Within 3,567,410 person-years of follow-up, 1,319 lymphoma cases [1,253 non-Hodgkin lymphomas (NHL) and 66 Hodgkin lymphomas (HL)] were identified. Cox proportional hazard regression was used to examine the association between highest educational level (primary school or less, technical/professional school, secondary school, university) and lymphoma risk. Results: Overall, no consistent associations between educational level and lymphoma risk were observed; however, associations were found for sub-groups of the cohort. We observed a higher risk of B-NHL (HR = 1.31, 95% CI = 1.02-1.68; n = 583) in women with the highest education level (university) but not in men. Concerning sub-classes of B-NHL, a positive association between education and risk of B cell chronic lymphatic leukaemia (BCLL) was observed only in women. In both genders, the risk of diffuse large B cell lymphoma (DLBCL) was significantly lower for subjects with university degree (HR = 0.46, 95% CI = 0.27-0.79) versus lowest educational level. No association was found for HL. Conclusion: We could not confirm an overall consistent association of education and risk of HL or NHL in this large prospective study; although, education was positively related to the incidence of BCLL and B-NHL (in women) but inversely to incidence of DLBCL. Due to limited number of cases in sub-classes and the large number of comparisons, the possibility of chance findings can not be excluded. © 2009 Springer-Verlag.
Published: 2010

32. Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and risk of in situ breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort

Author: Christina C. Dahm, Marc J. Gunter, Carlotta Sacerdote, Carmen Santiuste, Sabine Rohrmann, Merete Ellingjord-Dale, Cecilie Kyrø, Anika Hüsing, Renée T. Fortner, Eva Ardanaz, Antonia Trichopoulou, María Dolores López, Claudia Agnoli, Elisabete Weiderpass, Virginia Menéndez, Rudolf Kaaks, Signe Borgquist, Marina Kvaskoff, Patrick Arveux, Anne Tjønneland, Carlo La Vecchia, Helene Tilma Vistisen, Marije F. Bakker, Antonio Agudo, María José Sánchez, Agnès Fournier, Laure Dossus, Kay-Tee Khaw, Timothy J. Key, Guri Skeie, Eleni Peppa, Rosario Tumino, Elio Riboli, Salma Butt, Carla H. van Gils, Nena Karavasiloglou, Kostantinos K. Tsilidis, Tilman Kühn, Giovanna Masala, Inge Huybrechts, Matthias B. Schulze, Domenico Palli, Anna Karakatsani, Jenny Chang-Claude, Salvatore Panico, Apollo - University of Cambridge Repository, [Karavasiloglou,N, Rohrmann,S] Division of Chronic Disease Epidemiology, Institute for Epidemiology, Biostatistics and Prevention, University of Zurich, Zurich, Switzerland. [Karavasiloglou,N, Rohrmann,S] Cancer Registry Zurich and Zug, University Hospital Zurich, Zurich, Switzerland. [Karavasiloglou,N, Hüsing,A, Turzanski Fortner,R, Chang-Claude,J, Kaaks,R, Kühn,T] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Masala,G, Palli,D] Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy. [van Gils,CH, Bakker,MF] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. [Huybrechts,I, Weiderpass,E, Dossus,L] International Agency for Research on Cancer, Lyon, France. [Weiderpas,E, Skeie,G] Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. [Arveux,P, Fournier,A, Kvaskoff,M] CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France. [Arveux,P, Kvaskoff,M] Gustave Roussy, Villejuif, France. [Arveux,P] Breast and Gynaecologic Cancer Registry of Côte d’Or, Georges-François Leclerc Cancer Centre, UNICANCER, Dijon, France. [Tjønneland,A] Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. [Tjønneland,A, Kyrø,C] Danish Cancer Society Research Center, Copenhagen, Denmark. [Dahm,CC, Vistisen,HT] Department of Public Health, Aarhus University, Aarhus, Denmark. [Sánchez,MJ] Andalusian School of Public Health (EASP), Granada, Spain. [Sánchez,MJ] Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain. [Sánchez,MJ, Chirlaque López,MD, Santiuste,C, Ardanaz,E] CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. [Sánchez,MJ] Universidad de Granada, Granada, Spain. [Chirlaque López,MD, Santiuste,C] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Chirlaque López,MD] Department of Health and Social Sciences, Murcia University, Murcia, Spain. [Ardanaz,E] Navarra Public Health Institute, Pamplona, Spain. [Ardanaz,E] IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. [Menéndez,V] Public Health Directorate, Asturias, Spain. [Agudo,A] Unit of Nutrition and Cancer, Catalan Institute of Oncology - ICO, Nutrition and Cancer Group, Bellvitge Biomedical Research Institute - IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. [Trichopoulou,A, Karakatsani,A, La Vecchia,C, Peppa,E] Hellenic Health Foundation, Athens, Greece. [Karakatsani,A] 2nd Pulmonary Medicine Department, School of Medicine, 'ATTIKON' University Hospital, National and Kapodistrian University of Athens, Haidari, Greece. [La Vecchia,C] Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy. [Agnoli,C] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Panico,S] Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy. [Tumino,R] Cancer Registry and Histopathology Department, Azienda Sanitaria Provinciale (ASP), Ragusa, Italy. [Sacerdote,C] Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy. [Butt,ST] Department of Clinical Sciences, Lund University, Malmö, Sweden. [Butt,ST] Department of Surgery, Skåne University Hospital, Malmö, Sweden. [Borgquist,S] Department of Oncology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark. [Borgquist,S] Division of Oncology and Pathology, Clinical Sciences, Lund University, Lund, Sweden. [Skeie,G] Nutritional Epidemiology Group, School of Food Science and Nutrition, University of Leeds, Leeds, UK. [Schulze,M] Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany. [Key,T] Nuffield Department of Population Health, University of Oxford, Oxford, UK. [Khaw,KT] Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. [Tsilidis,KK, Ellingjord-Dale,M, Riboli,E] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. [Tsilidis,KK] Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece., The coordination of the European Prospective Investigation into Cancer and Nutrition (EPIC) is supported financially by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (France), German Cancer Aid, German Cancer Research Center (German Cancer Research Center), Federal Ministry of Education and Research (Federal Ministry of Education and Research), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research (Germany), Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (Ministry of Health, Welfare and Sport), Netherlands Cancer Registry (Netherlands Cancer Registry), LK Research Funds, Dutch Prevention Funds, Dutch Zorg Onderzoek Nederland, World Cancer Research Fund, Statistics Netherlands (the Netherlands), Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS) - Instituto de Salud Carlos III (ISCIII), the Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology - ICO, Swedish Cancer Society, Swedish Research Council, and County Councils of Skåne and Västerbotten (Sweden), Cancer Research UK (14136 to EPIC-Norfolk, C570/A16491 and C8221/A19170 to EPIC-Oxford), and the Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK)., Tjønneland, Anne [0000-0003-4385-2097], Dahm, Christina C [0000-0003-0481-2893], Tumino, Rosario [0000-0003-2666-414X], and Borgquist, Signe [0000-0001-7938-8893]
Subjects: 0301 basic medicine, Male, Breastfeeding, lcsh:Medicine, Breast carcinoma in situ, GUIDELINES, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Cohort Studies, 0302 clinical medicine, Breast cancer, Risk Factors, Medicine, Prospective Studies, Prospective cohort study, 11 Medical and Health Sciences, Medicine(all), Geographical Locations::Geographic Locations::Americas::North America::United States [Medical Subject Headings], Hazard ratio, Academies and Institutes, Cohort, General Medicine, Middle Aged, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Lifestyle Score, Europe, POSTMENOPAUSAL WOMEN, 030220 oncology & carcinogenesis, Female, CONCORDANCE, Life Sciences & Biomedicine, PROJECT, In situ breast cancer, Cohort study, Research Article, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Estudios de cohortes, RECREATIONAL PHYSICAL-ACTIVITY, Check Tags::Male [Medical Subject Headings], Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Data Collection::Nutrition Assessment [Medical Subject Headings], Breast Neoplasms, Estilo de vida, Càncer de mama, 03 medical and health sciences, Medicine, General & Internal, Medicina preventiva, DIETARY, General & Internal Medicine, Journal Article, Humans, VDP::Medisinske Fag: 700, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Carcinoma de mama in situ, Preventive medicine, 030109 nutrition & dietetics, Cancer prevention, Science & Technology, business.industry, Prevention, lcsh:R, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], medicine.disease, Lifestyle, United States, VDP::Medical disciplines: 700, Nutrition Assessment, Health Care::Health Care Economics and Organizations::Organizations::Academies and Institutes [Medical Subject Headings], Check Tags::Female [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings], Cancer research, Life style, Geographical Locations::Geographic Locations::Europe [Medical Subject Headings], business
Abstract: Background Even though in situ breast cancer (BCIS) accounts for a large proportion of the breast cancers diagnosed, few studies have investigated potential risk factors for BCIS. Their results suggest that some established risk factors for invasive breast cancer have a similar impact on BCIS risk, but large population-based studies on lifestyle factors and BCIS risk are lacking. Thus, we investigated the association between lifestyle and BCIS risk within the European Prospective Investigation into Cancer and Nutrition cohort. Methods Lifestyle was operationalized by a score reflecting the adherence to the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations. The recommendations utilized in these analyses were the ones pertinent to healthy body weight, physical activity, consumption of plant-based foods, energy-dense foods, red and processed meat, and sugary drinks and alcohol, as well as the recommendation on breastfeeding. Cox proportional hazards regression was used to assess the association between lifestyle score and BCIS risk. The results were presented as hazard ratios (HR) and corresponding 95% confidence intervals (CI). Results After an overall median follow-up time of 14.9 years, 1277 BCIS cases were diagnosed. Greater adherence to the WCRF/AICR cancer prevention recommendations was not associated with BCIS risk (HR = 0.98, 95% CI 0.93–1.03; per one unit of increase; multivariable model). An inverse association between the lifestyle score and BCIS risk was observed in study centers, where participants were recruited mainly via mammographic screening and attended additional screening throughout follow-up (HR = 0.85, 95% CI 0.73–0.99), but not in the remaining ones (HR = 0.99, 95% CI 0.94–1.05). Conclusions While we did not observe an overall association between lifestyle and BCIS risk, our results indicate that lifestyle is associated with BCIS risk among women recruited via screening programs and with regular screening participation. This suggests that a true inverse association between lifestyle habits and BCIS risk in the overall cohort may have been masked by a lack of information on screening attendance. The potential inverse association between lifestyle and BCIS risk in our analyses is consistent with the inverse associations between lifestyle scores and breast cancer risk reported from previous studies.
Published: 2019

33. Prospective analysis of circulating metabolites and breast cancer in EPIC

Author: José María Huerta, Salvatore Panico, Antonia Trichopoulou, Joseph A. Rothwell, Sabina Sieri, Anja Olsen, Christina C. Dahm, Ruth C. Travis, Audrey Gicquiau, Pilar Amiano, Elisabete Weiderpass, N. Charlotte Onland-Moret, Antonio Agudo, Anna Karakatsani, Isabelle Romieu, Paolo Vineis, Mathilde His, Elio Riboli, Marc J. Gunter, Guri Skeie, Tilman Kühn, Augustin Scalbert, Carla H. van Gils, Georgia Martimianaki, Therese Haugdahl Nøst, Anne Tjønneland, Heiner Boeing, Laure Dossus, Pietro Ferrari, Julie A. Schmidt, Rosario Tumino, Konstantinos K. Tsilidis, David Achaintre, Torkjel M. Sandanger, Agnès Fournier, Sofia Christakoudi, María José Sánchez, Vivian Viallon, Renée T. Fortner, Kim Overvad, Giovanna Masala, Sabina Rinaldi, J. Ramón Quirós, Gianluca Severi, Eva Ardanaz, [His,M, Viallon,V, Dossus,L, Gicquiau,A, Achaintre,D, Scalbert,A, Ferrari,P, Weiderpass,E, Gunter,MJ, Rinaldi,S] International Agency for Research on Cancer, Lyon, France. [Romieu,I] Centre for Research on Population Health, National Institute of Public Health, Cuernavaca, Mexico. [Onland-Moret,NC, van Gils,CH] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. [Dahm,CC, Overvad,K] Department of Public Health, Aarhus University, Aarhus, Denmark. [Overvad,K] Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark. [Olsen,A, Tjønneland,A] Danish Cancer Society Research Center, Copenhagen, Denmark. [Tjønneland,A] University of Copenhagen, Copenhagen, Denmark. [Fournier,A, Rothwell,JA, Severi,G] CESP, Université Paris-Sud, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France. [Fournier,A, Severi,G] Gustave Roussy, Villejuif, France. [Kühn,T, Fortner,R] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Boeing,H] Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany. [Trichopoulou,A, Karakatsani,A, Martimianaki,G] Hellenic Health Foundation, Athens, Greece. [Karakatsani,A] Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, 'ATTIKON' University Hospital, Haidari, Greece. [Masala,G] Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network – ISPRO, Florence, Italy. [Sieri,S] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. [Tumino,R] Cancer Registry and Histopathology Department, 'M.P.Arezzo'Hospital, ASP Ragusa, Ragusa, Italy. [Vineis,P] Italian Institute for Genomic Medicine (IIGM), Turin, Italy. [Vineis,P] MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK. [Panico,S] Dipartimento di medicina clinica e chirurgia, Federico II University, Naples, Italy. [Nøst,TH, Sandanger,TM, Skeie,G] Department of Community Medicine, UiT the Arctic University of Norway, Tromso, Norway. [Skeie,G] Nutritional Epidemiology Group, School of Food Science and Nutrition, University of Leeds, Leeds, UK. [Quirós,JR] Public Health Directorate, Asturias, Spain. [Agudo,A] Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain. [Sánchez,MJ] Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Universidad de Granada, Granada, Spain. [Sánchez,MJ, Amiano,P, Huerta,JM, Ardanaz,E] CIBER Epidemiology and Public Health CIBERESP, Madrid, Spain. [Amiano,P] Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain. [Huerta,JM] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Ardanaz,E] Navarra Public Health Institute, Pamplona, Spain. [Ardanaz,E] IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. [Schmidt,JA, Travis,RC] Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. [Riboli,E, Tsilidis,KK, Christakoudi,S] Department of Epidemiology and Biostatistics, Imperial College London, St Mary’s Campus, Norfolk Place, London, UK. [Tsilidis,KK] Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. [Christakoudi,S] MRC Centre for Transplantation, King’s College London, Great Maze Pond, London, SE1 9RT, UK, This work was funded by the French National Cancer Institute (grant number 2015-166). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany), the Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), European Research Council (ERC-2009-AdG 232997), and Nordforsk, Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (no. 6236), Navarra, and the CERCA Program (Generalitat de Catalunya) (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden), and Cancer Research UK (14136 to EPIC-Norfolk, and C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom).
Subjects: 0301 basic medicine, Oncology, lcsh:Medicine, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Mass Spectrometry, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Cohort Studies, 0302 clinical medicine, Breast cancer, Information Science::Information Science::Data Collection::Vital Statistics::Morbidity::Incidence [Medical Subject Headings], Risk Factors, Estudios prospectivos, Prospective Studies, Prospective cohort study, 11 Medical and Health Sciences, Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], education.field_of_study, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings], VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801, Incidence, Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biochemistry::Metabolomics [Medical Subject Headings], General Medicine, Metabolómica, Middle Aged, metabolomics, 3. Good health, Research Design, 030220 oncology & carcinogenesis, Cohort, Neoplasias de la mama, Female, Chemicals and Drugs::Biological Factors::Biological Markers::Biomarkers, Pharmacological [Medical Subject Headings], Cohort study, Research Article, prospective study, Adult, medicine.medical_specialty, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Population, Breast Neoplasms, Càncer de mama, 03 medical and health sciences, breast cancer, Internal medicine, Cell Line, Tumor, General & Internal Medicine, medicine, Journal Article, Metabolomics, Humans, Prospective study, education, Persons::Persons::Age Groups::Adult [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Aged, business.industry, lcsh:R, Case-control study, Cancer, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Odds ratio, medicine.disease, 030104 developmental biology, Check Tags::Female [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings], Case-Control Studies, VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801, business, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Chemistry Techniques, Analytical::Mass Spectrometry [Medical Subject Headings], Biomarkers
Abstract: BackgroundMetabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk.MethodsA nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivariable conditional logistic regression.ResultsAmong women not using hormones at baseline (n = 2248), and after control for multiple tests, concentrations of arginine (odds ratio [OR] per SD = 0.79, 95% confidence interval [CI] = 0.70–0.90), asparagine (OR = 0.83 (0.74–0.92)), and phosphatidylcholines (PCs) ae C36:3 (OR = 0.83 (0.76–0.90)), aa C36:3 (OR = 0.84 (0.77–0.93)), ae C34:2 (OR = 0.85 (0.78–0.94)), ae C36:2 (OR = 0.85 (0.78–0.88)), and ae C38:2 (OR = 0.84 (0.76–0.93)) were inversely associated with breast cancer risk, while the acylcarnitine C2 (OR = 1.23 (1.11–1.35)) was positively associated with disease risk. In the overall population, C2 (OR = 1.15 (1.06–1.24)) and PC ae C36:3 (OR = 0.88 (0.82–0.95)) were associated with risk of breast cancer, and these relationships did not differ by breast cancer subtype, age at diagnosis, fasting status, menopausal status, or adiposity.ConclusionsThese findings point to potentially novel pathways and biomarkers of breast cancer development. Results warrant replication in other epidemiological studies.
Published: 2019

34. Osteoprotegerin and breast cancer risk by hormone receptor subtype: A nested case-control study in the EPIC cohort

Author: Miren Dorronsoro, Marc J. Gunter, Mathilde His, Helena Schock, Sabina Sieri, Maria Dolores Chirlaque, Aurélie Affret, Rudolf Kaaks, Elisabete Weiderpass, H. Bas Bueno-de-Mesquita, Philippos Orfanos, Melissa A. Merritt, Anne Tjønneland, Domenico Palli, J. Ramón Quirós, María José Sánchez, Theron Johnson, Danja Sarink, Eva Ardanaz, Antonio Agudo, Renée T. Fortner, Laure Dossus, Timothy J. Key, Kim Overvad, Rosario Tumino, Androniki Naska, Petra H.M. Peeters, Heiner Boeing, Amalia Mattiello, Anja Olsen, Sabina Rinaldi, Eiliv Lund, Antonia Trichopoulou, Carla H. van Gils, Marie-Christine Boutron-Ruault, Kay-Tee Khaw, Elio Riboli, Fulvio Ricceri, Khaw, Kay-Tee [0000-0002-8802-2903], Apollo - University of Cambridge Repository, University Medical Center Utrecht, Imperial College Trust, [Fortner,RT, Sarink,D, Schock,H, Johnson,T, Kaaks,R] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Tjønneland,A, Olsen,A] Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark. [Overvad,K] Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark. [Affret,A, His,M, Boutron-Ruault,MC] Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France. [Affret,A, Boutron-Ruault,MC] Villejuif, France. [Boeing,H] Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany. [Trichopoulou,A, Naska,A, Orfanos,P] Hellenic Health Foundation, Athens, Greece. [Trichopoulou,A, Orfanos,P] WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece. [Palli,D] Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, Florence, Italy. [Sieri,S] Epidemiology and Prevention Unit, Department of Preventive & Predictive Medicine Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Mattiello,A] Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy. [Tumino,R] Cancer Registry and Histopathology Unit, 'Civic - M.p.Arezzo' Hospital, ASP Ragusa, Italy. [Ricceri,F] Unit of Epidemiology, Regional Health Service ASL TO3, Grugliasco (TO), Italy. [Ricceri,F] Unit of Cancer Epidemiology, Department of Medical Sciences, University of Turin, Turin, Italy. [Bueno-de-Mesquita,HB] Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. [Bueno-de-Mesquita,HB, Merritt,MA, Riboli,E] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. [Bueno-de-Mesquita,HB] Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. [Peeters,PH, Van Gils,CH] Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands. [Peeters,PH] MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, UK. [Weiderpass,E, Lund,E] Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. [Weiderpass,E] Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway. [Weiderpass,E] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. [Weiderpass,E] Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland. [Quirós,JR] Public Health Directorate, Asturias, Spain. [Agudo,A] Unit of Nutrition and Cancer. Cancer Epidemiology Research Program. Catalan Institute of Oncology-IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain. [Sánchez,MJ] Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs. GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. [Sánchez,MJ, Chirlaque,MD, Ardanaz,E] CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Chirlaque,MD] Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Chirlaque,MD] Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain. [Ardanaz,E] Navarra Public Health Institute, Pamplona, Spain. [Ardanaz,E] IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. [Dorronsoro,M] Public Health Direction and Biodonostia Research Institute CIBERESP, Basque Regional Health Department, San Sebastian, Spain. [Key,T] Nuffield Department of Population Health, University of Oxford, Oxford, UK. [Khaw,KT] Cancer Epidemiology Unit, University of Cambridge, Cambridge, UK. [Rinaldi,S, Dossus,L, Gunter,M] International Agency for Research on Cancer, Lyon, France., This project was funded by research grant 111454 from the Deutsche Kresbshilfe. RT Fortner was supported by a Marie Curie International Incoming Fellowship of the European Commission’s Seventh Framework Programme (MC-IIF-623984). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research (Germany), the Hellenic Health Foundation (Greece), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and the National Research Council (Italy), the Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (The Netherlands), ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia, and Navarra, and ISCIII RETIC (RD06/0020) (Spain), the Swedish Cancer Society, Swedish Research Council, and County Councils of Skåne and Västerbotten (Sweden), and Cancer Research UK (14136 to EPIC-Norfolk, and C570/A16491 and C8221/A19170 to EPIC-Oxford), and the Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK).
Subjects: 0301 basic medicine, Oncology, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Transcription Factors::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Progesterone [Medical Subject Headings], Estrogen receptor, Progesterone receptor, Cohort Studies, 0302 clinical medicine, Breast cancer, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Cytokine::Receptors, Tumor Necrosis Factor::Receptor Activator of Nuclear Factor-kappa B [Medical Subject Headings], Risk Factors, Prospective Studies, Prospective cohort study, Medicine(all), Osteoprotegerina, biology, VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801, 11 Medical And Health Sciences, General Medicine, Middle Aged, Necrosi, 3. Good health, European Prospective Investigation into Cancer and Nutrition, RANK axis, RANKL, 030220 oncology & carcinogenesis, Neoplasias de la mama, Female, Research Article, musculoskeletal diseases, medicine.medical_specialty, Receptores estrogénicos, Health Care::Environment and Public Health::Public Health::Epidemiologic Factors::Causality::Risk Factors [Medical Subject Headings], Breast Neoplasms, Receptores de progesterona, Receptores de hormonas, Hormone receptor, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Estrogen [Medical Subject Headings], Càncer de mama, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings], Necrosis, 03 medical and health sciences, Osteoprotegerin, General & Internal Medicine, Internal medicine, Journal Article, medicine, Humans, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], business.industry, Case-control study, medicine.disease, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Prospective Studies [Medical Subject Headings], 030104 developmental biology, Endocrinology, Case-Control Studies, Nested case-control study, Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Climacteric::Menopause::Postmenopause [Medical Subject Headings], biology.protein, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Cytokine::Receptors, Tumor Necrosis Factor::Tumor Necrosis Factor Decoy Receptors::Osteoprotegerin [Medical Subject Headings], VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801, business
Abstract: All Author: Renée T. Fortner, Danja Sarink, Helena Schock, Theron Johnson, Anne Tjønneland, Anja Olsen, Kim Overvad, Aurélie Affret, Mathilde His, Marie-Christine Boutron-Ruault, Heiner Boeing, Antonia Trichopoulou, Androniki Naska, Philippos Orfanos, Domenico Palli, Sabina Sieri, Amalia Mattiello, Rosario Tumino, Fulvio Ricceri, H. Bas Bueno-de-Mesquita, Petra H. M. Peeters, Carla H. Van Gils, Elisabete Weiderpass, Eiliv Lund, J. Ramón Quirós, Antonio Agudo, Maria-José Sánchez, María-Dolores Chirlaque, Eva Ardanaz, Miren Dorronsoro, Tim Key, Kay-Tee Khaw, Sabina Rinaldi, Laure Dossus, Marc Gunter, Melissa A. Merritt, Elio Riboli and Rudolf Kaaks, Background: Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study. Methods: A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER–, n = 386), matched 1:1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT). Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. Results: The associations between OPG and ER+ and ER– breast cancer differed significantly. Higher concentrations of OPG were associated with increased risk of ER– breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24–3.02]; ptrend = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women premenopausal at blood collection. Results for ER– disease did not differ by menopausal status at blood collection (phet = 0.97), and we observed no heterogeneity by HT use at blood collection (phet ≥ 0.43) or age at breast cancer diagnosis (phet ≥ 0.30). Conclusions: This study provides the first prospective data on OPG and breast cancer risk by hormone receptor subtype. High circulating OPG may represent a novel risk factor for ER– breast cancer., This project was funded by research grant 111454 from the Deutsche Kresbshilfe. RT Fortner was supported by a Marie Curie International Incoming Fellowship of the European Commission’s Seventh Framework Programme (MC-IIF-623984). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and the National Research Council (Italy); the Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia, and Navarra, and ISCIII RETIC (RD06/0020) (Spain); the Swedish Cancer Society, Swedish Research Council, and County Councils of Skåne and Västerbotten (Sweden); and Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), and the Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK).
Published: 2017

35. The INSIG2 rs7566605 polymorphism is not associated with body mass index and breast cancer risk

Author: Olga M. Sinilnikova, Rudolf Kaaks, Pilar Amiano, Anne Tjønneland, José Ramón Quirós, Eiliv Lund, Daniele Campa, Carla H. van Gils, Göran Hallmans, Kay-Tee Khaw, H. Bas Bueno-de-Mesquita, Anika Hüsing, Sabina Rinaldi, Nicholas J. Wareham, Nathalie Chabbert-Buffet, Kim Overvad, Eva Ardanaz, Sabine Rohrmann, Vittorio Krogh, Federico Canzian, Giovanna Masala, Françoise Clavel-Chapelon, María Dolores Chirlaque, Per Lenner, Carlotta Sacerdote, Esther Molina-Montes, Guy Fagherazzi, Jakob Stegger, James McKay, N. Charlotte Onland-Moret, Salvatore Panico, Rosario Tumino, Afshan Siddiq, Birgit Teucher, Timothy J. Key, Erifili Oustoglou, Ruth C. Travis, Veronique Chajes, Dimosthenis Zylis, Ulla Vogel, Antonia Trichopoulou, Elio Riboli, Nadia Slimani, Heiner Boeing, Núria Sala, Eva Fisher, Wareham, Nicholas [0000-0003-1422-2993], Khaw, Kay-Tee [0000-0002-8802-2903], Apollo - University of Cambridge Repository, Campa, D, Hüsing, A, Mckay, Jd, Sinilnikova, O, Vogel, U, Tjønneland, A, Overvad, K, Stegger, J, Clavel Chapelon, F, Chabbert Buffet, N, Fagherazzi, G, Trichopoulou, A, Zylis, D, Oustoglou, E, Rohrmann, S, Teucher, B, Fisher, E, Boeing, H, Masala, G, Krogh, V, Sacerdote, C, Panico, Salvatore, Tumino, R, Onland Moret, Nc, van Gils, Ch, Bueno de Mesquita, Hb, Lund, E, Chirlaque, Md, Sala, N, Quirós, Jr, Ardanaz, E, Amiano, P, Molina Montes, E, Hallmans, G, Lenner, P, Travis, Rc, Key, Tj, Wareham, N, Khaw, Kt, Rinaldi, S, Slimani, N, Chajes, V, Siddiq, A, Riboli, E, Kaaks, R, Canzian, F., and [Campa D, Hüssing A, Rohrmann S, Teucher B, Kaaks R, Canzian F] German Cancer Research Center (DKFZ), Heidelberg, Germany. [McKay JD, Slimani N, Chajes V] International Agency for Research on Cancer, Lyon, France. [Sinilnikova O] Hospices Civils de Lyon/Centre Léon Bérard, UMR5201 CNRS-Université Claude Bernard, Lyon, France. [Vogel U] National Food Institute Technical University of Denmark, Denmark. [Tjønneland A] Danish Cancer Society, Copenhagen, Denmark. [Overvad K] Aarhus University Hospital, Aalborg, Denmark. [Stegger J] Department of Cardiology, Cardiovascular Research Centre, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark. [Clavel-Chapelon F, Chabbert-Buffet N, Fagherazzi G] Institut Gustave Roussy, Villejuif, France. [Trichopoulou A, Zylis D] WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece. [Trichopoulou A, Oustoglou E] Hellenic Health Foundation, Athens, Greece. [Fisher E, Boeing H] German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany. [Masala G] Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy. [Krogh V] Istituto Nazionale dei Tumori (IRCCS), Milan, Italy. [Sacerdote C] CPO Piemonte, Turin, Italy. [Panico S] Department of Clinical and Experimental Medicine Federico II University, Naples, Italy. [Tumino R] Azienda Ospedaliera 'Civile M.P.Arezzo' Ragusa, Italy. [Onland-Moret NC, van Gils CH] Julius Center, University Medical Center, Utrecht, The Netherlands. [Bueno-de-Mesquita HB] National Institute for Public Health and the Environment, Bilthoven, The Netherlands. [Lund E] Institute of Community Medicine University of Tromsø, Tromsø, Norway. [Chirlaque MD] Murcia Regional Health Council, Murcia, Spain. [Sala N] Catalan Institute of Oncology, Barcelona, Spain. [Quirós JR] Consejería de Salud y Servicios Sanitarios Principado de Asturias, Oviedo, Spain. [Ardanaz E] Public Health Institute of Navarra, Pamplona, Spain. [Amiano P] Public Health Department of Gipuzkoa, San Sebastian, Spain. [Molina-Montes E] Andalusian School of Public Health, Granada, Spain. [Chirlaque MD, Amiano P, Molina-Montes E] CIBER de Epidemiología y Salud Pública (CIBERESP), Spain. [Hallmans G, Lenner2 P] Umeå University, Umeå, Sweden. [Travis RC, Key TJ] Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK OX3 7LF. [Wareham N, Khaw KT] University of Cambridge, Cambridge, UK. [Siddiq A, Riboli E] Imperial College, London, UK.
Subjects: Oncology, Aging, Cancer Research, Genome-wide association study, 32 Biomedical and Clinical Sciences, Body Mass Index, Cohort Studies, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Research Design::Genome-Wide Association Study [Medical Subject Headings], 0302 clinical medicine, 2.1 Biological and endogenous factors, membrane protein, POPULATION, Cancer, 2. Zero hunger, 2 Aetiology, 0303 health sciences, education.field_of_study, Intracellular Signaling Peptides and Proteins, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 4203 Health Services and Systems, 3. Good health, Índice de masa muscular, INSIG2 protein, Adipose Tissue, Neoplasias de la mama, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intracellular Signaling Peptides and Proteins [Medical Subject Headings], Female, Life Sciences & Biomedicine, Cohort study, Research Article, Adult, Risk, medicine.medical_specialty, VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk genetikk: 714, Genotype, Estudios de cohortes, Population, Polimorfismo Genético, COMMON GENETIC VARIANT, PHENOTYPES, 030209 endocrinology & metabolism, Single-nucleotide polymorphism, Breast Neoplasms, VDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Medical genetics: 714, lcsh:RC254-282, Estudio de Asociación del Genoma Completo, 03 medical and health sciences, Breast cancer, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings], SDG 3 - Good Health and Well-being, Clinical Research, Internal medicine, Breast Cancer, POLYGENIC CONTRIBUTION, medicine, Genetics, Humans, signal peptide, Neoplasm Invasiveness, Obesity, human, education, Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], 030304 developmental biology, Nutrition, Aged, Science & Technology, Polymorphism, Genetic, Models, Genetic, business.industry, VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762, Prevention, Case-control study, 42 Health Sciences, Membrane Proteins, DNA, Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic [Medical Subject Headings], medicine.disease, 3211 Oncology and Carcinogenesis, Health Care::Environment and Public Health::Public Health::Epidemiologic Measurements::Biometry::Anthropometry::Body Mass Index [Medical Subject Headings], VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762, Case-Control Studies, Immunology, INSIG2 protein, human, business, Body mass index, Genome-Wide Association Study
Abstract: Background The single nucleotide polymorphism rs7566605, located in the promoter of the INSIG2 gene, has been the subject of a strong scientific effort aimed to elucidate its possible association with body mass index (BMI). The first report showing that rs7566605 could be associated with body fatness was a genome-wide association study (GWAS) which used BMI as the primary phenotype. Many follow-up studies sought to validate the association of rs7566605 with various markers of obesity, with several publications reporting inconsistent findings. BMI is considered to be one of the measures of choice to evaluate body fatness and there is evidence that body fatness is related with an increased risk of breast cancer (BC). Methods we tested in a large-scale association study (3,973 women, including 1,269 invasive BC cases and 2,194 controls), nested within the EPIC cohort, the involvement of rs7566605 as predictor of BMI and BC risk. Results and Conclusions In this study we were not able to find any statistically significant association between this SNP and BMI, nor did we find any significant association between the SNP and an increased risk of breast cancer overall and by subgroups of age, or menopausal status.
Published: 2016

36. Consumption of vegetables and fruit and the risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition

Author: Anne Tjønneland, Carlos González, Ole Raaschou-Nielsen, Marina Touillaud, Sabina Sieri, Françoise Clavel-Chapelon, Salvatore Panico, Lambertus A. Kiemeney, Jonas Manjer, Pagona Lagiou, Rudolf Kaaks, Dimitrios Trichopoulos, Nina Roswall, Andrew W. Roddam, Carla H. van Gils, Inger T. Gram, Steffen Weikert, Frederike L. Büchner, Kim Overvad, Paolo Vineis, Roy Ehrnström, Eva Ardanaz, Nadia Slimani, Martine M. Ros, H. Bas Bueno-de-Mesquita, Sheila Bingham, Traci Mouw, Eiliv Lund, Antonia Trichopoulou, Laudina Rodríguez, Göran Hallmans, Lars Egevad, Ellen Kampman, Rosario Tumino, Carmen Enid Martínez, Heiner Boeing, Kay-Tee Khaw, Marie-Christine Boutron-Ruault, Domenico Palli, Dagrun Engeset, Jenny Chang-Claude, Mazda Jenab, Dominique S. Michaud, Carmen Navarro, Naomi E. Allen, Petra H.M. Peeters, Nerea Larrañaga, Elio Riboli, Alina Vrieling, Börje Ljungberg, Paolo Boffetta, Büchner, F.L., Bueno-De-Mesquita, H.B., Ros, M.M., Kampman, E., Egevad, L., Overvad, K., Raaschou-Nielsen, O., Tjønneland, A., Roswall, N., Clavel-Chapelon, F., Boutron-Ruault, M.-C., Touillaud, M., Chang-Claude, J., Kaaks, R., Boeing, H., Weikert, S., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Palli, D., Sieri, S., Vineis, P., Tumino, R., Panico, S., Vrieling, A., Peeters, P.H.M., Van Gils, C.H., Lund, E., Gram, I.T., Engeset, D., Martinez, C., Gonzalez, C.A., Larrañaga, N., Ardanaz, E., Navarro, C., Rodríguez, L., Manjer, J., Ehrnström, R.A., Hallmans, G., Ljungberg, B., Allen, N.E., Roddam, A.W., Bingham, S., Khaw, K.-T., Slimani, N., Boffetta, P., Jenab, M., Mouw, T., Michaud, D.S., Kiemeney, L.A.L.M., Riboli, E., Büchner, Fl, Bueno de Mesquita, Hb, Ros, Mm, Kampman, E, Egevad, L, Overvad, K, Raaschou Nielsen, O, Tjønneland, A, Roswall, N, Clavel Chapelon, F, Boutron Ruault, Mc, Touillaud, M, Chang Claude, J, Kaaks, R, Boeing, H, Weikert, S, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Palli, D, Sieri, S, Vineis, P, Tumino, R, Panico, Salvatore, Vrieling, A, Peeters, Ph, van Gils, Ch, Lund, E, Gram, It, Engeset, D, Martinez, C, Gonzalez, Ca, Larrañaga, N, Ardanaz, E, Navarro, C, Rodríguez, L, Manjer, J, Ehrnström, Ra, Hallmans, G, Ljungberg, B, Allen, Ne, Roddam, Aw, Bingham, S, Khaw, Kt, Slimani, N, Boffetta, P, Jenab, M, Mouw, T, Michaud, D, and Kiemeney, La
Subjects: Male, Cancer Research, Nutrition and Disease, Aetiology, screening and detection [ONCOL 5], Cohort Studies, 0302 clinical medicine, Risk Factors, Voeding en Ziekte, Vegetables, Epidemiology, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, 2. Zero hunger, carotenoids, Middle Aged, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Oncology, 030220 oncology & carcinogenesis, Female, epidemiology, vitamin-c, Cohort study, Adult, medicine.medical_specialty, prospective cohort, consumption vegetables fruit risk bladder cancer European Prospective Investigation Cancer Nutrition, folate, Molecular epidemiology [NCEBP 1], 03 medical and health sciences, Translational research [ONCOL 3], Environmental health, medicine, Humans, Risk factor, Aged, VLAG, Consumption (economics), Gynecology, Bladder cancer, Hereditary cancer and cancer-related syndromes [ONCOL 1], cigarette-smoking, business.industry, food, Cancer, medicine.disease, Urinary Bladder Neoplasms, Fruit, diet, business, Follow-Up Studies
Abstract: Contains fulltext : 81056.pdf (Publisher’s version ) (Closed access) Previous epidemiologic studies found inconsistent associations between vegetables and fruit consumption and the risk of bladder cancer. We therefore investigated the association between vegetable and fruit consumption and the risk of bladder cancer among participants of the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Data on food consumption and complete follow-up for cancer occurrence was available for a total of 478,533 participants, who were recruited in 10 European countries. Estimates of rate ratios were obtained by Cox proportional hazard models, stratified by age at recruitment, gender and study centre, and adjusted for total energy intake, smoking status, duration of smoking and lifetime intensity of smoking. A calibration study in a subsample was used to control for dietary measurement errors. After a mean follow-up of 8.7 years, 1015 participants were newly diagnosed with bladder cancer. Increments of 100 g/day in fruit and vegetable consumption combined did not affect bladder cancer risk (i.e., calibrated HR = 0.98; 95%CI: 0.95-1.01). Borderline statistically significant lower bladder cancer risks were found among never smokers with increased consumption of fruit and vegetables combined (HR = 0.94 95%CI: 0.87-1.00 with increments of 100 g/day; calibrated HR = 0.92 95%CI 0.79-1.06) and increased consumption of apples and pears (hard fruit; calibrated HR = 0.90 95%CI: 0.82-0.98 with increments of 25 g/day). For none of the associations a statistically significant interaction with smoking status was found. Our findings do not support an effect of fruit and vegetable consumption, combined or separately, on bladder cancer risk.
Published: 2009

37. Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort

Author: Amanda J. Cross, Petra H.M. Peeters, Pietro Ferrari, Françoise Clavel-Chapelon, Salvatore Panico, Augustin Scalbert, Anja Olsen, José María Huerta, Paolo Vineis, Gianluca Severi, Eva Ardanaz, H. Bas Bueno-de-Mesquita, Ruth C. Travis, Bénédicte Elena-Herrmann, Nicholas J. Wareham, Pagona Lagiou, Talita Duarte-Salles, Christina Bamia, Anne Tjønneland, Rudolf Kaaks, Bodil Ohlsson, Magdalena Stepien, Antonio Agudo, Krasimira Aleksandrova, Heiner Boeing, Isabelle Romieu, Kay-Tee Khaw, Veronika Fedirko, Domenico Palli, Julie A. Schmidt, Anne Fages, Rosario Tumino, Valeria Pala, Anna Floegel, Dimitrios Trichopoulos, Miren Dorronsoro, Marc J. Gunter, Klas Sjöberg, Clément Pontoizeau, Marie-Christine Boutron-Ruault, Elisabete Weiderpass, Tilman Kühn, Elio Riboli, Mazda Jenab, Antonia Trichopoulou, Esther Molina-Montes, Fages, Anne, Duarte Salles, Talita, Stepien, Magdalena, Ferrari, Pietro, Fedirko, Veronika, Pontoizeau, Clément, Trichopoulou, Antonia, Aleksandrova, Krasimira, Tjønneland, Anne, Olsen, Anja, Clavel Chapelon, Françoise, Boutron Ruault, Marie Christine, Severi, Gianluca, Kaaks, Rudolf, Kuhn, Tilman, Floegel, Anna, Boeing, Heiner, Lagiou, Pagona, Bamia, Christina, Trichopoulos, Dimitrio, Palli, Domenico, Pala, Valeria, Panico, Salvatore, Tumino, Rosario, Vineis, Paolo, Bueno de Mesquita, H. Ba, Peeters, Petra H, Weiderpass, Elisabete, Agudo, Antonio, Molina Montes, Esther, Huerta, José María, Ardanaz, Eva, Dorronsoro, Miren, Sjöberg, Kla, Ohlsson, Bodil, Khaw, Kay Tee, Wareham, Nick, Travis, Ruth C, Schmidt, Julie A, Cross, Amanda, Gunter, Marc, Riboli, Elio, Scalbert, Augustin, Romieu, Isabelle, Elena Herrmann, Benedicte, Jenab, Mazda, ISA NMR Methods for Metabolism - Methodes RMN en métabolomique (2014-2018), Institut des Sciences Analytiques (ISA), Institut de Chimie du CNRS (INC)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), ISA - Centre de RMN à très hauts champs, Centre International de Recherche contre le Cancer - International Agency for Research on Cancer (CIRC - IARC), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), parent, International Agency for Cancer Research (IACR), Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School [Athens], Department of Epidemiology, Deutsches Institut für Ernahrungsforschung Potsdam-Rehbrücke (DIFE), Institute of Cancer Epidemiology, Danish Cancer Society, Department of Food Science [Copenhagen] (UCPH FOOD), Faculty of Science [Copenhagen], University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut Gustave Roussy (IGR), Human Genetics Foundation (HuGeF), Università degli studi di Torino (UNITO), Division of Cancer Epidemiology, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Thermo Fisher Scientific, Thermo Fisher Scientific Inc., German Institute of Human Nutrition Potsdam-Rehbruecke, German Institute of Human Nutrition, Harvard School of Public Health, WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute – ISPO, Nutritional Epidemiology Unit, National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH)-National Institutes of Health [Bethesda] (NIH)-IRCCS Foundation, Department of Clinical and Experimental Medicine, Università degli studi di Napoli Federico II, Cancer Registry and Histopathology Unit, Civile - M.P.Arezzo Hospital, Department of Epidemiology and Biostatistics, MRC-HPA Centre for Environment and Health, School of Public Health, Imperial College London, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Julius Center for Health Sciences and Primary Care, VU University Medical Center [Amsterdam], Imperial College London-School of public health, The University of Hong Kong (HKU)-The University of Hong Kong (HKU), Department of Community Medicine, University of Tromsø (UiT), Department of Research, Cancer Registry of Norway-Samfundet Folkhälsan, Helsinki, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet [Stockholm], Institut Català d'Oncologia, Spain Institute of Oncology, Andalusian School of Public Health [Granada], Consortium for Biomedical Research in Epidemiology and Public Health, CIBER de Epidemiología y Salud Pública (CIBERESP), Danish Cancer Society Research Center, Murcia Regional Health Council, Sección de Epidemiología de Enfermedades No Transmisibles, Navarre Public Health Institute, Epidemiology and Health Information, Public Health Department of Gipuzkoa, Volvo, VOLVO-VOLVO, Skane University Hospital [Lund], University of Cambridge School of Clinical Medicine, MRC epidemiology Unit, Addenbrooke's Hospital, Cancer Epidemiology Unit, University of Oxford [Oxford], Laboratoire d'informatique Fondamentale de Marseille (LIF), Centre National de la Recherche Scientifique (CNRS)-École Centrale de Marseille (ECM)-Aix Marseille Université (AMU), School of Public Health [London, UK] (Faculty of Medicine), Imperial College London, Department of Chemistry, University of Cambridge [UK] (CAM), Nutrition and Metabolism Section, Biomarkers Group, Nutrition and Metabolism Section, This work was supported by the French National Cancer Institute (L'Institut National du Cancer, INCA, grant number 2009-139, PI: M. Jenab). AF received financial support (BDI fellowship) from the Centre National de la Recherche Scientifique (CNRS) and Bruker Biospin. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, and Institut National de la Sante et de la Recherche Medicale (INSERM) (France), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum (DKFZ), and Federal Ministry of Education and Research (Germany), Hellenic Health Foundation (Greece), Italian Association for Research on Cancer (AIRC), National Research Council, Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, and AIRE-ONLUS Ragusa, AVIS Ragusa, Sicilian Government (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (the Netherlands), European Research Council (ERC, grant number ERC-2009-AdG 232997) and Nordforsk, and Nordic Center of Excellence Programme on Food, Nutrition and Health (Norway), Health Research Fund (FIS), Regional Governments of Andalucia, Asturias, Basque Country, Murcia (No. 6236) and Navarra, and ISCIII RETIC (RD06/0020) (Spain), Swedish Cancer Society, Swedish Scientific Council, and Regional Government of Skane and Vasterbotten (Sweden), Cancer Research UK, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, and Wellcome Trust (UK). The funders had no role in the study design, data collection, analysis, and interpretation presented in this article. They were neither involved in the writing of the manuscript, nor in the decision to submit it for publication., Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Centre Européen de Résonance Magnétique Nucléaire à Très Hauts Champs (CERMNTHC), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Hôpital Paul Brousse-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), 'Civile M. P. Arezzo' Hospital, Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), [Fages,A, Pontoizeau,C, Elena-Herrmann,B] Institut des Sciences Analytiques, Centre de RMN à très hauts champs, CNRS/ENS Lyon/UCB Lyon-1, Université de Lyon, Villeurbanne, France. [Duarte-Salles,T, Stepien,M, Ferrari,P, Scalbert,A, Romieu,I, Jenab,M] International Agency for Research on Cancer (IARC-WHO), Lyon, France. [Fedirko,V] Department of Epidemiology, Rollins School of Public Health, Winship Cancer Institute, Emory University, Atlanta, USA. [Trichopoulou,A] Hellenic Health Foundation, Athens, Greece. Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece. [Aleksandrova,K, Floegel,A, Boeing,H] Department of Epidemiology, German Institute of Human Nutrition (DIfE), Potsdam-Rehbrücke, Germany. [Tjønneland,A, Olsen,A] Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark. [Clavel-Chapelon,F, Boutron-Ruault,M] INSERM, Centre for Research in Epidemiology and Population Health (CESP), nutrition, Hormones and Women’s Health Team, Villejuif, France. Université Paris Sud, Villejuif, France. Institut Gustave Roussy, Villejuif, France. [Severi,G, Vineis,P] Human Genetics Foundation (HuGeF), Torino, Italy. [Kaaks,R, Kuhn,T] Department of Cancer Epidemiology, German Cancer Research Centre, Heidelberg, Germany. [Lagiou,P, Bamia,C] Department of Hygiene, Epidemiology, and Medical Statistics, University of Athens Medical School, Goudi, Athens, Greece. [Lagiou,P, Trichopoulos,D] Department of Epidemiology, Harvard School of Public Health, Boston, USA. [Palli,D] Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute – ISPO, Florence, Italy. [Pala,V] Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. [Panico,S] Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy. [Tumino,R] Cancer Registry and Histopathology Unit, 'Civic - M.P. Arezzo' Hospital, Ragusa, Italy. [Vineis,P, Peeters,PH] MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK. [Bueno-de-Mesquita,HB] Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands. Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. [Bueno-de-Mesquita,HB, Cross,A, Gunter,M, RibolI,E] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. [Peeters,PH] Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. [Weiderpass,E] Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. Department of Research, Cancer Registry of Norway, Oslo, Norway. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Samfundet Folkhälsan, Helsinki, Finland. [Agudo,A] Unit of Nutrition and Cancer, IDIBELL, Catalan Institute of Oncology-ICO, L’Hospitalet de Llobregat, Barcelona, Spain. [Molina-Montes,E] Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. [Molina-Montes,E, Huerta,JM, Ardanaz, E] CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Huerta,JM] Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. [Ardanaz,E] Navarre Public Health Institute, Pamplona, Spain. [Dorronsoro,M] Public Health Direction and Biodonostia CIBERESP, Basque Regional Health Department, San Sebastian, Spain. [Sjöberg,K] Department of Clinical Sciences, Lund University, Malmö, Sweden. Department of Gastroenterology and Nutrition, Skåne University Hospital, Malmö, Sweden. [Ohlsson,B] Department of Clinical Sciences, Division of Internal Medicine, Skåne University Hospital, Lund University, Malmö, Sweden. [Khaw,K] University of Cambridge School of Clinical Medicine, Clinical Gerontology Unit, Addenbrooke’s Hospital, Cambridge, UK. [Wareham,N] MRC Epidemiology Unit, University of Cambridge, Cambridge, UK. [Travis,RC, Schmidt,JA] Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., This work was supported by the French National Cancer Institute (L’Institut National du Cancer, Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France), Health Research Fund (FIS), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (No. 6236) and Navarra, and ISCIII RETIC (RD06/0020) (Spain), Swedish Cancer Society, Swedish Scientific Council, and Regional Government of Skåne and Västerbotten (Sweden), Cancer Research UK, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, and Wellcome Trust (UK). The funders had no role in the study design, data collection, analysis, and interpretation presented in this article. They were neither involved in the writing of the manuscript, nor in the decision to submit it for publication, Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Università degli studi di Torino = University of Turin (UNITO), University of Naples Federico II = Università degli studi di Napoli Federico II, and University of Oxford
Subjects: Oncology, Male, Neoplasias Hepáticas, Cirrhosis, Magnetic Resonance Spectroscopy, Epidemiology, Hepatocellular carcinoma, Nuclear magnetic resonance, Cohort Studies, Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma::Carcinoma, Hepatocellular [Medical Subject Headings], 0302 clinical medicine, Risk Factors, Prospective Studies, Prospective cohort study, CIRRHOSIS, Early Detection of Cancer, Medicine(all), 0303 health sciences, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [Medical Subject Headings], Liver Neoplasms, Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biochemistry::Metabolomics [Medical Subject Headings], Metabolómica, Estudios Prospectivos, General Medicine, Middle Aged, CANCER, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Europe, Liver Neoplasm, 030220 oncology & carcinogenesis, Female, Liver cancer, Case-Control Studie, Life Sciences & Biomedicine, Metabolomics, Carcinoma Hepatocelular, Research Article, Human, Adult, medicine.medical_specialty, Carcinoma, Hepatocellular, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], TISSUE METABOLOMICS, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Habits::Smoking [Medical Subject Headings], Metabolomic, Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus [Medical Subject Headings], Càncer de fetge, 03 medical and health sciences, Medicine, General & Internal, [CHIM.ANAL]Chemical Sciences/Analytical chemistry, IDENTIFY SERUM BIOMARKERS, Internal medicine, General & Internal Medicine, medicine, Humans, Obesity, Epidemiologia, 030304 developmental biology, FATTY LIVER-DISEASE, Aged, Hepatitis, Science & Technology, business.industry, Case-control study, METABONOMICS, Cancer, MASS-SPECTROMETRY, medicine.disease, NMR, Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings], Prospective Studie, Case-Control Studies, DISCOVERY, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Drinking Behavior::Alcohol Drinking [Medical Subject Headings], Immunology, RISK-FACTORS, Cohort Studie, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Background: Hepatocellular carcinoma (HCC), the most prevalent form of liver cancer, is difficult to diagnose and has limited treatment options with a low survival rate. Aside from a few key risk factors, such as hepatitis, high alcohol consumption, smoking, obesity, and diabetes, there is incomplete etiologic understanding of the disease and little progress in identification of early risk biomarkers. Methods: To address these aspects, an untargeted nuclear magnetic resonance metabolomic approach was applied to pre-diagnostic serum samples obtained from first incident, primary HCC cases (n = 114) and matched controls (n = 222) identified from amongst the participants of a large European prospective cohort. Results: A metabolic pattern associated with HCC risk comprised of perturbations in fatty acid oxidation and amino acid, lipid, and carbohydrate metabolism was observed. Sixteen metabolites of either endogenous or exogenous origin were found to be significantly associated with HCC risk. The influence of hepatitis infection and potential liver damage was assessed, and further analyses were made to distinguish patterns of early or later diagnosis. Conclusion: Our results show clear metabolic alterations from early stages of HCC development with application for better etiologic understanding, prevention, and early detection of this increasingly common cancer., This work was supported by the French National Cancer Institute (L’Institut National du Cancer; INCA; grant number 2009-139; PI: M. Jenab). AF received financial support (BDI fellowship) from the Centre National de la Recherche Scientifique (CNRS) and Bruker Biospin. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum (DKFZ), and Federal Ministry of Education and Research (Germany); Hellenic Health Foundation (Greece); Italian Association for Research on Cancer (AIRC), National Research Council, Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, and AIRE-ONLUS Ragusa, AVIS Ragusa, Sicilian Government (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (the Netherlands); European Research Council (ERC; grant number ERC-2009-AdG 232997) and Nordforsk, and Nordic Center of Excellence Programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (No. 6236) and Navarra, and ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Scientific Council, and Regional Government of Skåne and Västerbotten (Sweden); Cancer Research UK, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, and Wellcome Trust (UK).
Published: 2015

38. The Association between Dietary Energy Density and Type 2 Diabetes in Europe: Results from the EPIC-InterAct Study

Author: InterAct Consortium, Saskia W van den Berg, Daphne L van der A, Annemieke M W Spijkerman, Geertruida J van Woudenbergh, Mariken J Tijhuis, Pilar Amiano, Eva Ardanaz, Joline W J Beulens, Heiner Boeing, Françoise Clavel-Chapelon, Francesca L Crowe, Blandine de Lauzon-Guillain, Guy Fagherazzi, Paul W Franks, Heinz Freisling, Carlos Gonzalez, Sara Grioni, Jytte Halkjaer, José María Huerta, Inge Huybrechts, Rudolf Kaaks, Kay Tee Khaw, Giovanna Masala, Peter M Nilsson, Kim Overvad, Salvatore Panico, J Ramón Quirós, Olov Rolandsson, Carlotta Sacerdote, María-José Sánchez, Matthias B Schulze, Nadia Slimani, Ellen A Struijk, Anne Tjonneland, Rosario Tumino, Stephen J Sharp, Claudia Langenberg, Nita G Forouhi, Edith J M Feskens, Elio Riboli, Nicholas J Wareham, The InterAct Consortium, [van den Berg,SW, van der A,DL, Spijkerman,AMW, Tijhuis,MJ] Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. [van Woudenbergh,GJ, Feskens,EJM] Division of Human Nutrition - Section Nutrition and Epidemiology, Wageningen University, Wageningen, The Netherlands. [Amiano,P] Instituto BIO-Donostia, Basque Government, Donostia, Spain. [Amiano,P, Ardanaz,E, Huerta,JM, Sánchez,M] Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública), Madrid, Spain. [Amiano,P] Public Health Division of Gipuzkoa, San Sebastian, Spain. [Ardanaz,E] Navarre Public Health Institute (ISPN), Pamplona, Spain. [Beulens,JWJ, Struijk,EA] Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands. [Boeing,H] Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany. [Clavel-Chapelon,F, Fagherazzi,G] Nutrition, Hormones and Women’s Health, Institut National de la Santé et de la Recherche Médicale (INSERM) and Center for Research in Epidemiology and Population Health (CESP), Villejuif, France. [Clavel-Chapelon,F, de Lauzon-Guillain,B, Fagherazzi,G] University Paris Sud, Villejuif, France. [Crowe,FL] Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom. [de Lauzon- Guillain,B] Institut National de la Santé et de la Recherche Médicale (INSERM) and Center for Research in Epidemiology and Population Health (CESP), Villejuif, France. [Franks,PW] Department of Clinical Sciences, Skane University Hospital, Lund University, Malmö, Sweden. [Rolandsson,O] Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden. [Freisling,H, Huybrechts,I] International Agency for Research on Cancer, Lyon, France. [Gonzalez,C] Unit Nutrition, Environment and Cancer, Department of Epidemiology, Catalan Institute of Oncology, Barcelona, Spain. [Grioni,S] Nutritional Epidemiology Unit, Milan, Italy. [Halkjaer,J, Tjonneland,A] Danish Cancer Society Research Center, Copenhagen, Denmark. [Huerta,JM] Department of Epidemiology, Murcia Regional Health Authority, Murcia, Spain. [Kaaks,R] Division of Cancer Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany. [Khaw,KT] Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom. [Masala,G] Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute, Florence, Italy. [Nilsson,PM] Department of Clinical Sciences Medicine, University Hospital Scania, Lund University, Malmö, Sweden. [Overvad,K] Department of Cardiology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark. [Overvad,K] Department of Epidemiology, School of Public Health, Aarhus, Denmark. [Panico,S] Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy. [Quirós,JR] Asturias Health & Health Care Council, Oviedo, Spain. [Sacerdote,C] Human Genetic Foundation (HuGeF), Torino, Italy. Center for Cancer Prevention, Torino, Italy. [Sánchez,MJ] Andalusian School of Public Health, Granada, Spain. [Schulze,MB] Department of Molecular Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany. [Slimani,N] Dietary Exposure Assessment Group (DEX), International Agency for Research on Cancer, Lyon, France. [Tumino,R] Cancer Registry and Histopathology Unit, Ragusa, Italy. Aire Onlus, Ragusa, Spain. [Sharp,SJ, Langenberg,C, Forouhi,NG, Wareham,NJ] MRC Epidemiology Unit, Cambridge, United Kingdom. [Riboli,E] Department of Epidemiology and Biostatistics, Imperial College London, London, UK., The EPIC-InterAct Study received funding from the European Union (Integrated project LSHM-CT-2006-037197 in the Framework Programme 6 of the European Community). DLvdA: Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands, AMWS: Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands, EA: Health Research Fund (FIS) of the Spanish Ministry of Health, Navarre Regional Government and CIBER Epidemiologı´a y Salud Pu´ blica (CIBERESP)., JWJB: Verification of diabetes cases in EPIC-NL was additionally funded by NL Agency grant IGE05012 and an Incentive Grant from the Board of the UMC Utrecht., FLC: Cancer Research UK, PWF: Swedish Research Council, Novo Nordisk, Swedish Diabetes Association, Swedish Heart- Lung Foundation, JH: Danish Cancer Society, JMH: Health Research Fund of the Spanish Ministry of Health, Murcia Regional Government (Nu 6236), RK: German Cancer Aid, German Ministry of Research (BMBF), KTK: Medical Research Council UK, Cancer Research UK, PN: Swedish Research Council, KO: Danish Cancer Society, SP: Compagnia di San Paolo, JRQ: Asturias Regional Government, OR: The Vasterboten County Council, AT: Danish Cancer Society, RT: AIRE-ONLUS Ragusa, AVIS-Ragusa, Sicilian Regional Government, ER: ER was supported in this work by the Imperial College Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Epidemiology and Data Science, ACS - Diabetes & metabolism, ACS - Heart failure & arrhythmias, APH - Health Behaviors & Chronic Diseases, van den Berg, Sw, van der A., Dl, Spijkerman, Am, van Woudenbergh, Gj, Tijhuis, Mj, Amiano, P, Ardanaz, E, Beulens, Jw, Boeing, H, Clavel Chapelon, F, Crowe, Fl, de Lauzon Guillain, B, Fagherazzi, G, Franks, Pw, Freisling, H, Gonzalez, C, Grioni, S, Halkjaer, J, Huerta, Jm, Huybrechts, I, Kaaks, R, Khaw, Kt, Masala, G, Nilsson, Pm, Overvad, K, Panico, Salvatore, Quir?s, Jr, Rolandsson, O, Sacerdote, C, S?nchez, Mj, Schulze, Mb, Slimani, N, Struijk, Ea, Tjonneland, A, Tumino, R, Sharp, Sj, Langenberg, C, Forouhi, Ng, Feskens, Ej, Riboli, E, Wareham, Nj, and Interact, Consortium
Subjects: Gerontology, Anatomy and Physiology, endocrine system diseases, Nutrition and Disease, Epidemiology, lcsh:Medicine, Type 2 diabetes, Diabetes Mellitus Tipo 2, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Cohort Studies, Impaired glucose tolerance, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], MELLITUS, Endocrinology, Risk Factors, Voeding en Ziekte, Medicine and Health Sciences, Longitudinal Studies, lcsh:Science, Prospective cohort study, risk, METABOLIC SYNDROME, RISK, Multidisciplinary, Estudios de casos y controles, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings], weight change, Ingestión de energía, WOMEN, Geographicals::Geographic Locations::Europe [Medical Subject Headings], Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Energy Intake [Medical Subject Headings], Humanos, Europe, us adults, Endokrinologi och diabetes, Observational Studies, Medicine, Science & Technology - Other Topics, Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2 [Medical Subject Headings], impaired glucose-tolerance, LIFE-STYLE, Dieta, women, Europa, Research Article, WEIGHT CHANGE, Factores de riesgo, life-style, Clinical Research Design, united-states, UNITED-STATES, Endocrine System, Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet [Medical Subject Headings], Endocrinology and Diabetes, metabolic syndrome, IMPAIRED GLUCOSE-TOLERANCE, US ADULTS, Environmental health, Glycemic load, glycemic load, medicine, GLYCEMIC LOAD, Humans, Obesity, Biology, Nutrition, VLAG, Diabetic Endocrinology, Science & Technology, Population Biology, business.industry, MULTIDISCIPLINARY SCIENCES, lcsh:R, Weight change, Case-control study, Diabetes Mellitus Type 2, medicine.disease, Diet, Diabetes Mellitus, Type 2, Case-Control Studies, Other Clinical Medicine, lcsh:Q, Metabolic syndrome, Energy Intake, business, mellitus
Abstract: Journal Article; Research Support, Non-U.S. Gov't; BACKGROUND Observational studies implicate higher dietary energy density (DED) as a potential risk factor for weight gain and obesity. It has been hypothesized that DED may also be associated with risk of type 2 diabetes (T2D), but limited evidence exists. Therefore, we investigated the association between DED and risk of T2D in a large prospective study with heterogeneity of dietary intake. METHODOLOGY/PRINCIPAL FINDINGS A case-cohort study was nested within the European Prospective Investigation into Cancer (EPIC) study of 340,234 participants contributing 3.99 million person years of follow-up, identifying 12,403 incident diabetes cases and a random subcohort of 16,835 individuals from 8 European countries. DED was calculated as energy (kcal) from foods (except beverages) divided by the weight (gram) of foods estimated from dietary questionnaires. Prentice-weighted Cox proportional hazard regression models were fitted by country. Risk estimates were pooled by random effects meta-analysis and heterogeneity was evaluated. Estimated mean (sd) DED was 1.5 (0.3) kcal/g among cases and subcohort members, varying across countries (range 1.4-1.7 kcal/g). After adjustment for age, sex, smoking, physical activity, alcohol intake, energy intake from beverages and misreporting of dietary intake, no association was observed between DED and T2D (HR 1.02 (95% CI: 0.93-1.13), which was consistent across countries (I(2) = 2.9%). CONCLUSIONS/SIGNIFICANCE In this large European case-cohort study no association between DED of solid and semi-solid foods and risk of T2D was observed. However, despite the fact that there currently is no conclusive evidence for an association between DED and T2DM risk, choosing low energy dense foods should be promoted as they support current WHO recommendations to prevent chronic diseases. Yes
Published: 2013

39. Impact of cigarette smoking on cancer risk in the European prospective investigation into cancer and nutrition study

Author: Rudolf Kaaks, Catalina Bonet, Kim Overvad, Petra H.M. Peeters, Göran Hallmans, Ingegerd Johansson, Martin Almquist, Rosario Tumino, Antonio Agudo, Eiliv Lund, Christina C. Dahm, Isabelle Romieu, Dimitrios Trichopoulos, Signe Borgquist, Françoise Clavel-Chapelon, Anne Tjønneland, Antonia Trichopoulou, J. Ramón Quirós, Domenico Palli, Eva Ardanaz, Elisabete Weiderpass, Elio Riboli, Annekatrin Lukanova, H. Bas Bueno-de-Mesquita, Pagona Lagiou, Hendriek Boshuizen, Heiner Boeing, María José Sánchez, Sabina Sieri, Inger T. Gram, Noémie Travier, Paolo Boffetta, Frederike L. Büchner, Naomi E. Allen, Kay-Tee Khaw, Jytte Halkjaer, Madlen Schütze, Carmen Navarro, Nicholas J. Wareham, Marie-Christine Boutron-Ruault, Salvatore Panico, Nerea Larrañaga, Timothy J. Key, Paolo Vineis, Carlos A. González, International Prevention Research Institute (IPRI), The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai [New York] (MSSM), Agudo, A., Bonet, C., Travier, N., González, C.A., Vineis, P., Bueno-de-Mesquita, H.B., Trichopoulos, D., Boffetta, P., Clavel-Chapelon, F., Boutron-Ruault, M.-C., Kaaks, R., Lukanova, A., Schu?ze, M., Boeing, H., Tjonneland, A., Halkjaer, J., Overvad, K., Dahm, C.C., Quirós, J.R., Sánchez, M.-J., Larrañaga, N., Navarro, C., Ardanaz, E., Khaw, K.-T., Wareham, N.J., Key, T.J., Allen, N.E., Trichopoulou, A., Lagiou, P., Palli, D., Sieri, S., Tumino, R., Panico, S., Boshuizen, H., Büchner, F.L., Peeters, P.H.M., Borgquist, S., Almquist, M., Hallmans, G., Johansson, I., Gram, I.T., Lund, E., Weiderpass, E., Romieu, I., Riboli, E., Agudo, A, Bonet, C, Travier, N, Gonz?lez, Ca, Vineis, P, Bueno de Mesquita, Hb, Trichopoulos, D, Boffetta, P, Clavel Chapelon, F, Boutron Ruault, Mc, Kaaks, R, Lukanova, A, Sch?tze, M, Boeing, H, Tjonneland, A, Halkjaer, J, Overvad, K, Dahm, Cc, Quir?s, Jr, S?nchez, Mj, Larra?aga, N, Navarro, C, Ardanaz, E, Khaw, Kt, Wareham, Nj, Key, Tj, Allen, Ne, Trichopoulou, A, Lagiou, P, Palli, D, Sieri, S, Tumino, R, Panico, Salvatore, Boshuizen, H, B?chner, Fl, Peeters, Ph, Borgquist, S, Almquist, M, Hallmans, G, Johansson, I, Gram, It, Lund, E, Weiderpass, E, and Romieu, I
Subjects: Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, MEDLINE, tobacco related cancer(TRC), cigarette smoking, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Cigarette smoking, Risk Factors, Neoplasms, Surveys and Questionnaires, medicine, Humans, 030212 general & internal medicine, Prospective Studies, Young adult, tobacco smoking, Adolescent Adult Europe/epidemiology Female Humans Male Neoplasms/*epidemiology/etiology Prospective Studies Questionnaires Risk Factors Smoking/*epidemiology Young Adult, Prospective cohort study, Gynecology, business.industry, Smoking, Cancer, medicine.disease, PE&RC, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Europe, Oncology, 030220 oncology & carcinogenesis, Family medicine, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Cancer risk, International agency
Abstract: Agudo, Antonio Bonet, Catalina Travier, Noemie Gonzalez, Carlos A Vineis, Paolo Bueno-de-Mesquita, H Bas Trichopoulos, Dimitrios Boffetta, Paolo Clavel-Chapelon, Francoise Boutron-Ruault, Marie-Christine Kaaks, Rudolf Lukanova, Annekatrin Schutze, Madlen Boeing, Heiner Tjonneland, Anne Halkjaer, Jytte Overvad, Kim Dahm, Christina C Quiros, J Ramon Sanchez, Maria-Jose Larranaga, Nerea Navarro, Carmen Ardanaz, Eva Khaw, Kay-Tee Wareham, Nicholas J Key, Timothy J Allen, Naomi E Trichopoulou, Antonia Lagiou, Pagona Palli, Domenico Sieri, Sabina Tumino, Rosario Panico, Salvatore Boshuizen, Hendriek Buchner, Frederike L Peeters, Petra H M Borgquist, Signe Almquist, Martin Hallmans, Goran Johansson, Ingegerd Gram, Inger T Lund, Eiliv Weiderpass, Elisabete Romieu, Isabelle Riboli, Elio eng 11692/Cancer Research UK/United Kingdom G1000143/Medical Research Council/United Kingdom British Heart Foundation/United Kingdom Cancer Research UK/United Kingdom Department of Health/United Kingdom Medical Research Council/United Kingdom Wellcome Trust/United Kingdom Research Support, Non-U.S. Gov't 2012/11/22 06:00 J Clin Oncol. 2012 Dec 20;30(36):4550-7. doi: 10.1200/JCO.2011.41.0183. Epub 2012 Nov 19.; International audience; PURPOSE: Our aim was to assess the impact of cigarette smoking on the risk of the tumors classified by the International Agency for Research on Cancer as causally associated with smoking, referred to as tobacco-related cancers (TRC). METHODS: The study population included 441,211 participants (133,018 men and 308,193 women) from the European Prospective Investigation Into Cancer and Nutrition. We investigated 14,563 participants who developed a TRC during an average follow-up of 11 years. The impact of smoking cigarettes on cancer risk was assessed by the population attributable fraction (AF(p)), calculated using the adjusted hazard ratios and 95% CI for current and former smokers, plus either the prevalence of smoking among cancer cases or estimates from surveys in representative samples of the population in each country. RESULTS: The proportion of all TRC attributable to cigarette smoking was 34.9% (95% CI, 32.5 to 37.4) using the smoking prevalence among cases and 36.2% (95% CI, 33.7 to 38.6) using the smoking prevalence from the population. The AF(p) were above 80% for cancers of the lung and larynx, between 20% and 50% for most respiratory and digestive cancers and tumors from the lower urinary tract, and below 20% for the remaining TRC. CONCLUSION: Using data on cancer incidence for 2008 and our AF(p) estimates, about 270,000 new cancer diagnoses per year can be considered attributable to cigarette smoking in the eight European countries with available data for both men and women (Italy, Spain, United Kingdom, the Netherlands, Greece, Germany, Sweden, Denmark).
Published: 2012

40. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study

Author: Elio Riboli, Sabina Sieri, Sabina Rinaldi, Birgit Teucher, Petra H.M. Peeters, José Ramón Quirós, Rudolf Kaaks, Rebecca Ritte, María José Sánchez, Kim Overvad, Isabelle Romieu, Sanda Krum-Hansen, Franco Berrino, Naomi E. Allen, Françoise Clavel-Chapelon, Genevieve Buckland, Salvatore Panico, Anja Olsen, Afshan Siddiq, Heiner Boeing, David Cox, Eiliv Lund, Krasimira Aleksandrova, Malin Sund, Per Lenner, Rosario Tumino, Nicholas J. Wareham, Agnès Fournier, Annekatrin Lukanova, Eva Ardanaz, Carla H. van Gils, Pagona Lagiou, Inger T. Gram, Bas Bueno-de-Mesquita, Paolo Vineis, Sabine Rohrmann, Guy Fagherazzi, Thure Filskov Overvad, Antonia Trichopoulou, María Dolores Chirlaque, Pilar Amiano, Kay-Tee Khaw, Domenico Palli, Dimitrios Trichopoulos, Timothy J. Key, Anne Tjønneland, Laure Dossus, Ritte, R, Lukanova, A, Berrino, F, Dossus, L, Tj?nneland, A, Olsen, A, Overvad, Tf, Overvad, K, Clavel Chapelon, F, Fournier, A, Fagherazzi, G, Rohrmann, S, Teucher, B, Boeing, H, Aleksandrova, K, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Palli, D, Sieri, S, Panico, Salvatore, Tumino, R, Vineis, P, Quir?s, Jr, Buckland, G, S?nchez, Mj, Amiano, P, Chirlaque, Md, Ardanaz, E, Sund, M, Lenner, P, Bueno de Mesquita, B, van Gils, Ch, Peeters, Ph, Krum Hansen, S, Gram, It, Lund, E, Khaw, Kt, Wareham, N, Allen, Ne, Key, Tj, Romieu, I, Rinaldi, S, Siddiq, A, Cox, D, Riboli, E, Kaaks, R., Khaw, Kay-Tee [0000-0002-8802-2903], Wareham, Nicholas [0000-0003-1422-2993], Apollo - University of Cambridge Repository, Division of Cancer Epidemiology, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Department of Preventive and Predictive Medicine, Fondazione IRCCS Instituto Nazionale dei Tumori, Cancer Epidemiology Institute, Danish Cancer Society, Department of Cardiology, Aarhus University [Aarhus], Department of Epidemiology, Aarhus University [Aarhus]-School of public health, The University of Hong Kong (HKU)-The University of Hong Kong (HKU), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Division of Cancer Epidemiology and Prevention, Institute of Social and Preventive Medicine, German Institute of Human Nutrition, Hellenic Health Foundation, WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene-Epidemiology and Medical Statistics-Athens Medical School, Harvard School of Public Health, Bureau of Epidemiologic Research, Academy of Athens, Molecular and Nutritional Epidemiology Unit, Scientific Institute of Tuscany-Cancer Research and Prevention Institute (ISPO), Nutritional Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Clinical and Experimental Medicine, Università degli studi di Napoli Federico II-Medical School, Cancer Registry and Histopathology Unit, Civile - M.P.Arezzo Hospital, Centre for Environment and Health, Imperial College London-School of public health, Human Genetics Foundation (HuGeF), Università degli studi di Torino (UNITO), Public Health and Health Planning Directorate, Universidad de Oviedo, Unit of Nutrition, Environment and Cancer, Catalan Institute of Oncology (ICO-IDIBELL)-Cancer Epidemiology Research Programme, Granada Cancer Registry, Andalusian School of Public Health [Granada], Consorcio de Investigación Biomédica en Red especializado en Epidemiología y Salud Pública (CIBERESP), Los Centros de Investigación Biomédica en Red (CIBER), Public Health Division of Gipuzkoa, Institute BIO Donostia-Health Department, Murcia Regional Health Authority, Navarra Public Health Institute, Leyre 15, Department of Surgery and Perioperative Sciences, Umea University Hospital, Department of Oncology and Radiation Sciences, Oncology, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Department of Gastroenterology and Hepatology, University Medical Centre, Julius Center for Health Sciences and Primary Care, VU University Medical Center [Amsterdam], Department of Epidemiology and Biostatistics, Imperial College London-Faculty of Medicine-School of public health, Institute of Community Medicine, University of Tromsø (UiT), School of Clinical Medicine, University of Cambridge [UK] (CAM), Medical Research Council, Addenbrooke's Hospital-Epidemiology Unit, Cancer Epidemiology Unit, University of Oxford [Oxford], Unité d'épidémiologie nutritionnelle, Section Nutrition et Métabolisme-Centre Internationale de la recherche sur le cancer (CIRC), Department of Genomics of Common Disease, This work was (partly) supported by a grant from the German Research Foundation, Graduiertenkolleg 793: Epidemiology of communicable and chronic noncommunicable diseases and their interrelationships. The coordination of EPIC is financially supported by the European Commission Directorate General for Health and Consumer Protection (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark), Ligue contre le Cancer, Mutuelle Générale de l'Education Nationale, and the Institut National de la Santé et de la Recherche Médicale (France), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and the Federal Ministry of Education and Research (Germany), the Hellenic Health Foundation, the Stavros Niarchos Foundation and the Hellenic Ministry of Health and Social Solidarity, the Italian Association for Research on Cancer (AIRC) and the National Research Council (Italy), the Dutch Ministry of Public Health, Welfare and Sport (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (The Netherlands), ERC-2009-AdG 232997 and Nordforsk, the Nordic Centre of Excellence programme on Food, Nutrition and Health. (Norway), the Health Research Fund (FIS), Regional Governments of Andalucía, Asturias, Basque Country, Murcia (number 6236) and Navarra, and ISCIII RTICC Red Temática de Investigación Cooperativa en Cáncer (R06/0020) (Spain), the Swedish Cancer Society, Swedish Scientific Council and the Regional Government of Skåne and Västerbotten (Sweden), Cancer Research UK, and the Medical Research Council, (United Kingdom)., [Ritte,R, Lukanova,A, Dossus,L, Rohrmann,S, Teucher,B, Kaaks,R] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Berrino,F] Department of Ritte et al. Breast Cancer Research Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Tjønneland,A, Olsen,A] Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark. [Overvad,TF] Department of Cardiology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark. [Overvad,K] Department of Epidemiology, School of Public Health, Aarhus University, Aarhus, Denmark. [Clavel-Chapelon,F, Fournier,A, Fagherazzi,G] Centre for Research in Epidemiology and Population Health, INSERM, Institut Gustave Roussy, Villejuif, France. Paris South University, Villejuif, France. [Rohrmann,S] Division of Cancer Epidemiology and Prevention, Institute of Social and Preventive Medicine, Zurich, Switzerland. [Boeing,H, Aleksandrova,K] Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, Germany. [Trichopoulou,A, Lagiou,P] WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Goudi, Athens, Greece. [Trichopoulou, A] Hellenic Health Foundation, Athens, Greece. [Trichopoulos,D] Department of Epidemiology, Harvard School of Public Health, Boston, USA. Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece. [Palli,D] Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Scientific Institute of Tuscany, Florence, Italy. [Sieri,S] Nutritional Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. [Panico,S] Department of Clinical and Experimental Medicine Medical School Federico II University, Naples, Italy. [Tumino, R] Cancer Registry and Histopathology Unit, ‘Civile M.P. Arezzo’ Hospital ASP 7, Ragusa, Italy. [Vineis,P, Riboli,E] Centre for Environment and Health School of Public Health, Imperial College London, London, UK. [Vineis,P] Human Genetics Foundation (HuGeF), Torino, Italy. [Quirós,JR] Public Health and Health Planning Directorate, Asturias, Spain. [Buckland,G] Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain. [Sánchez,MJ] Andalusian School of Public Health, Granada, Spain. [Sánchez,MJ, Amiano,P, Chirlaque,MD, Ardanaz,E] CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Amiano,P] Public Health Division of Gipuzkoa, Institute BIO Donostia, Health Department, Basque Region, Gipuzkoa, Spain. [Chirlaque,MD] Department of Epidemiology, Murcia Regional Health Authority, Murcia, Spain. [Ardanaz,E] Navarra Public Health Institute, Pamplona, Spain. [Sund,M] Department of Surgery and Perioperative Sciences, Umeå University Hospital, Umeå, Sweden. [Lenner,P] Department of Oncology and Radiation Sciences, Oncology, Umeå University Hospital, Umeå, Sweden. [Bueno-de-Mesquita,B] National Institute for Public Health and the Environment, Bilthoven, The Netherlands. Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands. [van Gils,CH, Peeters,PHM] Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands. [Peeters,PHM, Siddiq,A, Cox,D] Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College, London, London, UK. [Krum-Hansen,S, Gram,IT, Lund,E] Institute of Community Medicine, University of Tromsø, Tromsø, Norway. [Khaw,KT] School of Clinical Medicine, University of Cambridge, The Old Schools, Trinity Lane, Cambridge, UK. [Wareham,N] Medical Research Council, Epidemiology Unit, Addenbrooke’s Hospital, Cambridge, UK. [Allen,NE, Key,TJ] Cancer Epidemiology Unit, University of Oxford, Oxford, UK. [Romieu,I, Rinaldi,S] Nutritional Epidemiology Group, Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC), Lyon, France. [Siddiq,A] Department of Genomics of Common Disease, School of Public Health, Imperial College London, London UK., University of Zurich, Kaaks, Rudolf, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Medical School-University of Naples Federico II = Università degli studi di Napoli Federico II, Università degli studi di Torino = University of Turin (UNITO), Universidad de Oviedo [Oviedo], University of Oxford, and BMC, Ed.
Subjects: Oncology, medicine.medical_treatment, body-mass index, Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Body Mass Index, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Medicine, 1306 Cancer Research, Prospective Studies, Adiposity, estrogen-receptor, Aged, 80 and over, Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Age Factors [Medical Subject Headings], 3. Good health, Postmenopause, nutrition, Receptors, Estrogen, PREMENOPAUSAL WOMEN, Adiposidad, premenopausal omen, fat distribution, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk [Medical Subject Headings], 030220 oncology & carcinogenesis, Cohort, 2730 Oncology, Receptors, Progesterone, Factores de riesgo, Cohort study, medicine.medical_specialty, Named Groups::Persons::Age Groups::Adult::Young Adult [Medical Subject Headings], Estudios de cohortes, united-states, 03 medical and health sciences, Breast cancer, [SDV.CAN] Life Sciences [q-bio]/Cancer, Named Groups::Persons::Age Groups::Adult [Medical Subject Headings], Humans, Aged, Gynecology, Cancer och onkologi, Science & Technology, Proportional hazards model, weight, ONCOLOGY, medicine.disease, Check Tags::Female [Medical Subject Headings], Premenopause, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings], Cancer and Oncology, Surgery, Body mass index, Named Groups::Persons::Age Groups::Adult::Aged::Aged, 80 and over [Medical Subject Headings], postmenopausal women, Overweight, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Fat Distribution::Adiposity [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Cohort Studies, Risk Factors, 030212 general & internal medicine, Prospective cohort study, physical-activity, 2. Zero hunger, Medicine(all), Estrogen Replacement Therapy, Age Factors, Hormone replacement therapy (menopause), Estudios Prospectivos, Middle Aged, POSTMENOPAUSAL WOMEN, Neoplasias de la mama, NUTRITION, Female, medicine.symptom, Life Sciences & Biomedicine, Research Article, Factores de Edad, Adult, Risk, Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Climacteric::Menopause::Premenopause [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Hormone Replacement Therapy::Estrogen Replacement Therapy [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Progesterone [Medical Subject Headings], UNITED-STATES, 610 Medicine & health, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings], [SDV.CAN]Life Sciences [q-bio]/Cancer, Breast Neoplasms, size, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Estrogen [Medical Subject Headings], Young Adult, Internal medicine, Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings], Receptores de Progesterona, business.industry, Kirurgi, FAT DISTRIBUTION, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), Receptores Estrogénicos, BODY-MASS INDEX, ESTROGEN-RECEPTOR, PHYSICAL-ACTIVITY, SIZE, WEIGHT, business
Abstract: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; INTRODUCTION Associations of hormone-receptor positive breast cancer with excess adiposity are reasonably well characterized; however, uncertainty remains regarding the association of body mass index (BMI) with hormone-receptor negative malignancies, and possible interactions by hormone replacement therapy (HRT) use. METHODS Within the European EPIC cohort, Cox proportional hazards models were used to describe the relationship of BMI, waist and hip circumferences with risk of estrogen-receptor (ER) negative and progesterone-receptor (PR) negative (n = 1,021) and ER+PR+ (n = 3,586) breast tumors within five-year age bands. Among postmenopausal women, the joint effects of BMI and HRT use were analyzed. RESULTS For risk of ER-PR- tumors, there was no association of BMI across the age bands. However, when analyses were restricted to postmenopausal HRT never users, a positive risk association with BMI (third versus first tertile HR = 1.47 (1.01 to 2.15)) was observed. BMI was inversely associated with ER+PR+ tumors among women aged ≤49 years (per 5 kg/m2 increase, HR = 0.79 (95%CI 0.68 to 0.91)), and positively associated with risk among women ≥65 years (HR = 1.25 (1.16 to 1.34)). Adjusting for BMI, waist and hip circumferences showed no further associations with risks of breast cancer subtypes. Current use of HRT was significantly associated with an increased risk of receptor-negative (HRT current use compared to HRT never use HR: 1.30 (1.05 to 1.62)) and positive tumors (HR: 1.74 (1.56 to 1.95)), although this risk increase was weaker for ER-PR- disease (Phet = 0.035). The association of HRT was significantly stronger in the leaner women (BMI ≤22.5 kg/m2) than for more overweight women (BMI ≥25.9 kg/m2) for, both, ER-PR- (HR: 1.74 (1.15 to 2.63)) and ER+PR+ (HR: 2.33 (1.84 to 2.92)) breast cancer and was not restricted to any particular HRT regime. CONCLUSIONS An elevated BMI may be positively associated with risk of ER-PR- tumors among postmenopausal women who never used HRT. Furthermore, postmenopausal HRT users were at an increased risk of ER-PR- as well as ER+PR+ tumors, especially among leaner women. For hormone-receptor positive tumors, but not for hormone-receptor negative tumors, our study confirms an inverse association of risk with BMI among young women of premenopausal age. Our data provide evidence for a possible role of sex hormones in the etiology of hormone-receptor negative tumors. Yes
Published: 2012

41. A Genome-Wide Association Study of Upper Aerodigestive Tract Cancers Conducted within the INHANCE Consortium

Author: J. Ramón Quirós, Eva Ardanaz, Stefania Boccia, Wilbert H.M. Peters, Dimitrios Trichopoulos, Mario Foglio, Luigi Barzan, Lenka Foretova, Joshua E. Muscat, Françoise Clavel-Chapelon, Elio Riboli, Diana Zelenika, Paul Brennan, Salvatore Panico, Eleonora Fabianova, Lars J. Vatten, Kay-Tee Khaw, David I. Conway, Pilar Galan, Doris Lechner, Erich M. Sturgis, Shilong Zhong, Shama Buch, Jolanta Lissowska, Franco Merletti, Carmen Enid Martínez, Li E. Wang, H. Bas Bueno-de-Mesquita, Vittorio Krogh, Andres Metspalu, Anne Tjønneland, Shen Chih Chang, Rayjean J. Hung, Silvia Franceschi, Amelie Chabrier, Kristina Kjærheim, Gabriella Cadoni, Sergio Koifman, Ariana Znaor, Chu Chen, Pagona Lagiou, Ivana Holcatova, Richard B. Hayes, James McKay, Graham Byrnes, Philip Lazarus, Christine Bouchardy, Ray Lowry, Vladimir Bencko, Merethe Kumle, Jingchun Luo, Antonio Agudo, Mark Lathrop, David R. Doody, Victor Wünsch-Filho, Joanna Trubicka, Lorenzo Simonato, Martin Lacko, Cristina Canova, John K. Field, Sherianne Fish, Valerie Gaborieau, Xavier Castellsagué, Mary Toner, Thérèse Truong, Tomoko Nukui, Carla J. Gallagher, Wolfgang Ahrens, Triantafillos Liloglou, Kim Overvad, Vladimir Janout, Ivo Gut, Paolo Boffetta, Shu Chun Chuang, Göran Hallmans, Jakob Linseisen, Marjorie Romkes, David Zaridze, Mark C. Weissler, Simone Benhamou, Antonia Trichopoulou, Nerea Larrañaga, José Eluf Neto, Neonila Szeszenia-Dabrowska, Jan Lubinski, Stephen M. Schwartz, Peter Rudnai, Hélène Blanché, Mia Hashibe, William K. Funkhouser, Paolo Vineis, Maria Paula Curado, Gary J. Macfarlane, Marcin Lener, Claire M. Healy, Michael D. McClean, Domenico Palli, Marc Delepine, Tõnu Voodern, Carmen J. Marsit, Zuo-Feng Zhang, Kristjan Välk, Dorota Oszutowska, Heiner Boeing, Ana M. B. Menezes, Rolando Herrero, Leticia Fernández Garrote, Heather H. Nelson, Renato Talamini, Anne Boland, Alexandru Bucur, Qingyi Wei, Gary E. Goodman, Lorenzo Richiardi, Carmen Navarro, Karl T. Kelsey, Rosario Tumino, Inger Njølstad, Johannes J. Manni, Carlos A. González, Oxana Shangina, John R. McLaughlin, Patricia A. McKinney, Timothy J. Key, Andrew F. Olshan, Dario Arzani, Tatiana V. Macfarlane, Simon Heath, Petra H.M. Peeters, International Agency for Research on Cancer (IARC), Russian Academy of Medical Sciences, Department of Epidemiology, Institute of Occupational Medicine, Maria Skłodowska Curie Memorial Cancer Center, National Institute for Environment, Partenaires INRAE, Regional Authority of Public Health, Institute of Public Health, Charles University [Prague] (CU), Palacky University Olomouc, Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute (RECAMO), National and Kapodistrian University of Athens (NKUA), The Netherlands Cancer Institute, Variabilité Génétique et Maladies Humaines, Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Stabilité Génétique et Oncogenèse (UMR 8200), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS), Université de Genève (UNIGE), Bremen Institute for Prevention Research and Social Medicine (BIPS), University of Bremen, Universita di Torino, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), General Hospital, Cancer Registry of Norway, School of Medicine and Dentistry, Universita di Padova, Imperial College London, Catalan Institute of Oncology, CIBER de Epidemiología y Salud Pública (CIBERESP), Newcastle University [Newcastle], Dental School, Centre for Epidemiology and Biostatistics, University of Leeds, NHS NSS ISD, School of Dental Science, University of Liverpool, National Institute of Public Health, National School of Public Health, Universidade Federal de Pelotas = Federal University of Pelotas (UFPel), Universidade de São Paulo (USP), Institute of Oncology and Radiobiology, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Institute of Hygiene, Università cattolica del Sacro Cuore [Milano] (Unicatt), University of North Carolina, Pomeranian Medical University, Fred Hutchinson Cancer Research Center [Seattle] (FHCRC), Penn State College of Medicine, Pennsylvania Commonwealth System of Higher Education (PCSHE)-Penn State System, University of California [Los Angeles] (UCLA), University of California, Anderson Cancer Center, The University of Texas Health Science Center at Houston (UTHealth), Instituto de Investigación Epidemiológica, Brown University, School of public health, The University of Hong Kong (HKU), Masonic Cancer Center, University of Minnesota [Twin Cities] (UMN), University of Minnesota System-University of Minnesota System, University of Pittsburgh (DEPARTMENT OF MATHEMATICS), University of Pittsburgh (PITT), Pennsylvania Commonwealth System of Higher Education (PCSHE)-Pennsylvania Commonwealth System of Higher Education (PCSHE), Maastricht University [Maastricht], Radboud University Medical Center [Nijmegen], Mount Sinai Hospital [Toronto, Canada] (MSH), Cancer Care Ontario, Norwegian University of Science and Technology (NTNU), University of Tromsø (UiT), Piedmont Reference Center for Epidemiology and Cancer Prevention, Department of Epidemiology and Public Health, Institut National de la Santé et de la Recherche Médicale (INSERM), Istituto per lo Studio e la Prevezione Oncologica, Civile - M.P.Arezzo Hospital, Department of Clinical and Experimental Medicine, Università degli studi di Napoli Federico II, Unité de Recherche en Epidémiologie Nutritionnelle (UREN), Université Paris 13 (UP13)-Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université (HESAM)-HESAM Université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), INCa, France, US NCI [R01 CA092039 05/05S1], Benhamou, Simone, Bouchardy Magnin, Christine, Charles University in Prague, Università cattolica del Sacro Cuore [Roma] (Unicatt), Penn State System-Pennsylvania Commonwealth System of Higher Education (PCSHE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Sorbonne Paris Cité (USPC)-Université Paris 13 (UP13)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Institut National de la Recherche Agronomique (INRA), [McKay, JD, Truong, T, Gaborieau, V, Chabrier, A, Chuang, SC, Byrnes, G, Curado, MP, Franceschi, S, Hashibe, M, Boffetta, P, Brennan, P] IARC, Lyon, France. [Zaridze, D, Shangina, O] Russian Acad Med Sci, Canc Res Ctr, Inst Carcinogenesis, Moscow, Russia. [Szeszenia-Dabrowska, N] Inst Occupat Med, Dept Epidemiol, Lodz, Poland. [Lissowska, J] M Sklodowska Curie Mem Canc Ctr, Warsaw, Poland. [Lissowska, J] Inst Oncol, Warsaw, Poland. [Rudnai, P] Natl Inst Environm Hlth, Budapest, Hungary. [Fabianova, E] Reg Author Publ Hlth, Banska Bystrica, Slovakia. [Bucur, A] Inst Publ Hlth, Bucharest, Romania. [Bencko, V, Holcatova, I] Charles Univ Prague, Inst Hyg & Epidemiol, Fac Med 1, Prague, Czech Republic. [Janout, V] Palacky Univ, CR-77147 Olomouc, Czech Republic. [Foretova, L] Masaryk Mem Canc Inst, Dept Canc Epidemiol & Genet, Brno, Czech Republic. [Trichopoulos, D] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Benhamou, S] INSERM U946, Paris, France. [Benhamou, S] Inst Gustave Roussy, CNRS UMR8200, Villejuif, France. [Bouchardy, C] Univ Geneva, Geneva Canc Registry, Inst Social & Prevent Med, Geneva, Switzerland. [Ahrens, W] Univ Bremen, Bremen Inst Prevent Res & Social Med BIPS, Bremen, Germany. [Merletti, F, Richiardi, L] Univ Turin, Canc Epidemiol Unit, Turin, Italy. [Talamini, R] IRCCS, Natl Canc Inst, Aviano, Italy. [Barzan, L] Gen Hosp Pordenone, Pordenone, Italy. [Kjaerheim, K] Canc Registry Norway, Oslo, Norway. [Macfarlane, GJ, Macfarlane, TV] Univ Aberdeen, Sch Med & Dent, Aberdeen, Scotland. [Simonato, L, Canova, C] Univ Padua, Dept Environm Med & Publ Hlth, Padua, Italy. [Canova, C] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England. [Agudo, A, Castellsague, X] ICO, Barcelona, Spain. [Castellsague, X, Navarro, C, Ardanaz, E] CIBERESP, Madrid, Spain. [Lowry, R] Univ Newcastle Dent Sch, Newcastle Upon Tyne, Tyne & Wear, England. [Conway, DI] Univ Glasgow Dent Sch, Glasgow, Lanark, Scotland. [McKinney, PA] Univ Leeds Ctr Epidemiol & Biostat, Leeds, W Yorkshire, England. [McKinney, PA] NHS NSS ISD, Edinburgh, Midlothian, Scotland. [Healy, CM, Toner, ME] Trinity Coll Sch Dent Sci, Dublin, Ireland. [Znaor, A] Croatian Natl Inst Publ Hlth, Croatian Natl Canc Registry, Zagreb, Croatia. [Koifman, S] Natl Sch Publ Hlth FIOCRUZ, Rio De Janeiro, Brazil. [Menezes, A] Univ Fed Pelotas, Pelotas, Brazil. [Wuensch, V, Neto, JE] Univ Sao Paulo, Sao Paulo, Brazil. [Garrote, LF] Inst Oncol & Radiobiol, Havana, Cuba. [Boccia, S, Cadoni, G, Arzani, D] Univ Cattolica Sacro Cuore, Inst Hyg, Rome, Italy. [Boccia, S] IRCCS San Raffaele Pisana, Rome, Italy. [Olshan, AF] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Weissler, MC, Funkhouser, WK, Luo, JC] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Lubinski, J, Trubicka, J, Lener, M, Oszutowska, D] Pomeranian Med Univ, Dept Genet & Pathomorphol, Int Hereditary Canc Ctr, Szczecin, Poland. [Oszutowska, D] Pomeranian Med Univ, Dept Hyg Epidemiol & Publ Hlth, Szczecin, Poland. [Schwartz, SM, Chen, C, Fish, S, Doody, DR, Goodman, GE] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Muscat, JE, Lazarus, P, Gallagher, CJ] Penn State Coll Med, Hershey, PA USA. [Chang, SC, Zhang, ZF] Univ Calif Los Angeles Sch Publ Hlth, Los Angeles, CA USA. [Wei, QY, Sturgis, EM, Wang, LE] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Herrero, R] Inst Invest Epidemiol, San Jose, Costa Rica. [Kelsey, KT, Marsit, CJ] Brown Univ, Providence, RI 02912 USA. [McClean, MD] Boston Univ Sch Publ Hlth, Boston, MA USA. [Nelson, HH] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA. [Romkes, M, Buch, S, Nukui, T, Zhong, SL] Univ Pittsburgh, Pittsburgh, PA USA. [Lacko, M, Manni, JJ] Maastricht Univ Med Ctr, Dept Otorhinolaryngol & Head & Neck Surg, Maastricht, Netherlands. [Peters, WHM] St Radboud Univ Nijmegen Med Ctr, Dept Gastroenterol, Nijmegen, Netherlands. [Hung, RJ] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. [McLaughlin, J] Canc Care Ontario, Toronto, ON, Canada. [Vatten, L] Norwegian Univ Sci & Technol, N-7034 Trondheim, Norway. [Njolstad, I] Univ Tromso, Dept Community Med, Fac Hlth Sci, Tromso, Norway. [Field, JK, Liloglou, T] Univ Liverpool Canc Res Ctr, Roy Castle Lung Canc Res Programme, Liverpool, Merseyside, England. [Vineis, P] Univ Turin, Serv Epidemiol Tumori, Turin, Italy. [Vineis, P] CPO Piemonte, Turin, Italy. [Vineis, P, Riboli, E] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, London, England. [Clavel-Chapelon, F] E3N EPIC Grp Inst Gustave Roussy, INSERM, Villejuif, France. [Palli, D] Canc Res & Prevent Inst ISPO, Mol & Nutr Epidemiol Unit, Florence, Italy. [Tumino, R] Azienda Osped Civile MP Arezzo, Canc Registry, Ragusa, Italy. [Tumino, R] Azienda Osped Civile MP Arezzo, Histopathol Unit, Ragusa, Italy. [Krogh, V] Fdn IRCCS, Ist Nazl Tumori, Milan, Italy. [Panico, S] Univ Naples Federico 2, Dipartimento Med Clin & Sperimentale, Naples, Italy. [Gonzalez, CA] ICO, RETICC DR06 0020, IDIBELL, Unit Nutr Environm & Canc, Barcelona, Spain. [Quiros, JR] Principado Asturias, Consejeria Serv Sociales, Jefe Secc Informac Sanitaria, Oviedo, Spain. [Martinez, C] Escuela Andaluza Salud Publ, Granada, Spain. [Navarro, C] Murcia Hlth Council, Dept Epidemiol, Murcia, Spain. [Ardanaz, E] Navarra Publ Hlth Inst, Pamplona, Spain. [Larranaga, N] Gobierno Vasco, Subdirecc Salud Publ Gipuzkoa, San Sebastian, Spain. [Khaw, KT] Univ Cambridge, Sch Clin Med, Cambridge, England. [Key, T] Univ Oxford, Canc Res UK, Oxford, England. [Bueno-de-Mesquita, HB] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands. [Peeters, PHM] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Dept Epidemiol, Utrecht, Netherlands. [Trichopoulou, A] Univ Athens Sch Med, WHO Collaborating Ctr Nutr, Dept Hyg Epidemiol & Med Stat, Athens, Greece. [Linseisen, J] Helmholtz Ctr Munich, Inst Epidemiol, Neuherberg, Germany. [Linseisen, J] German Canc Res Ctr, Div Clin Epidemiol, D-6900 Heidelberg, Germany. [Boeing, H] Deutsch Inst Ernahrungsforsch, Dept Epidemiol, Potsdam, Germany. [Hallmans, G] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden. [Overvad, K] Aarhus Univ, Dept Epidemiol & Social Med, Aarhus, Denmark. Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark. [Kumle, M] Univ Hosp No Norway, Tromso, Norway. [Valk, K, Voodern, T, Metspalu, A] Univ Tartu, EE-50090 Tartu, Estonia. [Zelenika, D, Boland, A, Delepine, M, Foglio, M, Lechner, D, Gut, IG, Heath, S, Lathrop, M] Commissariat Energie Atom, Inst Genom, Ctr Natl Genotypage, Evry, France. [Blanche, H, Lathrop, M] Fdn Jean Dausset CEPH, Paris, France. [Galan, P] Univ Paris 13, INSERM INRA CNAM U557 U1125, Bobigny, France. [Hayes, RB] New York Univ Langone Med Ctr, New York, NY USA, Support for the central Europe and ARCAGE genome-wide studies and follow-up genotyping was provided by INCa, France. Additional funding for study coordination, genotyping of replication studies, and statistical analysis was provided by the US NCI (R01 CA092039 05/05S1)., Norges teknisk-naturvitenskapelige universitet, Det medisinske fakultet, Institutt for samfunnsmedisin, McKay, J.D., Truong, T., Gaborieau, V., Chabrier, A., Chuang, S.-C., Byrnes, G., Zaridze, D., Shangina, O., Szeszenia-Dabrowska, N., Lissowska, J., Rudnai, P., Fabianova, E., Bucur, A., Bencko, V., Holcatova, I., Janout, V., Foretova, L., Lagiou, P., Trichopoulos, D., Benhamou, S., Bouchardy, C., Ahrens, W., Merletti, F., Richiardi, L., Talamini, R., Barzan, L., Kjaerheim, K., Macfarlane, G.J., Macfarlane, T.V., Simonato, L., Canova, C., Agudo, A., Castellsagué, X., Lowry, R., Conway, D.I., McKinney, P.A., Healy, C.M., Toner, M.E., Znaor, A., Curado, M.P., Koifman, S., Menezes, A., Wünsch-Filho, V., Neto, J.E., Garrote, L.F., Boccia, S., Cadoni, G., Arzani, D., Olshan, A.F., Weissler, M.C., Funkhouser, W.K., Luo, J., Lubinski, J., Trubicka, J., Lener, M., Oszutowska, D., Schwartz, S.M., Chen, C., Fish, S., Doody, D.R., Muscat, J.E., Lazarus, P., Gallagher, C.J., Chang, S.-C., Zhang, Z.-F., Wei, Q., Sturgis, E.M., Wang, L.-E., Franceschi, S., Herrero, R., Kelsey, K.T., McClean, M.D., Marsit, C.J., Nelson, H.H., Romkes, M., Buch, S., Nukui, T., Zhong, S., Lacko, M., Manni, J.J., Peters, W.H.M., Hung, R.J., McLaughlin, J., Vatten, L., Njølstad, I., Goodman, G.E., Field, J.K., Liloglou, T., Vineis, P., Clavel-Chapelon, F., Palli, D., Tumino, R., Krogh, V., Panico, S., González, C.A., Quirós, J.R., Martínez, C., Navarro, C., Ardanaz, E., Larrañaga, N., Khaw, K.-T., Key, T., Bueno-de-Mesquita, H.B., Peeters, P.H.M., Trichopoulou, A., Linseisen, J., Boeing, H., Hallmans, G., Overvad, K., Tjønneland, A., Kumle, M., Riboli, E., Välk, K., Voodern, T., Metspalu, A., Zelenika, D., Boland, A., Delepine, M., Foglio, M., Lechner, D., Blanché, H., Gut, I.G., Galan, P., Heath, S., Hashibe, M., Hayes, R.B., Boffetta, P., Lathrop, M., Brennan, P., Promovendi PHPC, Metamedica, KNO, RS: MHeNs School for Mental Health and Neuroscience, and RS: GROW - School for Oncology and Reproduction
Subjects: Male, Cancer Research, Candidate gene, Linkage disequilibrium, [SDV]Life Sciences [q-bio], Genome-wide association study, FAMILY-HISTORY, genome-wide, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Research Design::Genome-Wide Association Study [Medical Subject Headings], 0302 clinical medicine, Gene Frequency, NECK-CANCER, Risk Factors, Càncer, SUSCEPTIBILITY LOCUS, SENSITIVITY PROTEIN MUS308, Genetics (clinical), Cancer, Genetics & Heredity, Genetics, Publication Characteristics::Study Characteristics::Multicenter Study [Medical Subject Headings], 0303 health sciences, TOBACCO-RELATED CANCERS, Tumor, Continental Population Groups, Middle Aged, 3. Good health, LUNG-CANCER, POOLED ANALYSIS, EPIDEMIOLOGY CONSORTIUM, INTERNATIONAL HEAD, ALCOHOL-DRINKING, Head and Neck Neoplasms, Drinking of alcoholic beverages, 030220 oncology & carcinogenesis, NEOPLASIAS, Consum d'alcohol, Head and Neck Neoplasms/enzymology/epidemiology/genetics, Genetics and Genomics/Gene Discovery, Female, Settore MED/31 - OTORINOLARINGOIATRIA, Life Sciences & Biomedicine, Medical Genetics, Research Article, Adult, VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk genetikk: 714, Diseases::Neoplasms::Neoplasms by Site::Head and Neck Neoplasms [Medical Subject Headings], lcsh:QH426-470, Neoplasias de Cabeza y Cuello, VDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Medical genetics: 714, Genetics and Genomics/Complex Traits, Biology, association study, Estudio de Asociación del Genoma Completo, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Susceptibility::Genetic Predisposition to Disease [Medical Subject Headings], 03 medical and health sciences, upper aerodigestive tract, Genetic variation, Biomarkers, Tumor, medicine, cancers, cancer, Humans, Genetic Predisposition to Disease, ddc:610, Tumor Markers, Biological/genetics, Genetics and Genomics/Cancer Genetics, Molecular Biology, Genotyping, Allele frequency, Settore MED/42 - IGIENE GENERALE E APPLICATA, Ecology, Evolution, Behavior and Systematics, 030304 developmental biology, Genetic association, ddc:613, Aged, Medicinsk genetik, Estudio Multicéntrico, Science & Technology, Racial Groups, Genetic Variation, Aldehyde Dehydrogenase, medicine.disease, lcsh:Genetics, Aldehyde Dehydrogenase/genetics, Genome-Wide Association Study, Persons::Persons::Population Groups::Continental Population Groups [Medical Subject Headings], INHANCE consortium, sensitivity protein mus308, tobacco-related cancers, lung-cancer, pooled analysis, susceptibility locus, neck-cancer, epidemiology consortium, international head, alcohol-drinking, family-history, INHANCE Consortium, Biomarkers, Genètica
Abstract: Genome-wide association studies (GWAS) have been successful in identifying common genetic variation involved in susceptibility to etiologically complex disease. We conducted a GWAS to identify common genetic variation involved in susceptibility to upper aero-digestive tract (UADT) cancers. Genome-wide genotyping was carried out using the Illumina HumanHap300 beadchips in 2,091 UADT cancer cases and 3,513 controls from two large European multi-centre UADT cancer studies, as well as 4,821 generic controls. The 19 top-ranked variants were investigated further in an additional 6,514 UADT cancer cases and 7,892 controls of European descent from an additional 13 UADT cancer studies participating in the INHANCE consortium. Five common variants presented evidence for significant association in the combined analysis (p≤5×10−7). Two novel variants were identified, a 4q21 variant (rs1494961, p = 1×10−8) located near DNA repair related genes HEL308 and FAM175A (or Abraxas) and a 12q24 variant (rs4767364, p = 2×10−8) located in an extended linkage disequilibrium region that contains multiple genes including the aldehyde dehydrogenase 2 (ALDH2) gene. Three remaining variants are located in the ADH gene cluster and were identified previously in a candidate gene study involving some of these samples. The association between these three variants and UADT cancers was independently replicated in 5,092 UADT cancer cases and 6,794 controls non-overlapping samples presented here (rs1573496-ADH7, p = 5×10−8; rs1229984-ADH1B, p = 7×10−9; and rs698-ADH1C, p = 0.02). These results implicate two variants at 4q21 and 12q24 and further highlight three ADH variants in UADT cancer susceptibility., Author Summary We have used a two-phased study approach to identify common genetic variation involved in susceptibility to upper aero-digestive tract cancer. Using Illumina HumanHap300 beadchips, 2,091 UADT cancer cases and 3,513 controls from two large European multi-centre UADT cancer studies, as well as 4,821 generic controls, were genotyped for a panel 317,000 genetic variants that represent the majority of common genetic in the human genome. The 19 top-ranked variants were then studied in an additional series of 6,514 UADT cancer cases and 7,892 controls of European descent from an additional 13 UADT cancer studies. Five variants were significantly associated with UADT cancer risk after the completion of both stages, including three residing within the alcohol dehydrogenase genes (ADH1B, ADH1C, ADH7) that have been previously described. Two additional variants were found, one near the ALDH2 gene and a second variant located in HEL308, a DNA repair gene. These results implicate two variants 4q21 and 12q24 and further highlight three ADH variants UADT cancer susceptibility.
Published: 2011

42. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case-control study

Author: Jakob Linseisen, Pierre Hainaut, Antonia Trichopoulou, Eiliv Lund, Pietro Ferrari, Sophie Morois, Kay-Tee Khaw, Kim Overvad, Philippe Autier, Gesthimani Misirli, Dimitrios Trichopoulos, Timothy J. Key, Andrew W. Roddam, Carla H. van Gils, Salvatore Panico, María J. Tormo, Paolo Vineis, Graham Byrnes, Eugene Jansen, Fränzel J.B. Van Duijnhoven, María José Sánchez, Martine M. Ros, Teresa Norat, Anja Olsen, Anne Tjønneland, Rudolf Kaaks, H. Bas Bueno-de-Mesquita, Tobias Pischon, Göran Hallmans, R. Palmqvist, Domenico Palli, Rosario Tumino, Sabina Rinaldi, Manuela M. Bergmann, Franco Berrino, Magritt Brustad, Eva Ardanaz, Heiner Boeing, Miren Dorronsoro, Nadia Slimani, Françoise Clavel-Chapelon, Petra H.M. Peeters, Elio Riboli, Mazda Jenab, Laudina Rodríguez, Marie-Christine Boutron-Ruault, Carlos A. González, [Jenab M, Ferrari P, Slimani N, Byrnes G, Rinaldi S, Autier P, Hainaut P] International Agency for Research on Cancer (IARC-WHO), Lyon, France. [Bueno-de-Mesquita HB, van Duijnhoven FJB, Jansen EHJM, Ros MM] National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands. [Ferrari P] Data Collection and Exposure Unit, European Food Safety Authority (EFSA), Parma, Italy. [van Duijnhoven FJB, van Gils CH, Peeters PH] Julius Centre for Health Sciences and Primary Care, University Medical Centre, Utrecht, Netherlands. [Norat T, Vineis P, Riboli E] School of Public Health, Imperial College, London, UK. [Pischon T, Boeing H, Bergmann MM] Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany. [Tjonneland A, Olsen A] Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark. [Overvad K] Department of Epidemiology, School of Public Health, Aarhus University, Aarhus, Denmark. [Boutron-Ruault M-C, Clavel-Chapelon F, Morois S] Inserm (Institut National de la Santé et de la Recherche Médicale) ERI 20, EA. [Kaaks R, Linseisen J] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Trichopoulou A, Misirli G] Department of Hygiene and Epidemiology, University of Athens Medical School, Greece. [Trichopoulou A] Hellenic Health Foundation, Greece. [Trichopoulos D] Department of Epidemiology, Harvard School of Public Health, USA and Bureau of Epidemiologic Research, Academy of Athens, Greece. [Berrino F] Department of Preventive and Predictive Medicine, Etiologic Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori (National Cancer Institute), Milan, Italy. [Vineis P] ISI Foundation, Turin, Italy. [Panico S] Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy. [Palli D] Molecular and Nutritional Epidemiology Unit, ISPO (Cancer Research and Prevention Institute), Florence, Italy. [Tumino R] Ragusa Cancer Registry and Histopathology Unit, 'Civile M.P.Arezzo' Hospital, ASP 7 Ragusa, Italy. [Ros MM] Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. [Brustad M, Lund E] Centre for Sami Health Research, Institute of Community Medicine, University of Tromsø, Tromsø, Norway. [Tormo MJ] Epidemiology Service, Murcia Regional Health Authority, Spain. [Ardanaz E] Public Health Institute of Navarra, Pamplona, Spain. [Ardanaz E, Sánchez MJ] CIBER Epidemiología y Salud Pública (CIBERESP), Spain. [Rodríguez L] Health Information Section, Public Health and Participation Directorate, Health and Health Care Services Council, Asturias, Spain. [Sánchez MJ] Andalusian School of Public Health-Granada (Spain). [Dorronsoro M] Epidemiology Unit, Public Health Division of Guipuzkoa, San Sebastian, Spain. [Gonzalez CA] Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain. [Hallmans G] Department of Public Health and Clinical Medicine, Nutritional Research, Umeå, Sweden. [Palmqvist R] Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden. [Roddam A, Key TJ] Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. [Khaw KT] Clinical Gerontology Unit, University of Cambridge, Cambridge, UK. [Bueno-de-Mesquita HB] Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, Netherlands. [Linseisen J] Institute of Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany, We thank the World Cancer Research Fund (WCRF, London, UK, grant number 2005/12) for grant funding for the present study. The EPIC study was supported by the Europe Against Cancer Programme of the European Commission (SANCO), Ligue contre le Cancer (France), Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM), German Cancer Aid, German Cancer Research Center, German Federal Ministry of Education and Research, Danish Cancer Society, Health Research Fund (FIS) of the Spanish Ministry of Health (RETIC-RD06/0020), the participating regional governments and institutions of Spain, The ISCIII Red de Centro RCESP (C03/09), Cancer Research UK, Medical Research Council, UK, the Stroke Association, UK, British Heart Foundation, Department of Health, UK, Food Standards Agency, UK, the Wellcome Trust, UK, Greek Ministry of Health and Social Solidarity, Hellenic Health Foundation and Stavros Niarchos Foundation, Greek Ministry of Education, Italian Association for Research on Cancer, Italian National Research Council, Compagnia di San Paolo, Dutch Ministry of Public Health, Welfare and Sports, Dutch Ministry of Health, Dutch Prevention Funds, LK Research Funds, Dutch ZON (Zorg Onderzoek Nederland), Swedish Cancer Society, Swedish Scientific Council, Regional Governments of Skane and Vasterbotten, Sweden, and Norwegian Cancer Society., Jenab, M, Bueno de Mesquita, Hb, Ferrari, P, van Duijnhoven, Fj, Norat, T, Pischon, T, Jansen, Eh, Slimani, N, Byrnes, G, Rinaldi, S, Tjønneland, A, Olsen, A, Overvad, K, Boutron Ruault, Mc, Clavel Chapelon, F, Morois, S, Kaaks, R, Linseisen, J, Boeing, H, Bergmann, Mm, Trichopoulou, A, Misirli, G, Trichopoulos, D, Berrino, F, Vineis, P, Panico, Salvatore, Palli, D, Tumino, R, Ros, Mm, van Gils, Ch, Peeters, Ph, Brustad, M, Lund, E, Tormo, Mj, Ardanaz, E, Rodríguez, L, Sánchez, Mj, Dorronsoro, M, Gonzalez, Ca, Hallmans, G, Palmqvist, R, Roddam, A, Key, Tj, Khaw, Kt, Autier, P, Hainaut, P, Riboli, E., and University of Groningen
Subjects: Oncology, Male, Colorectal cancer, 0302 clinical medicine, Risk Factors, Neoplasias colorrectales, SERUM 25-HYDROXYVITAMIN-D, DIETARY-INTAKE, Epidemiology, 030212 general & internal medicine, Vitamin D, General Environmental Science, 2. Zero hunger, Colon Cancer, COLON-CANCER, Confounding, General Engineering, Estudios de Casos y Controles, Geographicals::Geographic Locations::Europe [Medical Subject Headings], General Medicine, Middle Aged, META-ANALYSIS, 3. Good health, Europe, 030220 oncology & carcinogenesis, Cohort, Female, Risk assessment, Colorectal Neoplasms, Europa, Life Sciences & Biomedicine, D SUPPLEMENTATION, medicine.medical_specialty, CALCIUM INTAKE, Vitamina D, Chemicals and Drugs::Polycyclic Compounds::Steroids::Secosteroids::Vitamin D [Medical Subject Headings], Enzyme-Linked Immunosorbent Assay, Molecular epidemiology [NCEBP 1], 03 medical and health sciences, Health Care::Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings], Medicine, General & Internal, D-RECEPTOR, General & Internal Medicine, Internal medicine, Vitamin D and neurology, medicine, Humans, ddc:610, Life Style, Immunology (Including Allergy), Science & Technology, Dose-Response Relationship, Drug, 25-HYDROXYVITAMIN-D LEVELS, business.industry, Research, Case-control study, Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [Medical Subject Headings], medicine.disease, RANDOMIZED-CONTROLLED-TRIALS, Diet, Epidemiologic Studies, Endocrinology, Cardiovascular and Metabolic Diseases, Case-Control Studies, Nested case-control study, General Earth and Planetary Sciences, Calcium, D METABOLITES, business
Abstract: Contains fulltext : 88351.pdf (Publisher’s version ) (Open Access) OBJECTIVE: To examine the association between pre-diagnostic circulating vitamin D concentration, dietary intake of vitamin D and calcium, and the risk of colorectal cancer in European populations. DESIGN: Nested case-control study. Setting The study was conducted within the EPIC study, a cohort of more than 520 000 participants from 10 western European countries. PARTICIPANTS: 1248 cases of incident colorectal cancer, which developed after enrolment into the cohort, were matched to 1248 controls MAIN OUTCOME MEASURES: Circulating vitamin D concentration (25-hydroxy-vitamin-D, 25-(OH)D) was measured by enzyme immunoassay. Dietary and lifestyle data were obtained from questionnaires. Incidence rate ratios and 95% confidence intervals for the risk of colorectal cancer by 25-(OH)D concentration and levels of dietary calcium and vitamin D intake were estimated from multivariate conditional logistic regression models, with adjustment for potential dietary and other confounders. RESULTS: 25-(OH)D concentration showed a strong inverse linear dose-response association with risk of colorectal cancer (P for trend or=100.0 nmol/l: 0.77 (0.56 to 1.06)). In analyses by quintile of 25-(OH)D concentration, patients in the highest quintile had a 40% lower risk of colorectal cancer than did those in the lowest quintile (P
Published: 2010

43. Plasma vitamins B2, B6, B12, and related genetic variants as predictors of colorectal cancer risk

Author: Simone J. P. M. Eussen, Øivind Midttun, Kim Overvad, Elio Riboli, Tobias Pischon, Ole Thorlacius-Ussing, Paolo Vineis, Rudolf Kaaks, Laudina Rodríguez, Domenico Palli, Bethany VanGuelpen, Mazda Jenab, Per Magne Ueland, Ulrika Ericson, Cornelia Weikert, Åse Fredriksen, Anne Tjønneland, Carmen Enid Martínez, Petra H.M. Peeters, Paolo Boffetta, Klaus Meyer, Carmen Navarro, H. Bas Bueno-de-Mesquita, Jonas Manjer, Valeria Pala, Françoise Clavel-Chapelon, Teresa Norat, Sophie Morois, Fränzel J.B. Van Duijnhoven, Anja Olsen, Rosario Tumino, Kay-Tee Khaw, Steinar Hustad, Jakob Linseisen, Michael Katsoulis, Richard Palmqvist, Stein Emil Vollset, Sheila Bingham, Antonia Trichopoulou, Guri Skeie, Miren Dorronsoro, Demosthenes Zilis, Nadia Slimani, Eva Ardanaz, Salvatore Panico, Xavier Muñoz, Marie-Christine Boutron-Ruault, Eussen, Sj, Vollset, Se, Hustad, S, Midttun, Ø, Meyer, K, Fredriksen, A, Ueland, Pm, Jenab, M, Slimani, N, Boffetta, P, Overvad, K, Thorlacius Ussing, O, Tjønneland, A, Olsen, A, Clavel Chapelon, F, Boutron Ruault, Mc, Morois, S, Weikert, C, Pischon, T, Linseisen, J, Kaaks, R, Trichopoulou, A, Zilis, D, Katsoulis, M, Palli, D, Pala, V, Vineis, P, Tumino, R, Panico, Salvatore, Peeters, Ph, Bueno de Mesquita, Hb, van Duijnhoven, Fj, Skeie, G, Muñoz, X, Martínez, C, Dorronsoro, M, Ardanaz, E, Navarro, C, Rodríguez, L, Vanguelpen, B, Palmqvist, R, Manjer, J, Ericson, U, Bingham, S, Khaw, Kt, Norat, T, Riboli, E., Eussen, S.J.P.M., Vollset, S.E., Hustad, S., Midttun, Ø., Meyer, K., Fredriksen, Å., Ueland, P.M., Jenab, M., Slimani, N., Boffetta, P., Overvad, K., Thorlacius-Ussing, O., Tjønneland, A., Olsen, A., Clavel-Chapelon, F., Boutron-Ruault, M.-C., Morois, S., Weikert, C., Pischon, T., Linseisen, J., Kaaks, R., Trichopoulou, A., Zilis, D., Katsoulis, M., Palli, D., Pala, V., Vineis, P., Tumino, R., Panico, S., Peeters, P.H.M., Bueno-de-Mesquita, H.B., Van Duijnhoven, F.J.B., Skeie, G., Muñoz, X., Martínez, C., Dorronsoro, M., Ardanaz, E., Navarro, C., Rodríguez, L., VanGuelpen, B., Palmqvist, R., Manjer, J., Ericson, U., Bingham, S., Khaw, K.-T., and Norat, T.
Subjects: Oncology, Male, medicine.medical_specialty, Epidemiology, Colorectal cancer, Riboflavin, Polymorphism, Single Nucleotide, Article, Cohort Studies, Folic Acid, Risk Factors, Internal medicine, Genotype, medicine, Humans, Vitamin B12, ONE-CARBON METABOLISM, METHIONINE SYNTHASE GENE, METHYLENETETRAHYDROFOLATE REDUCTASE, FOLATE METABOLISM, MASS-SPECTROMETRY, HOMOCYSTEINE METABOLISM, DNA METHYLATION, DIETARY-INTAKE, RAT-LIVER, POLYMORPHISMS, B12, biology, colorectal cancer risk, business.industry, Case-control study, Cancer, Middle Aged, medicine.disease, Vitamin B 6, B vitamins, Vitamin B 12, Endocrinology, Methylenetetrahydrofolate reductase, Case-Control Studies, biology.protein, B6, Female, B2, business, Colorectal Neoplasms, Cohort study
Abstract: Background: B-vitamins are essential for one-carbon metabolism and have been linked to colorectal cancer. Although associations with folate have frequently been studied, studies on other plasma vitamins B2, B6, and B12 and colorectal cancer are scarce or inconclusive. Methods: We carried out a nested case-control study within the European Prospective Investigation into Cancer and Nutrition, including 1,365 incident colorectal cancer cases and 2,319 controls matched for study center, age, and sex. We measured the sum of B2 species riboflavin and flavin mononucleotide, and the sum of B6 species pyridoxal 5′-phosphate, pyridoxal, and 4-pyridoxic acid as indicators for vitamin B2 and B6 status, as well as vitamin B12 in plasma samples collected at baseline. In addition, we determined eight polymorphisms related to one-carbon metabolism. Relative risks for colorectal cancer were estimated using conditional logistic regression, adjusted for smoking, education, physical activity, body mass index, alcohol consumption, and intakes of fiber and red and processed meat. Results: The relative risks comparing highest to lowest quintile were 0.71 [95% confidence interval (95% CI), 0.56-0.91; Ptrend = 0.02] for vitamin B2, 0.68 (95% CI, 0.53-0.87; Ptrend Conclusions: Higher plasma concentrations of vitamins B2 and B6 are associated with a lower colorectal cancer risk. Impact: This European population-based study is the first to indicate that vitamin B2 is inversely associated with colorectal cancer, and is in agreement with previously suggested inverse associations of vitamin B6 with colorectal cancer. Cancer Epidemiol Biomarkers Prev; 19(10); 2549–61. ©2010 AACR.
Published: 2010

44. Plasma folate, related genetic variants, and colorectal cancer risk in EPIC

Author: Elio Riboli, Klaus Meyer, Rudolf Kaaks, Eiliv Lund, Salvatore Panico, Françoise Clavel-Chapelon, Åse Fredriksen, Laudina Rodríguez, H. Bas Bueno-de-Mesquita, Sophie Morois, Richard Palmqvist, Guri Skeie, Teresa Norat, Carmen Navarro, Inger T. Gram, Kim Overvad, Jakob Linseisen, Stein Emil Vollset, Jannicke Igland, Miren Dorronsoro, Demosthenes Zilis, Nadia Slimani, Mazda Jenab, Bethany Van Guelpen, Paolo Vineis, Paolo Boffetta, Ulrika Ericson, Carlos A. González, Petra H.M. Peeters, Marie-Christine Boutron-Ruault, Franco Berrino, Eva Ardanaz, Fränzel J.B. Van Duijnhoven, Sheila Bingham, Anja Olsen, Antonia Trichopoulou, Rosario Tumino, Jonas Manjer, Kay-Tee Khaw, Cornelia Weikert, Carmen Enid Martínez, Simone J. P. M. Eussen, Tobias Pischon, Domenico Palli, Per Magne Ueland, Michael Katsoulis, Anne Tjønneland, Eussen, Sj, Vollset, Se, Igland, J, Meyer, K, Fredriksen, A, Ueland, Pm, Jenab, M, Slimani, N, Boffetta, P, Overvad, K, Tjønneland, A, Olsen, A, Clavel Chapelon, F, Boutron Ruault, Mc, Morois, S, Weikert, C, Pischon, T, Linseisen, J, Kaaks, R, Trichopoulou, A, Zilis, D, Katsoulis, M, Palli, D, Berrino, F, Vineis, P, Tumino, R, Panico, Salvatore, Peeters, Ph, Bueno de Mesquita, Hb, van Duijnhoven, Fj, Gram, It, Skeie, G, Lund, E, González, Ca, Martínez, C, Dorronsoro, M, Ardanaz, E, Navarro, C, Rodríguez, L, Van Guelpen, B, Palmqvist, R, Manjer, J, Ericson, U, Bingham, S, Khaw, Kt, Norat, T, Riboli, E., Eussen, S.J.P.M., Vollset, S.E., Igland, J., Meyer, K., Fredriksen, Å., Ueland, P.M., Jenab, M., Slimani, N., Boffetta, P., Overvad, K., Tjønneland, A., Olsen, A., Clavel-Chapelon, F., Boutron-Ruault, M.-C., Morois, S., Weikert, C., Pischon, T., Linseisen, J., Kaaks, R., Trichopoulou, A., Zilis, D., Katsoulis, M., Palli, D., Berrino, F., Vineis, P., Tumino, R., Panico, S., Peeters, P.H.M., Bueno-de-Mesquita, H.B., Van Duijnhoven, F.J.B., Gram, I.T., Skeie, G., Lund, E., González, C.A., Martínez, C., Dorronsoro, M., Ardanaz, E., Navarro, C., Rodríguez, L., Van Guelpen, B., Palmqvist, R., Manjer, J., Ericson, U., Bingham, S., Khaw, K.-T., and Norat, T.
Subjects: Adult, Male, Oncology, medicine.medical_specialty, Epidemiology, Colorectal cancer, colorectal cancer, Biology, medicine.disease_cause, Polymorphism, Single Nucleotide, Article, Methylenetetrahydrofolate reductase polymorphism, Nested case-control, Human methionine synthase, Carbon metabolic pathway, C677T MTHFR polymorphism, Colon-cancer, Folic-acid, Mass-spectrometry, Dietary patterns, Common mutation, Folic Acid, Risk Factors, Molecular genetics, Internal medicine, Genetic variation, medicine, Humans, Genetic Predisposition to Disease, Prospective Studies, Prospective cohort study, Methylenetetrahydrofolate Reductase (NADPH2), Aged, Aged, 80 and over, Genetics, Plasma folate, Case-control study, Middle Aged, Prognosis, medicine.disease, digestive system diseases, Survival Rate, Case-Control Studies, Methylenetetrahydrofolate reductase, Nested case-control study, biology.protein, Female, EPIC, Colorectal Neoplasms, Carcinogenesis
Abstract: Background: A potential dual role of folate in colorectal cancer (CRC) is currently subject to debate. We investigate the associations between plasma folate, several relevant folate-related polymorphisms, and CRC risk within the large European Prospective Investigation into Cancer and Nutrition cohort.Methods: In this nested case-control study, 1,367 incident CRC cases were matched to 2,325 controls for study center, age, and sex. Risk ratios (RR) were estimated with conditional logistic regression and adjusted for smoking, education, physical activity, and intake of alcohol and fiber.Results: Overall analyses did not reveal associations of plasma folate with CRC. The RR (95% confidence interval; Ptrend) for the fifth versus the first quintile of folate status was 0.94 (0.74-1.20; 0.44). The polymorphisms MTHFR677C→T, MTHFR1298A→C, MTR2756A→G, MTRR66A→G, and MTHFD11958G→A were not associated with CRC risk. However, in individuals with the lowest plasma folate concentrations, the MTHFR 677TT genotype showed a statistically nonsignificant increased CRC risk [RR (95% CI; Ptrend) TT versus CC = 1.39 (0.87-2.21); 0.12], whereas those with the highest folate concentrations showed a nonsignificant decreased CRC risk [RR TT versus CC = 0.74 (0.39-1.37); 0.34]. The SLC19A180G→A showed a positive association with CRC risk [RR AA versus GG 1.30 (1.06-1.59); Conclusions: This large European prospective multicenter study did not show an association of CRC risk with plasma folate status nor with MTHFR polymorphisms.Impact: Findings of the present study tend to weaken the evidence that folate plays an important role in CRC carcinogenesis. However, larger sample sizes are needed to adequately address potential gene-environment interactions. Cancer Epidemiol Biomarkers Prev; 19(5); 1328–40. ©2010 AACR.
Published: 2010

45. The Role of Smoking and Diet in Explaining Educational Inequalities in Lung Cancer Incidence

Author: Elisabet Wirfält, Salvatore Panico, Jonas Manjer, Jakob Linseisen, Kay-Tee Khaw, Sheila Bingham, Rosario Tumino, María José Tormo, Petra H.M. Peeters, H. Bas Bueno-de-Mesquita, Naomi E. Allen, Anne Tjønneland, Torgny Rasmuson, Antonia Trichopoulou, Gwenn Menvielle, Pietro Ferrari, Nadia Slimani, Paolo Boffetta, Valentina Gallo, Ole Raaschou-Nielsen, Domenico Palli, Timothy J. Key, Elio Riboli, Hendriek Boshuizen, Antonio Agudo, Anton E. Kunst, Susanne Oksbjerg Dalton, Eric J. Duell, Paolo Vineis, Tonje Braaten, Silke Hermann, Maria Kosti, Carla H. van Gils, Vardis Dilis, Göran Hallmans, Eva Ardanaz, Manuela M. Bergmann, María José Sánchez, Inger T. Gram, Vittorio Krogh, Eiliv Lund, Laudina Rodríguez, Frederike L. Büchner, Rudolf Kaaks, Kaniewski, Nadine, Department of Public Health, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Santé publique et épidémiologie des déterminants professionnels et sociaux de la santé, Epidémiologie, sciences sociales, santé publique (IFR 69), Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Institute of Cancer Epidemiology, Danish Cancer Society, University of Torino and CPO-Piemonte, Università degli studi di Torino = University of Turin (UNITO), Department of Epidemiology, German Institute of Human Nutrition, Division of Cancer Epidemiology, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Unit of Nutrition, Environment, and Cancer, Catalan Institute of Oncology, Molecular and Nutritional Epidemiology Unit, CSPO-Scientific Institute of Tuscany, Department of Preventive & Predictive Medicine, Italian National Center Institute, Department of Clinical and Experimental Medicine, Frederico II University, Cancer Registry Azienda, Civile - M.P.Arezzo Hospital, Julius Center for Health Sciences and Primary Care, VU University Medical Center [Amsterdam], Institute of Community Medicine, University of Tromsø (UiT), Public Health Directorate, Unit of Nutrition, Environment and Cancer, Andalusian School of Public Health [Granada], CIBER Epidemiologia y Salud Publica, CIBER de Epidemiología y Salud Pública (CIBERESP), Murcia Health Council, Public Health Institute of Navarra, Department of surgery, Lund University [Lund]-Malmö University Hospital, Department of Clinical Sciences, Nutrition Epidemiology, Lund University [Lund], Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, Department of Radiation Sciences, Oncology, MRC Centrer for Nutritional Epidemiology and Cancer Prevention and Survival, University of Cambridge [UK] (CAM), Cancer Epidemiology Unit, University of Oxford, Departement of Epidemiolgy and Public Health, Imperial College London, Menvielle, G, Boshuizen, H, Kunst, Ae, Dalton, So, Vineis, P, Bergmann, Mm, Hermann, S, Ferrari, P, Raaschou Nielsen, O, Tjønneland, A, Kaaks, R, Linseisen, J, Kosti, M, Trichopoulou, A, Dilis, V, Palli, D, Krogh, V, Panico, Salvatore, Tumino, R, Büchner, Fl, van Gils, Ch, Peeters, Ph, Braaten, T, Gram, It, Lund, E, Rodriguez, L, Agudo, A, Sánchez, Mj, Tormo, Mj, Ardanaz, E, Manjer, J, Wirfält, E, Hallmans, G, Rasmuson, T, Bingham, S, Khaw, Kt, Allen, N, Key, T, Boffetta, P, Duell, Ej, Slimani, N, Gallo, V, Riboli, E, Bueno de Mesquita, Hb, Public and occupational health, Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Università degli studi di Torino (UNITO), University of Oxford [Oxford], Malmö University Hospital-Lund University [Lund], Public Health, Cell biology, Menvielle, G., Boshuizen, H., Kunst, A.E., Dalton, S.O., Vineis, P., Bergmann, M.M., Hermann, S., Ferrari, P., Raaschou-Nielsen, O., Tjønneland, A., Kaaks, R., Linseisen, J., Kosti, M., Trichopoulou, A., Dilis, V., Palli, D., Krogh, V., Panico, S., Tumino, R., Büchner, F.L., Van Gils, C.H., Peeters, P.H.M., Braaten, T., Gram, I.T., Lund, E., Rodriguez, L., Agudo, A., Sánchez, M.-J., Tormo, M.-J., Ardanaz, E., Manjer, J., Wirfält, E., Hallmans, G., Rasmuson, T., Bingham, S., Khaw, K.-T., Allen, N., Key, T., Boffetta, P., Duell, E.J., Slimani, N., Gallo, V., Riboli, E., and Bueno-De-Mesquita, H.B.
Subjects: Male, Cancer Research, Lung Neoplasms, Aetiology, screening and detection [ONCOL 5], 0302 clinical medicine, Risk Factors, Surveys and Questionnaires, Vegetables, Odds Ratio, Prospective Studies, 030212 general & internal medicine, 10. No inequality, Prospective cohort study, education, Mediterranean Region, Incidence, Incidence (epidemiology), 1. No poverty, Confounding Factors, Epidemiologic, Middle Aged, 3. Good health, European Prospective Investigation into Cancer and Nutrition, Europe, Oncology, Research Design, 030220 oncology & carcinogenesis, Cohort, Educational Status, lung cancer incidence, Female, women, Cohort study, Adult, medicine.medical_specialty, men, Risk Assessment, Article, smoking, Molecular epidemiology [NCEBP 1], 03 medical and health sciences, Sex Factors, SDG 3 - Good Health and Well-being, medicine, cohort study, Humans, ddc:610, Sex Distribution, Risk factor, Lung cancer, Socioeconomic status, Aged, Proportional Hazards Models, business.industry, Feeding Behavior, medicine.disease, Social Mobility, Surgery, Social Class, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Fruit, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, EPIC, diet, Demography
Abstract: Background: Studies in many countries have reported higher lung cancer incidence and mortality in individuals with lower socioeconomic status. Methods: To investigate the role of smoking in these inequalities, we used data from 391 251 participants in the European Prospective Investigation into Cancer and Nutrition study, a cohort of individuals in 10 European countries. We collected information on smoking (history and quantity), fruit and vegetable consumption, and education through questionnaires at study entry and gathered data on lung cancer incidence for a mean of 8.4 years. Socioeconomic status was defined as the highest attained level of education, and participants were grouped by sex and region of residence (Northern Europe, Germany, or Southern Europe). Relative indices of inequality (RIIs) of lung cancer risk unadjusted and adjusted for smoking were estimated using Cox regression models. Additional analyses were performed by histological type. Results: During the study period, 939 men and 692 women developed lung cancer. Inequalities in lung cancer risk (RII men = 3.62, 95% confidence interval [CI] = 2.77 to 4.73, 117 vs 52 per 100 000 person-years for lowest vs highest education level; RII women = 2.39, 95% CI = 1.77 to 3.21, 46 vs 25 per 100 000 person-years) decreased after adjustment for smoking but remained statistically significant (RIImen = 2.29, 95% CI = 1.75 to 3.01; RII women = 1.59, 95% CI = 1.18 to 2.13). Large RIIs were observed among men and women in Northern European countries and among men in Germany, but inequalities in lung cancer risk were reverse (RIIs < 1) among women in Southern European countries. Inequalities differed by histological type. Adjustment for smoking reduced inequalities similarly for all histological types and among men and women in all regions. In all analysis, further adjustment for fruit and vegetable consumption did not change the estimates. Conclusion: Self-reported smoking consistently explains approximately 50% of the inequalities in lung cancer risk due to differences in education. © The Author 2009. Published by Oxford University Press. All rights reserved.
Published: 2009

46. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC)

Author: Salvatore Panico, Marga C. Ocké, H. Bas Bueno-de-Mesquita, Carla H. van Gils, Teresa Norat, Antonio Agudo, Pilar Amiano, Göran Berglund, Mazda Jenab, Eva Ardanaz, Rudolf Kaaks, Jonas Manjer, Pietro Ferrari, Dolores C. López, Jakob Linseisen, Elio Riboli, Françoise Clavel-Chapelon, Sophie Morois, María José Sánchez, Mathieu Mazuir, Heiner Boeing, Rosario Tumino, Majken K. Jensen, Christina Kassapa, Marie-Christine Boutron-Ruault, Petra H.M. Peeters, Eiliv Lund, Paolo Vineis, Kim Overvad, Anja Olsen, Timothy J. Key, Paolo Boffetta, Giovanna Masala, Manuela M. Bergmann, Sabine Rohrmann, Vittorio Krogh, Nadia Slimani, Guri Skeie, Naomi E. Allen, Aurelie Moskal, José Ramón Quirós, Bethany Van Guelpen, Richard Palmqvist, Dimitra Kontopoulou, Anne Tjønneland, Sheila Bingham, Antonia Trichopoulou, Ferrari, P, Jenab, M, Norat, T, Moskal, A, Slimani, N, Olsen, A, Tjonneland, A, Overvad, K, Jensen, Mk, BOUTRON RUAULT, Mc, CLAVEL CHAPELON, F, Morois, S, Rohrmann, S, Linseisen, J, Boeing, H, Bergmann, M, Kontopoulou, D, Trichopoulou, A, Kassapa, C, Masala, G, Krogh, V, Vineis, P, Panico, Salvatore, Tumino, R, Gils, Ch, Peeters, P, BUENO DE MESQUITA, Hb, Ocke, Mc, Skeie, G, Lund, E, Agudo, A, Ardanaz, E, Lopez, Dc, Sanchez, Mj, Quiros, Jr, Amiano, P, Berglund, G, Manjer, J, Palmqvist, R, Guelpen, Bv, Allen, N, Key, T, Bingham, S, Mazuir, M, Boffetta, P, Kaaks, R, Riboli, E., Ferrari, P., Jenab, M., Norat, T., Moskal, A., Slimani, N., Olsen, A., Tjønneland, A., Overvad, K., Jensen, M.K., Boutron-Ruault, M.-C., Clavel-Chapelon, F., Morois, S., Rohrmann, S., Linseisen, J., Boeing, H., Bergmann, M., Kontopoulou, D., Trichopoulou, A., Kassapa, C., Masala, G., Krogh, V., Vineis, P., Panico, S., Tumino, R., Van Gils, C.H., Peeters, P., Bueno-de-Mesquita, H.B., Ocké, M.C., Skeie, G., Lund, E., Agudo, A., Ardanaz, E., López, D.C., Sanchez, M.-J., Quirós, J.R., Amiano, P., Berglund, G., Manjer, J., Palmqvist, R., Van Guelpen, B., Allen, N., Key, T., Bingham, S., Mazuir, M., Boffetta, P., and Kaaks, R.
Subjects: Oncology, Male, Cancer Research, medicine.medical_specialty, Time Factors, Alcohol intake and risk of colon and rectal cancers, Alcohol Drinking, Colorectal cancer, alcohol, lifetime exposure, colorectal cancer, prospective study, EPIC, Gastroenterology, Risk Factors, Internal medicine, Epidemiology, medicine, Humans, ddc:610, Risk factor, Prospective cohort study, Colonic disease, Sex Characteristics, business.industry, Rectal Neoplasms, Middle Aged, medicine.disease, European Prospective Investigation into Cancer and Nutrition, Europe, Nutrition Assessment, Colonic Neoplasms, Alcohol intake, Female, business
Abstract: Alcohol consumption may be associated with risk of colorectal cancer (CRC), but the epidemiological evidence for an association with specific anatomical subsites, types of alcoholic beverages and current vs. lifetime alcohol intake is inconsistent. Within the European Prospective Investigation into Cancer and Nutrition (EPIC), 478,732 study subjects free of cancer at enrolment between 1992 and 2000 were followed up for an average of 6.2 years, during which 1,833 CRC cases were observed. Detailed information on consumption of alcoholic beverages at baseline (all cases) and during lifetime (1,447 CRC cases, 69% of the cohort) was collected from questionnaires. Cox proportional hazard models were used to examine the alcohol-CRC association. After adjustment for potential confounding factors, lifetime alcohol intake was significantly positively associated to CRC risk (hazard ratio, HR = 1.08, 95%CI = 1.04-1.12 for 15 g/day increase), with higher cancer risks observed in the rectum (HR = 1.12, 95%CI = 1.06-1.18) than distal colon (HR = 1.08, 95%CI = 1.01-1.16), and proximal colon (HR = 1.02, 95%CI = 0.92-1.12). Similar results were observed for baseline alcohol intake. When assessed by alcoholic beverages at baseline, the CRC risk for beer (HR = 1.38, 95%CI = 1.08-1.77 for 20-39.9 vs. 0.1-2.9 g/day) was higher than wine (HR = 1.21, 95%CI = 1.02-1.44), although the two risk estimates were not significantly different from each other. Higher HRs for baseline alcohol were observed for low levels of folate intake (1.13, 95%CI = 1.06-1.20 for 15 g/day increase) compared to high folate intake (1.03, 95%CI = 0.98-1.09). In this large European cohort, both lifetime and baseline alcohol consumption increase colon and rectum cancer risk, with more apparent risk increases for alcohol intakes greater than 30 g/day. © 2007 Wiley-Liss, Inc.
Published: 2007

47. Ethanol Intake and Risk of Lung Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC)

Author: Pietro Ferrari, Paolo Vineis, John C. Whittaker, Anne Tjønneland, Rosario Tumino, Torgny Rasmuson, Frederike L. Büchner, Hendriek C. Boshuizen, Timothy J. Key, María Dolores Chirlaque, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Domenico Palli, Salvatore Panico, Manuela M. Bergmann, Eva Ardanaz, Majken K. Jensen, H. Bas Bueno-de-Mesquita, Jakob Linseisen, Inger T. Gram, Sabine Rohrmann, Göran Berglund, Petra H.M. Peeters, Elio Riboli, Eiliv Lund, Teresa Norat, Kim Overvad, Stavroula Soukara, María José Sánchez Pérez, Sabina Sieri, Lars Weinehall, Anja Olsen, Antonio Agudo, Naomi E. Allen, Mazda Jenab, Georgia Kyriazi, Sheila Bingham, Antonia Trichopoulou, Lars Janzon, José Ramón Quirós, Paolo Boffetta, Miren Dorronsoro, Kay-Tee Khaw, Heiner Boeing, Rohrmann, S, Linseisen, J, Boshuizen, Hc, Whittaker, J, Agudo, A, Vineis, P, Boffetta, P, Jensen, Mk, Olsen, A, Overvad, K, Tjonneland, A, BOUTRON RUAULT, Mc, CLAVEL CHAPELON, F, Bergmann, Mm, Boeing, H, Allen, N, Key, T, Bingham, S, Khaw, Kt, Kyriazi, G, Soukara, S, Trichopoulou, A, Panico, Salvatore, Palli, D, Sieri, S, Tumino, R, Peeters, Ph, BUENO DE MESQUITA, Hb, Buchner, Fl, Gram, It, Lund, E, Ardanaz, E, Chirlaque, Md, Dorronsoro, M, Perez, Mj, Quiros, Jr, Berglund, G, Janzon, L, Rasmuson, T, Weinehall, L, Ferrari, P, Jenab, M, Norat, T, Riboli, E., Rohrmann, S., Linseisen, J., Boshuizen, H.C., Whittaker, J., Agudo, A., Vineis, P., Boffetta, P., Jensen, M.K., Olsen, A., Overvad, K., Tjønneland, A., Boutron-Ruault, M.-C., Clavel-Chapelon, F., Bergmann, M.M., Boeing, H., Allen, N., Key, T., Bingham, S., Khaw, K.-T., Kyriazi, G., Soukara, S., Trichopoulou, A., Panico, S., Palli, D., Sieri, S., Tumino, R., Peeters, P.H.M., Bueno-De-Mesquita, H.B., Büchner, F.L., Gram, I.T., Lund, E., Ardanaz, E., Chirlaque, M.-D., Dorronsoro, M., Pérez, M.-J.S., Quirós, J.R., Berglund, G., Janzon, L., Rasmuson, T., Weinehall, L., Ferrari, P., Jenab, M., and Norat, T.
Subjects: Adult, Male, medicine.medical_specialty, Epidemiology, lung neoplasms, Lower risk, Risk Assessment, cohort studies, Risk Factors, Interventional oncology [UMCN 1.5], Surveys and Questionnaires, Internal medicine, Determinants in Health and Disease [EBP 1], Humans, Medicine, Prospective Studies, ddc:610, Risk factor, Lung cancer, alcohol drinking, ethanol, Proportional Hazards Models, Ethanol intake and risk of lung cancer, business.industry, Incidence, Hazard ratio, Middle Aged, Anthropometry, medicine.disease, Confidence interval, European Prospective Investigation into Cancer and Nutrition, Surgery, Europe, Female, business, Follow-Up Studies, Cohort study
Abstract: Contains fulltext : 49956.pdf (Publisher’s version ) (Closed access) Within the European Prospective Investigation into Cancer and Nutrition (EPIC), the authors examined the association of ethanol intake at recruitment (1,119 cases) and mean lifelong ethanol intake (887 cases) with lung cancer. Information on baseline and past alcohol consumption, lifetime tobacco smoking, diet, and the anthropometric characteristics of 478,590 participants was collected between 1992 and 2000. Cox proportional hazards regression was used to calculate multivariate-adjusted hazard ratios and 95% confidence intervals. Overall, neither ethanol intake at recruitment nor mean lifelong ethanol intake was significantly associated with lung cancer. However, moderate intake (5-14.9 g/day) at recruitment (hazard ratio (HR) = 0.76, 95% confidence interval (CI): 0.63, 0.90) and moderate mean lifelong intake (HR = 0.80, 95% CI: 0.66, 0.97) were associated with a lower lung cancer risk in comparison with low consumption (0.1-4.9 g/day). Compared with low intake, a high (> or =60 g/day) mean lifelong ethanol intake tended to be related to a higher risk of lung cancer (HR = 1.29, 95% CI: 0.93, 1.74), but high intake at recruitment was not. Although there was no overall association between ethanol intake and risk of lung cancer, the authors cannot rule out a lower risk for moderate consumption and a possibly increased risk for high lifelong consumption.
Published: 2006

48. Dietary methyl-group donor intake and breast cancer risk in the european prospective investigation into cancer and nutrition (EPIC)

Author: Marc J. Gunter, Julie A. Schmidt, David C. Muller, Rosario Tumino, Inge Huybrechts, Matthias B. Schulze, Verena Katzke, Corinne Casagrande, Nikos Papadimitriou, Pietro Ferrari, María José Sánchez, Lode Godderis, Paolo Chiodini, Antonio Agudo, Anne Tjønneland, María Dolores López, Elisabete Weiderpass, Carine Biessy, Heleen Van Puyvelde, Valeria Pala, Alicia K Heath, Geneviève Nicolas, Kim Overvad, Eva Ardanaz, Giovanna Masala, Koen Van Herck, Therese Karlsson, Dirk De Bacquer, Björn Gylling, Carlotta Sacerdote, Ulrika Ericson, Renée T. Fortner, Marije F. Bakker, Joanna L Clasen, Jytte Halkjær, Jonas Manjer, Van Puyvelde, H., Papadimitriou, N., Clasen, J., Muller, D., Biessy, C., Ferrari, P., Halkjaer, J., Overvad, K., Tjonneland, A., Fortner, R. T., Katzke, V., Schulze, M. B., Chiodini, P., Masala, G., Pala, V., Sacerdote, C., Tumino, R., Bakker, M. F., Agudo, A., Ardanaz, E., Lopez, M. D. C., Sanchez, M. -J., Ericson, U., Gylling, B., Karlsson, T., Manjer, J., Schmidt, J. A., Nicolas, G., Casagrande, C., Weiderpass, E., Heath, A. K., Godderis, L., Van Herck, K., De Bacquer, D., Gunter, M. J., and Huybrechts, I.
Subjects: 0301 basic medicine, Folate, Physiology, ALCOHOL, EPIC, BETAINE, Choline, chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, Methionine, Risk Factors, Medicine and Health Sciences, Medicine, TX341-641, Prospective Studies, ONE-CARBON METABOLISM, DNA METHYLATION, Nutrition and Dietetics, ASSOCIATION, Middle Aged, European Prospective Investigation into Cancer and Nutrition, Näringslära, Europe, Hormone receptor, FOLATE INTAKE, 030220 oncology & carcinogenesis, Cohort, Alcohol intake, Female, Life Sciences & Biomedicine, Breast Neoplasm, Human, Adult, DATABASE, Breast Neoplasms, folate, Methylation, Article, 03 medical and health sciences, breast cancer, Folic Acid, choline, Humans, Aged, methionine, Postmenopausal women, Science & Technology, Nutrition & Dietetics, business.industry, Nutrition. Foods and food supply, medicine.disease, Diet, Betaine, Prospective Studie, 030104 developmental biology, Nutrition Assessment, chemistry, B-VITAMINS, 1111 Nutrition and Dietetics, business, 0908 Food Sciences, Food Science
Abstract: We thank the National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands, for their contribution to, and ongoing support of, the EPIC Study. We thank Aude De Bruycker for her graphical support., (1) Background: Methyl-group donors (MGDs), including folate, choline, betaine, and methionine, may influence breast cancer (BC) risk through their role in one-carbon metabolism; (2) Methods: We studied the relationship between dietary intakes of MGDs and BC risk, adopting data from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort; (3) Results: 318,686 pre- and postmenopausal women were followed between enrolment in 1992–2000 and December 2013–December 2015. Dietary MGD intakes were estimated at baseline through foodfrequency questionnaires. Multivariable Cox proportional hazards regression models were used to quantify the association between dietary intake of MGDs, measured both as a calculated score based on their sum and individually, and BC risk. Subgroup analyses were performed by hormone receptor status, menopausal status, and level of alcohol intake. During a mean follow-up time of 14.1 years, 13,320 women with malignant BC were identified. No associations were found between dietary intakes of the MGD score or individual MGDs and BC risk. However, a potential U-shaped relationship was observed between dietary folate intake and overall BC risk, suggesting an inverse association for intakes up to 350 µg/day compared to a reference intake of 205 µg/day. No statistically significant differences in the associations were observed by hormone receptor status, menopausal status, or level of alcohol intake; (4) Conclusions: There was no strong evidence for an association between MGDs involved in one-carbon metabolism and BC risk. However, a potential U-shaped trend was suggested for dietary folate intake and BC risk. Further research is needed to clarify this association., Research Foundation Flanders (FWO, 189019N), Research Foundation Flanders (FWO, V427019N), International Agency for Research on Cancer (IARC), Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, NIHR Imperial Biomedical Research Center (BRC), Danish Cancer Society (Denmark), Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France), German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany), Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy), Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands), Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology—ICO (Spain), Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden), Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford), (United Kingdom)
Published: 2021

49. Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991–2010 (Automated Childhood Cancer Information System): a population-based study

Author: Giovanna Tagliabue, Michel Velten, Stefano Ferretti, Giske Ursin, Staffan Khan, Ceri White, Marc Colonna, Xavier Troussard, Alain Monnereau, José Ramón Quirós Garcia, Brigitte Lacour, Zdravka Valerianova, Isabelle Soerjomataram, Marisa L. Vicente Raneda, Lucia Mangone, Laufey Tryggvadottir, Freddie Bray, Anna Zborovskaya, Anastasia Dolya, Christine Bouchardy, Brigitte Trétarre, Maria Ramos Monserrat, Franco Merletti, Rafael Marcos-Gragera, Enrique Almar Marqués, Fabio Falcini, Isabelle Konzelmann, Anne Sophie Woronoff, Bianca Caruso, Margit Mägi, David H. Brewster, Charles A. Stiller, Ryszard Mężyk, Sally Vernon, Rafael Peris-Bonet, Olivier Ganry, Eva Steliarova-Foucher, Marion Piñeros, Peter Kaatsch, Miranda M. Fidler, Jacqueline Clavel, Rafael Fernández-Delgado, Fabio Levi, Claudia E. Kuehni, Rosario Tumino, Eva Ardanaz, Arantza Lopez de Munain, Otto Visser, Murielle Colombet, Berndt Holleczek, Jan Willem Coebergh, José Laranja Pontes, Maja Primic Žakelj, Zsuzsanna Jakab, Jaume Galceran, Nadya Dimitrova, Pascale Grosclaude, Roberto Zanetti, Kamila Kepska, A.V. Guizard, Sabine Rohrmann, Véronique Bouvier, Ladislav Dušek, Emilie Marrer, Maria Michiara, Maria Jose Sanchez-Perez, Monika Hackl, University of Zurich, Steliarova-Foucher, Eva, ACCIS contributors, Hackl, M., Zborovskaya, A., Dimitrova, N., Valerianova, Z., Dušek, L., Mägi, M., Monnereau, A., Clavel, J., Velten, M., Guizard, A.V., Bouvier, V., Troussard, X., Woronoff, A.S., Marrer, E., Trétarre, B., Colonna, M., Ganry, O., Grosclaude, P., Holleczek, B., Jakab, Z., Tryggvadóttir, L., Mangone, L., Merletti, F., Ferretti, S., Caruso, B., Michiara, M., Tumino, R., Falcini, F., Zanetti, R., Tagliabue, G., Visser, O., Ursin, G., Mężyk, R., Kepska, K., Laranja Pontes, J., Primic Žakelj, M., Fernández-Delgado, R., Vicente Raneda, M.L., Almar Marqués, E., Quirós Garcia, J.R., Lopez de Munain, A., Marcos-Gragera, R., Sanchez-Perez, M.J., Ramos Monserrat, M., Ardanaz, E., Galceran, J., Khan, S., Kuehni, C.E., Bouchardy, C., Levi, F., Konzelmann, I., Rohrmann, S., Vernon, S., Brewster, D.H., White, C., Dolya, A., and Public Health
Subjects: Male, Càncer en els infants, Time Factors, Cancer in children, 0302 clinical medicine, Risk Factors, Neoplasms, 030212 general & internal medicine, Registries, Age of Onset, Child, media_common, education.field_of_study, Cancer in adolescence, Incidence (epidemiology), Incidence, 3. Good health, Europe, Oncology, 030220 oncology & carcinogenesis, Regional studies, Child, Preschool, Female, 2730 Oncology, Adolescent, Population, Childhood cancer, Socio-culturale, 610 Medicine & health, Risk Assessment, Article, 03 medical and health sciences, Young Adult, Age Distribution, SDG 3 - Good Health and Well-being, medicine, media_common.cataloged_instance, Humans, Càncer en els adolescents, European union, education, business.industry, Infant, Newborn, Cancer, Infant, Health Status Disparities, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), medicine.disease, Population based study, Cancer incidence, business, Demography
Abstract: List of ACCIS contributors = Monika Hackl, Anna Zborovskaya, Nadya Dimitrova, Zdravka Valerianova, Ladislav Dušek, Margit Mägi, Alain Monnereau, Jacqueline Clavel, Michel Velten, Anne-Valérie Guizard, Véronique Bouvier, Xavier Troussard, Anne-Sophie Woronoff, Emilie Marrer, Brigitte Trétarre, Marc Colonna, Olivier Ganry, Pascale Grosclaude, Berndt Holleczek, Zsuzsanna Jakab, Laufey Tryggvadóttir, Lucia Mangone, Franco Merletti, Stefano Ferretti, Bianca Caruso, Maria Michiara, Rosario Tumino, Fabio Falcini, Roberto Zanetti, Giovanna Tagliabue, Otto Visser, Giske Ursin, Ryszard Mężyk, Kamila Kepska, José Laranja Pontes, Maja Primic Žakelj, Rafael Fernández-Delgado, Marisa L Vicente Raneda, Enrique Almar Marqués, José Ramón Quirós Garcia, Arantza Lopez de Munain, Rafael Marcos-Gragera, Maria-Jose Sanchez-Perez, Maria Ramos Monserrat, Eva Ardanaz, Jaume Galceran, Staffan Khan, Claudia E Kuehni Christine Bouchardy, Fabio Levi, Isabelle Konzelmann, Sabine Rohrmann Sally Vernon, David H Brewster, Ceri White, Anastasia Dolya Background A deceleration in the increase in cancer incidence in children and adolescents has been reported in several national and regional studies in Europe. Based on a large database representing 1∙3 billion person-years over the period 1991–2010, we provide a consolidated report on cancer incidence trends at ages 0–19 years. Methods We invited all population-based cancer registries operating in European countries to participate in this population-based registry study. We requested a listing of individual records of cancer cases, including sex, age, date of birth, date of cancer diagnosis, tumour sequence number, primary site, morphology, behaviour, and the most valid basis of diagnosis. We also requested population counts in each calendar year by sex and age for the registration area, from official national sources, and specific information about the covered area and registration practices. An eligible registry could become a contributor if it provided quality data for all complete calendar years in the period 1991–2010. Incidence rates and the average annual percentage change with 95% CIs were reported for all cancers and major diagnostic groups, by region and overall, separately for children (age 0–14 years) and adolescents (age 15–19 years). We examined and quantified the stability of the trends with joinpoint analyses. Findings For the years 1991–2010, 53 registries in 19 countries contributed a total of 180335 unique cases. We excluded 15162 (8·4%) of 180335 cases due to differing practices of registration, and considered the quality indicators for the 165173 cases included to be satisfactory. The average annual age-standardised incidence was 137∙5 (95% CI 136∙7–138∙3) per million person-years and incidence increased significantly by 0∙54% (0∙44–0∙65) per year in children (age 0–14 years) with no change in trend. In adolescents, the combined European incidence was 176∙2 (174∙4–178∙0) per million person-years based on all 35138 eligible cases and increased significantly by 0·96% (0∙73–1∙19) per year, although recent changes in rates among adolescents suggest a deceleration in this increasing trend. We observed temporal variations in trends by age group, geographical region, and diagnostic group. The combined age-standardised incidence of leukaemia based on 48458 cases in children was 46∙9 (46∙5–47∙3) per million person-years and increased significantly by 0∙66% (0∙48–0∙84) per year. The average overall incidence of leukaemia in adolescents was 23∙6 (22∙9–24∙3) per million person-years, based on 4702 cases, and the average annual change was 0∙93% (0∙49–1∙37). We also observed increasing incidence of lymphoma in adolescents (average annual change 1·04% [0·65–1·44], malignant CNS tumours in children (average annual change 0·49% [0·20–0·77]), and other tumours in both children (average annual change 0·56 [0·40–0·72]) and adolescents (average annual change 1∙17 [0∙82–1∙53]). Interpretation Improvements in the diagnosis and registration of cancers over time could partly explain the observed increase in incidence, although some changes in underlying putative risk factors cannot be excluded. Cancer incidence trends in this young population require continued monitoring at an international level. Funding Federal Ministry of Health of the Federal German Government, the European Union’s Seventh Framework Programme, and International Agency for Research on Cancer
Published: 2018

50. Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study

Author: Pamela Minicozzi, Kaire Innos, Maria-José Sánchez, Annalisa Trama, Paul M. Walsh, Rafael Marcos-Gragera, Nadya Dimitrova, Laura Botta, Otto Visser, Silvia Rossi, Andrea Tavilla, Milena Sant, M. Hackl, N. Zielonke, E. Van Eycken, K. Henau, Z. Valerianova, N. Dimitrova, M. Sekerija, L. Dušek, M. Zvolský, M. Mägi, T. Aareleid, N. Malila, K. Seppä, A.M. Bouvier, J. Faivre, N. Bossard, Z. Uhry, M. Colonna, R. Stabenow, S. Luttmann, A. Eberle, H. Brenner, A. Nennecke, J. Engel, G. Schubert-Fritschle, J. Heidrich, B. Holleczek, A. Katalinic, K. Clough-Gorr, G. Mazzoleni, A. Bulatko, C. Buzzoni, A. Giacomin, S. Ferretti, A. Barchielli, A. Caldarella, G. Gatta, M. Sant, H. Amash, C. Amati, P. Baili, F. Berrino, S. Bonfarnuzzo, L. Botta, R. Capocaccia, F. Di Salvo, R. Foschi, C. Margutti, E. Meneghini, P. Minicozzi, A. Trama, D. Serraino, L. Dal Maso, R. De Angelis, M. Caldora, E. Carrani, S. Francisci, A. Knijn, S. Mallone, D. Pierannunzio, P. Roazzi, S. Rossi, M. Santaquilani, A. Tavilla, F. Pannozzo, M. Natali, R.A. Filiberti, E. Marani, M. Autelitano, G. Spagnoli, C. Cirilli, M. Fusco, M.F. Vitale, A. Traina, R. Staiti, F. Vitale, R. Cusimano, M. Michiara, R. Tumino, F. Falcini, A.L. Caiazzo, S. Maspero, A.C. Fanetti, R. Zanetti, S. Rosso, M. Rugge, S. Tognazzo, S. Pildava, G. Smailyte, T.B. Johannesen, J. Rachtan, S. Góźdź, R. Mężyk, J. Błaszczyk, K. Kępska, M. Bielska-Lasota, G. Forjaz de Lacerda, M.J. Bento, L. Antunes, A. Miranda, A. Mayer-da-Silva, C. Safaei Diba, M. Primic-Zakelj, E. Almar, A. Mateos, A. Lopez de Munain, N. Larrañaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, R. Marcos-Gragera, L. Vilardell, C. Moreno-Iribas, E. Ardanaz, M. Lambe, M. Mousavi, C. Bouchardy, M. Usel, S.M. Ess, H. Frick, M. Lorez, C. Herrmann, A. Bordoni, A. Spitale, I. Konzelmann, O. Visser, R. Damhuis, R. Otter, M. Coleman, C. Allemani, B. Rachet, J. Rashbass, J. Broggio, J. Verne, A. Gavin, D. Fitzpatrick, D.W. Huws, C. White, Minicozzi P., Innos K., Sanchez M.-J., Trama A., Walsh P.M., Marcos-Gragera R., Dimitrova N., Botta L., Visser O., Rossi S., Tavilla A., Sant M., Hackl M., Zielonke N., Van Eycken E., Henau K., Valerianova Z., Sekerija M., Dusek L., Zvolsky M., Magi M., Aareleid T., Malila N., Seppa K., Bouvier A.M., Faivre J., Bossard N., Uhry Z., Colonna M., Stabenow R., Luttmann S., Eberle A., Brenner H., Nennecke A., Engel J., Schubert-Fritschle G., Heidrich J., Holleczek B., Katalinic A., Clough-Gorr K., Mazzoleni G., Bulatko A., Buzzoni C., Giacomin A., Ferretti S., Barchielli A., Caldarella A., Gatta G., Amash H., Amati C., Baili P., Berrino F., Bonfarnuzzo S., Capocaccia R., Di Salvo F., Foschi R., Margutti C., Meneghini E., Serraino D., Maso L.D., De Angelis R., Caldora M., Carrani E., Francisci S., Knijn A., Mallone S., Pierannunzio D., Roazzi P., Santaquilani M., Pannozzo F., Natali M., Filiberti R.A., Marani E., Autelitano M., Spagnoli G., Cirilli C., Fusco M., Vitale M.F., Traina A., Staiti R., Vitale F., Cusimano R., Michiara M., Tumino R., Falcini F., Caiazzo A.L., Maspero S., Fanetti A.C., Zanetti R., Rosso S., Rugge M., Tognazzo S., Pildava S., Smailyte G., Johannesen T.B., Rachtan J., Gozdz S., Mezyk R., Blaszczyk J., Kepska K., Bielska-Lasota M., Forjaz de Lacerda G., Bento M.J., Antunes L., Miranda A., Mayer-da-Silva A., Safaei Diba C., Primic-Zakelj M., Almar E., Mateos A., Lopez de Munain A., Larranaga N., Torrella-Ramos A., Diaz Garcia J.M., Jimenez-Chillaron R., Vilardell L., Moreno-Iribas C., Ardanaz E., Lambe M., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Damhuis R., Otter R., Coleman M., Allemani C., Rachet B., Rashbass J., Broggio J., Verne J., Gavin A., Fitzpatrick D., Huws D.W., and White C.
Subjects: Male, medicine.medical_specialty, Cancer Research, Stage at diagnosi, Survival, Concordance, Cancer registrie, Cancer registries, Data quality, Stage at diagnosis, Socio-culturale, Reproducibility of Result, Predictive Value of Test, Data Accuracy, Europe, Female, Humans, Neoplasm Metastasis, Neoplasms, Predictive Value of Tests, Reproducibility of Results, Survival Analysis, Neoplasm Staging, Registries, Oncology, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, medicine, otorhinolaryngologic diseases, 030212 general & internal medicine, Stage (cooking), Intensive care medicine, Survival analysis, Cancer staging, business.industry, medicine.disease, Cancer registry, Clinical trial, Neoplasm Metastasi, 030220 oncology & carcinogenesis, Neoplasm, Survival Analysi, business, Human
Abstract: Background Cancer registries (CRs) are fundamental for estimating cancer burden, evaluating screening and monitoring health service performance. Stage at diagnosis—an essential information item collected by CRs—has been made available, for the first time, by CRs participating in EUROCARE-5. We analysed the quality of this information and estimated stage-specific survival across Europe for CRs with good data quality. Data and methods Sixty-two CRs sent stage (as TNM, condensed TNM or extent of disease) for 15 cancers diagnosed in 2000–2007. We assessed the quality, partly by comparing stage according to the three systems. We also developed procedures to reconstruct stage (categories: local, regional, metastatic and unknown) using information from all three systems, thus minimising the amount of missing information. Results Moderate-to-excellent stage concordance was found for practically all 24 CRs, for which it was possible to compare at least two staging systems. However, since stage was often incorrectly assigned, and information on the presence/absence of metastases was often lacking, data on only 7/15 cancers from 34/62 CRs (15 countries) were of sufficient quality for further analysis. Cases diagnosed ≥70 years had more advanced (or lacking) stage– and worse stage-specific survival than those Conclusions Many European CRs collect and record reasonably accurate stage information. Others have difficulties. Both the completeness of primary data and the accuracy of stage coding need to be improved in order for CRs to fulfil their expanding roles in cancer control. We propose our stage reconstruction/checking procedures as a means of fully exploiting the stage information provided by EUROCARE CRs. More advanced (or lacking) stage at diagnosis plus poorer stage-specific survival in the elderly are worrying.
Published: 2017

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

112 results on '"Ardanaz, E."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources